

Date Prepared: September 17, 2018

**HARVARD UNIVERSITY FACULTY OF MEDICINE
CURRICULUM VITAE
Reza Dana**

Education:

1981 *Diploma Summa Cum Laude*, Saint Paul's School, Concord NH
1985 *Bachelor of Arts (BA) Phi Beta Kappa*, Johns Hopkins University
1989 *Master of Public Health (MPH)*, Johns Hopkins University
1989 *Doctor of Medicine (MD)*, Johns Hopkins University
2005 *Master of Science (MSc) in Health Care Management*, Harvard University

Postdoctoral Training:

1989-1990 Intern in Medicine, Greater Baltimore Medical Center, Baltimore, MD
1990-1993 Resident in Ophthalmology, Illinois Eye & Ear Infirmary, Chicago, IL
1993-1994 Cornea & External Diseases, Wills Eye Hospital, Philadelphia
1994-1995 Immunology & Uveitis, Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston
1994-1996 NIH (NRSA) Research Fellow, Ocular & Transplantation Immunology, Schepens Eye Research Institute, Harvard Medical School, Boston

Licensure and Certification:

1990-1993 State of Illinois medical license
1993-1994 State of Pennsylvania medical license
1994- State of Massachusetts medical license
1995- Diplomate, American Board of Ophthalmology
2003 Harvard Medical School Leadership Development for Physicians and Scientists

Academic Appointments:

1988-1989 Student, Ocular Immunology Laboratory (Mentor: Elaine Young, PhD), Wilmer Eye Institute, Johns Hopkins University School of Medicine
1995-1997 Instructor, Department of Ophthalmology, Harvard Medical School
1997-2000 Assistant Professor of Ophthalmology, Harvard Medical School
2000-2007 Associate Professor of Ophthalmology, Harvard Medical School
2001- Member with full mentoring privileges, Committee on Immunology (Graduate Program in Immunology), Harvard Medical School
2007- Professor of Ophthalmology, Harvard Medical School
2007- Claes Dohlman Chair in Ophthalmology, Harvard Medical School
2008- Vice Chairman for Academic Programs, Harvard Department of Ophthalmology
2014- Honorary Professor, Shanghai Medical College, Fudan University, Shanghai, China.

Hospital & Harvard-Affiliated Institution Appointments:

1995-2002	Founder and Director, Ocular Immunology Service, Brigham & Women's Hospital, Boston
1995-2002	Director, Cornea and External Disease Service, Brigham & Women's Hospital, Boston
1995-2004; 2009-	Associate Surgeon, Department of Surgery, Brigham & Women's Hospital, Boston
1996-1997	Investigator, Schepens Eye Research Institute, Boston
1997-	Attending Physician and Surgeon, Cornea Service, Massachusetts Eye & Ear Infirmary, Boston
1997-2000	Assistant Scientist, Schepens Eye Research Institute, Boston
2000-2004	Associate Scientist, Schepens Eye Research Institute, Boston
2002-	W. Clement Stone Scholar, Schepens Eye Research Institute
2004-	Senior Scientist, Schepens Eye Research Institute, Boston
2005-	Clinical Associate, Surgery, Massachusetts General Hospital, Boston
2006-	Director, Cornea and Refractive Surgery Services, Massachusetts Eye & Ear Infirmary, Boston
2008-2010	Physician Director, Mass Eye and Ear Board
2008-	Associate Chief of Ophthalmology, Massachusetts Eye and Ear Infirmary
2012-2017	Member, Residency Selection Team
2017-	Consulting Staff, Department of Surgery, Dana-Farber Cancer Institute

Other Professional Positions and Administrative Responsibilities:

1992-1997	Principal Investigator, Multicenter Pediatric Keratoplasty Study Group
2000-2002	Ad Hoc Member, Food and Drug Administration (FDA) Orphan Drug Development Advisory Panel
2000-	Reviewer, Wellcome Trust grants, United Kingdom
2001-2002	Conference Chair, First International Workshop on Corneal Immunology, Bermuda
2001-2003	Scientific Advisory Board, Wadsworth Foundation for Multiple Sclerosis Research, Seattle, WA
2001-2004	Medical and Scientific Advisory Board, Sjogren's Syndrome Foundation, New York, NY
2002-2007	Visual Sciences A/Anterior Eye Disease Study Section, National Institutes of Health (Member, 2002-2004; Ad Hoc, 2006-2007)
2002-2009	Executive Committee, American Uveitis Society, New Orleans, LA
2002-	Reviewer, Republic of Ireland Science Foundation grants
2004-2006	Reviewer, Cora Verhagen Prize in Immunology, ARVO
2004-2005	Consultant, NIH Consensus Panel for Trials in Graft-versus-Host Disease
2005-2006	Co-Chair, Second International Workshop on Corneal Immunology, Berlin, Germany
2005-2008	Member, National Eye Institute Special Emphasis Review Panel (RO1, R21, RO3), NIH
2005-2008	Member (Chair, 2007-2008), Awards Committee, ARVO
2006-2007	Head, Immunity and Inflammation Research Subcommittee, International Dry Eye Workshop (DEWS)
2006-	Member and Chair (2012-), Dohlman Fellow Selection Committee

2006-2007	Ad hoc member, NIH Brain and Neuroscience Special Emphasis Review Panel ZRG1 BDCN
2007-2009	Maintenance of certification (MOC) examination question preparer, American Board of Ophthalmology (for Uveitis & Ocular Immunology)
2010	Member, National Eye Institute Workshop on Ocular Pain
2010-	Chair of Selection Committee and Director, Alcon Scholar Program at Harvard Department of Ophthalmology
2011-2015	Member, International Workshop on Classification, Diagnosis, and Treatment of Ocular Surface Stem Cell Insufficiency
2011-2016	Member, International Workshop on Classification, Diagnosis, and Treatment of Ocular Graft-versus-Host Disease
2011-	Grant Reviewer, Medical Research Council, United Kingdom
2011-	Member, Scientific Advisory Board, <i>Institut de la Vision</i> , Paris, France
2012-2013	Member, Scientific Review Committee, Lymphatic Research Foundation
2013-	Reviewer, Grant Agency, <i>Agence Nationale de la Recherche</i> (French National Research Agency)
2015-	Member, External Advisory Board, ARREST BLINDNESS Consortium of the European Union
2016-	Member, Advisory Board, Tej Kohli Cornea Institute, LV Prasad Eye Institute, India
2016-	Member, National Institutes of Health ZEY1 VSN (04) - NEI Mentored Basic Research and Pathways to Independence Award Review Panel
2016-	Member, National Eye Institute Special Emphasis Review Panel for the Cornea (RO1, R21) BDCN-J 91
2017-	Expert Mentor, MIT IDEA2 Global team, "Fabricating the Corneal Stroma"
2018	International Council of Ophthalmology Allergan Research Fellowship Jury
2018-	Member, Eversight Innovations Advisory Council

Harvard and Affiliated Academic Committee Assignments:

Harvard Medical School-

2006-2009	Robert Wood Johnson Faculty Scholar Nomination Committee
2008-2012; 2014-	Ad Hoc Subcommittees for Professorial promotions
2010-	Director (Co-Director, 2014-), Harvard Medical School Cornea Center of Excellence

Schepens Eye Research Institute-

1995-	Member: Immunity, Inflammation, and Transplantation Focus Group
1997-2000	Member: Training Committee
1997-2012	Member: Technology Transfer Committee
2000-2004	Head: Corneal Transplantation Research Program
2001-2012	Chair: Human Research Committee-IRB
2009-2012	Co-Director of Research, Schepens Eye Research Institute

Massachusetts Eye and Ear Infirmary

2007-	Research Leadership Committee
2007-2009	MEEI Strategy Committee
2008-2009	Physician Director, Mass Eye and Ear Board
2012-2018	Member, Intellectual Property Committee (committee disbanded after MEE integration into Partners network)
2012-2018	Member, Conflict of Interest Committee
2012-2017	Member, Translational Research Committee
2014-2016	Chair, Annual International Mini-Symposium in Ocular Research
2015-2018	Chair, Review Committee, Summit Fund (for incubating new technologies)
2016-	Member, Research Steering Committee
2017-	Member, Selection Committee, Distinguished Clinical and Research Alumni Awards

Department of Ophthalmology, Harvard Medical School-

2000-	Faculty Member, Harvard Department of Ophthalmology/National Eye Institute Training Grant program
2000-	Chair/Co-Chair, Biennial Cornea Research Conferences
2000-2005	Member, Curriculum Committee, NIH/NEI Training Program in the Molecular Bases of Eye Diseases, Harvard Department of Ophthalmology
2002-2007	Member, Predoctoral Training Grant in Immunology, Harvard Medical School
2003-2004	Course director and organizer, Neurobiology 300, "Biology of Ophthalmic Diseases"
2004-	Director, Harvard-Vision Clinical Scientist Development Program (K12)
2006-2009	Member, Harvard Ophthalmology Fellowship Committee
2007-	Member, Promotion and Reappointment Committee
2008-	Member, Executive (Full Professors') Committee
2011-2012	Member, Search Committee for Director of Research for Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary
2011-2016	Chair, Harvard Department of Ophthalmology Retreat Planning Committee
2013-	Chair, Harvard Medical School Cornea Center of Excellence Biennial International Workshop
2018-	Member, Award Nominations Committee, Harvard Department of Ophthalmology

Professional Societies:

1988-	Association for Research in Vision and Ophthalmology
1992-	American Academy of Ophthalmology
1993-1996; 2006-	Contact Lens Association of Ophthalmologists
1994-1997	Pediatric Keratoplasty Association
1994-	Ocular Microbiology and Immunology Group
1994-	Wills Eye Hospital Association
1995-	Society of Heed Fellows
1995-2012	American Uveitis Society (2002-2009, Executive Committee)
1996-2016	International Ocular Inflammation Society

1997-	Member with Thesis, (Castroviejo) Cornea Society
1998-	Transplantation Society
1998-	American Association of Immunologists
1999-2002	Medical Advisory Board, National Sjogren's Syndrome Association
2000-2003	Medical and Scientific Advisory Board, Sjogren's Syndrome Foundation
2000-	Paton Society, Eye Bank Association of America
2004-	American Society of Transplantation
2007-	American Ophthalmological Society
2009-2015	International Society of Contact Lens Research
2016-	Academia Ophthalmologica Internationalis

Editorial Activities:

2001-	Associate Editor (2011-2017). Prior to that: Editorial Board Member, <i>Investigative Ophthalmology and Visual Science</i>
2001-	Guest Editorial Board Member, <i>Current Eye Research</i>
2002-	Editorial Board Member, <i>Cornea</i>
2002-	Senior Associate Editor (2018-). Prior to that: Editorial Board Member, <i>The Ocular Surface</i>
2007-2011	Editorial Board Member, <i>Open Transplantation Journal</i>
2008-	Editorial Board Member, <i>The Journal of Ophthalmic and Vision Research</i>
2008-	Editorial Board Member, <i>Ophthalmologica</i>
2004-2007	Section co-editor for Immunology. Albert DM, Jakobiec FA. Principles and Practice of Ophthalmology. 3rd Ed. WB Saunders Co., 2007.
2006-	Editorial Board Member, <i>UpToDate Rheumatology</i>
2000-	Ad hoc Reviewer, <i>New England Journal of Medicine, Nature, Nature Medicine, Journal of Immunology, Journal of Clinical Investigation, Nature Reviews Drug Discovery, American Journal of Pathology, FASEB Journal, Transplantation, Microbes and Infection, Archives of Ophthalmology, American Journal of Ophthalmology, Ophthalmology, British Journal of Ophthalmology, Annals of Internal Medicine, Journal of Leukocyte Biology, Ocular Immunology and Inflammation, Laboratory Investigation, Journal of Interferon and Cytokine Research, PLoS ONE</i>
2007-	Senior Editor, <i>Encyclopedia of the Eye</i> , Elsevier
2016-	Editorial Board Member, <i>Scientific Reports</i> (Nature Publishing Group)
2018-	Editorial Board Member, <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i>

Awards and Honors:

1981	National Cum Laude Society
1984	Phi Beta Kappa (<i>Junior Year</i>), Johns Hopkins University
1981-1985	Dean's List (every semester), Johns Hopkins University
1989	Henry Strong Dennison Award for Research, Johns Hopkins University School of Medicine
1990	National Eye Institute/ARVO Travel Fellowship
1995	Heed Ophthalmic Foundation Fellowship (Ocular Immunology)
1996	Named Knapp Fellow of the Society of Heed Fellows
1996	Clinical Scientist Career Award (KO8) from NIH

- 1999 Invited Participant, Research to Prevent Blindness National Science Writers Seminar
- 1999 Research to Prevent Blindness William & Mary Greve Special Scholar
- 2002 Achievement Award, American Academy of Ophthalmology
- 2002 Kronfeld Memorial Lecturer, Illinois Eye & Ear Infirmary
- 2002 Fry Memorial Lecturer, Wills Eye Hospital Biennial Cornea Conference
- 2003 Cogan Award, ARVO
- 2003 Dohlman Lecturer, Boston Biennial Cornea Conference
- 2004 Alta Lecturer and visiting professorship, Univ. California San Francisco
- 2004 Keynote Address, 28th All-Japan Cornea Conference, Yonago, Japan
- 2005 Research to Prevent Blindness Physician Scientist-Merit Award
- 2006 Service Recognition Award, American Academy of Ophthalmology
- 2007- Listed, “Best Doctors of America” (selected by peers)
- 2007- Listed, “Best of Boston” Ophthalmologists (selected by peers), *Boston Magazine*
- 2007- Listed, “Best Ophthalmologists of America” (selected by peers)
- 2008 Alcon Research Institute Award
- 2009 Research to Prevent Blindness Lew R. Wasserman-Merit Award
- 2011 David Easty Lecturer, Bowman Club, Royal College of Surgeons, Edinburgh
- 2011 Joaquin Barraquer Lecture, Spanish Congress of Ophthalmology
- 2012 LSU Chancellor’s Award in Neuroscience and Ophthalmology
- 2012 Mentoring Award, European Young Investigator Network for Ocular Surface Inflammation
- 2013 Senior Scientific Investigator Award, Research to Prevent Blindness
- 2013 Gold Fellow, Association for Research in Vision and Ophthalmology
- 2013 Keynote Speaker, Biennial Meeting of the European Society of Ophthalmology (SOE), Copenhagen, Denmark
- 2014 Thygeson Lecture, Ocular Microbiology and Immunology Group
- 2014 A. Clifford Barger Excellence in Mentoring Award, Harvard Medical School
- 2015 Kersley Lecture, British Ocular Surface Society, London, England
- 2015 Keynote Address and Certificate of Honor, European Association for Vision and Eye Research (EVER), Nice, France
- 2016 Roger Meyer Lecture, University of Michigan Kellogg Eye Center
- 2016 Elected, Academia Ophthalmologica Internationalis
- 2016 Mooney Lecture, Irish College of Ophthalmologists, Rep. Ireland
- 2016 Endre A. Balazs Prize, International Society for Eye Research
- 2017 Plenary Address, 121st Mtg. Japanese Ophthalmological Society
- 2017 Senior Achievement Award, American Academy of Ophthalmology
- 2017 Streilein Lecture, 30th Biennial Cornea Conference
- 2018 Friedenwald Award, Association for Research in Vision and Ophthalmology (ARVO)
- 2018 Stein Innovation Award, Research to Prevent Blindness
- 2019 Champalimaud Lecture, LV Prasad Eye Institute (Expected)

RESEARCH, TEACHING, AND CLINICAL CONTRIBUTIONS

Major Research Interests: Narrative Report

I am an ophthalmologist and immunologist whose principal research interest is in determining the molecular and cellular regulation of ocular immunity, and the mechanisms by which immune homeostasis breaks down in chronic inflammation. In the 1990s the principal focus of my lab was on the function of specific cytokines and chemokines in induction of antigen-specific immunity, and the mechanisms of recruitment and activation of ocular antigen-presenting cells (APC). When we first embarked on these studies, the cornea was thought of as a simple tissue that was merely a passive target of immunity. Very little was known of how resident bone marrow-derived APC gain access to lymphoid tissues, and of the local mechanisms that regulate APC-lymphatic vessel interactions—all critical facets in the induction of antigen-specific immunity in both transplantation and autoimmunity.

Identification of novel APC populations- Our studies led to several novel and unexpected discoveries. My lab was the first to discover several distinct populations of uniformly MHC class II⁺ highly immature APCs (including epithelial Langerhans cells and stromal myeloid CD11c⁺ dendritic cells) in the central cornea (*IOVS 2002, J Leuk Bio 2003*), breaking a longstanding dogma that the cornea was devoid of functional antigen-presenting cells. We also showed that these immature/precursor myeloid populations can mature to acquire high levels of costimulatory molecules CD40 and CD80, as well as MHC class II expression as they egress the eye through selective upregulation of specific receptors to prime naïve T cells under conditions of inflammation. This discovery had practical implications, as it demonstrated how the cornea itself (including corneal transplants) can contribute to immunity through *resident* APC, a process known as ‘direct sensitization’, particularly in states of high tissue inflammation (*J Immunology 2004*).

APC-Lymphatic interactions- To determine precisely where and how corneal APC interact with T cells, we embarked on a series of investigations that established the local draining lymph nodes as the site of allosensitization (*IOVS 2001; J Exp Med 2002*). Remarkably, before these studies, the field was almost exclusively focused on APC-T cell interactions in the spleen. Subsequent studies showed that APC localization in these draining lymphoid tissues is reliant on a novel function of the VEGFR-3 receptor, known to be a growth factor for lymphatic and budding blood vessel endothelia. We determined that this receptor is acquired by mature MHC class II^{hi} dendritic cells in the cornea, and mediates their chemotactic mobilization into lymphatics, thereby allowing their egress from the inflamed eye. We also showed that blockade of this pathway can suppress the trafficking of APC from the eye to regional lymph nodes and suppress the induction of immunity to ocular antigens (*Nature Medicine 2004*). The identification of this novel role for VEGFR-3 in APC mobilization received considerable attention since subsequent work by others showed a similar mechanism to be operative for certain epithelial cancers and peritumor cells for gaining access to the lymphatic system for systemic spread.

Regulation of corneal angiogenesis and lymphangiogenesis- Our studies on VEGFR-3 function stumbled us onto entirely unexpected insights into how corneal avascularity is maintained. We found high constitutive ‘ectopic’ expression of non-signaling VEGFR-3 by the corneal *epithelium*, and described how this “sink” mechanism for binding VEGF-C/D prevents their ligation of their receptors VEGFR-2/3, thereby functioning as a critical mechanism for

maintaining corneal avascularity and regulating immunity (*PNAS* 2006). More recently, we have shown that this regulatory function can be subverted by IL-17 binding to epithelial cells, which have functional IL-17R signaling, inducing over-expression of VEGF-D by epithelial cells (*Blood* 2011).

Failure of immunoregulatory mechanisms in inflammation- We have determined that Foxp3+ regulatory T cells (Tregs) become dysfunctional in hosts prone to reject allografts as well as in chronic ocular surface disease (*J Immunology* 2009). Our work has uncovered mechanisms that regulate Treg plasticity and regulatory breakdown in highly inflamed microenvironments, identifying different Treg phenotypes (*Sci Reports* 2016). We have identified Treg plasticity as a key factor in loss of allotolerance, and have defined novel strategies to (i) enhance Treg homing to the immune synapse (*J Immunology* 2014) and (ii) promote Treg expansion (*Transplantation* 2016) for induction of graft tolerance.

Dry eye disease (DED) immunopathogenesis- Our work in corneal transplantation immunology permitted us since the mid 2000s to launch a program determining the immunopathogenesis of dry eye disease (DED), a chronic immune-mediated disease (and one of the most common reasons for patients seeking eye care) whose precise pathogenesis was barely understood even a few years earlier. We optimized a murine model for dry eye disease that did not rely on gene deletion or transgenic technology and used it in our basic research program to identify critical features in the immunopathogenesis of DED. Our work led to several novel discoveries, including identifying a select resistance of T helper-17 (Th17) cells, the principal pathogenic effectors in DED, to suppression by regulatory T cells (*J Immunology* 2009). We subsequently showed that failure in Treg function in chronic DED leads not only to expansion of Th17 effectors but also development of classic immunologic memory mediated by effector memory IL-17 secreting cells (*Mucosal Immunology* 2014). Very recently, we have focused on the molecular mechanisms that lead to *generation* and *maintenance* of memory Th17 cells— an almost entirely unexplored area—and showed the critical function of IL-7 and IL-15 in this process (*J Autoimmunity* 2017).

Translational research- In addition to these basic investigations, I am engaged in translational research. These projects have focused on novel immunomodulatory strategies to manage high-risk corneal and stem cell transplants, pathological corneal angiogenesis, graft-versus-host disease, dry eye, and in vivo corneal immuno- and neuro-imaging. Our group has been one of the first to develop and clinically test topical protein-based biologic approaches targeting specific inflammatory and pro-angiogenic cytokines (such as VEGF, IL-1, PDGF) in the management of corneal and ocular surface diseases in patients. These studies have been facilitated by 10 successful FDA Investigational New Drug (IND) submissions from my group since 2008.

New areas of investigation- While we have maintained our focus on immunology and immune regulation, our group has gradually broadened its focus to include novel animal models for high-risk corneal and stem cell transplantation, keratoprosthesis and biosynthetic corneal constructs. Our group was the first to develop a miniature keratoprosthesis for the mouse and stereotactic brain surgery models for corneal neuropathy.

Teaching & Mentoring- I have focused extensively on education of both clinical and basic researchers. This has included teaching of postdoctoral research fellows, clinical fellows and residents, and medical students and graduate students enrolled in various Harvard Medical School curricula—I have served as primary mentor to over 100 laboratory trainees from 32

countries as well as over 70 clinical fellows. I have always been a strong advocate for clinical scientists in bridging the wide gap between basic science and clinical applications, and I direct the Harvard-Vision Clinical Scientist Development Program funded by the NIH K12 mechanism with the express intent of recruiting, training, and retaining the brightest young minds to Harvard to contribute to our research efforts. I have served as PI/Director for this program since its inception at Harvard Ophthalmology in 2004. Lastly, I serve as an Expert Mentor for the MIT IDEA2 Global team working on fabricating the corneal stroma, advising an international team on fabrication of an artificial cornea.

Research Funding Information

<u>Current:</u>	2000-2021	NIH R01-EY12963: PI <i>Mechanisms of sensitization in high-risk corneal grafts</i>
	2010-2019	NIH RO1-EY20889: PI <i>Immunopathogenesis of dry eye disease</i>
	2018-2021	DOD/CDMRP Vision Research Award VR170189: PI <i>Novel Adhesive Biomaterials for Quick and Long-Lasting Sutureless Repair of Corneal Injuries</i>
	2018-2020	NIH/NEI R21: PI <i>Efficacy of the Neuropeptide Alpha-Melanocyte Stimulating Hormone (α-MSH) in Promoting Survival of Corneal Endothelial Cells in Eye Banking and Transplantation</i>
	2004-2021	NIH K12-EY016335: PI <i>Harvard-Vision Clinical Scientist Development Program</i>
	2018-2020	Stein Innovation Award, Research to Prevent Blindness: PI <i>Bioengineering a prosthetic cornea</i>
	2018-2022	DOD/CDMRP Vision Research Award VR170180: Co-PI (PI: A. Djalilian) <i>“Phase I/II Multicenter Randomized Controlled Clinical Trial of Mesenchymal Stem Cell Therapy for Severe Ocular Surface Chemical Injuries”</i>
	2014-2019	NIH U10-EY022879/EY022881: (Site PI: R. Dana; Program PIs: M. Maguire and P. Asbell) <i>The Dry Eye Evaluation And Management (DREAM) Study</i>
	2017-2021	NIH UG-1 (PI: U. Jurkunas) <i>Safety and Feasibility of Cultivated Autologous Limbal Epithelial Cell (CALEC) Transplantation in the Treatment of Limbal Stem Cell Deficiency</i>
	2015-2019	DOD Translational Award: Consulting Investigator (PI: J. Ciolino) <i>Vision restoration with a collagen crosslinked Boston keratoprosthesis unit</i>
	2017-2019	Massachusetts Lions Eye Research Fund: PI <i>Function of neuropeptides in regulating corneal endothelial cell survival and function</i>
	2018-2019	Eye Bank Association of America Research Grant: PI

Role of neuropeptide alpha-melanocyte stimulating hormone in preventing corneal endothelial cell loss in tissue storage and transplantation

2018-2019 Eversight Eye Bank Grant:PI

The role of neuropeptide alpha-melanocyte stimulating hormone in preventing corneal endothelial cell loss in tissue storage under inflammatory cytokine-induced stress

Past:

1988-1989 Fight For Sight Research Division of the National Society to Prevent Blindness Student Research Fellowship: PI

Development of a community-based survey of blindness in rural North America/Appalachia region.

1988-1989 Research Grant from the Eleanor Naylor Dana Charitable Trust, Wilmer Eye Institute, Johns Hopkins School of Medicine: PI

Prevalence and causes of blindness and visual impairment in an Appalachian river valley

1992-1993 Illinois Society for the Prevention of Blindness Research Grant: PI

Dynamic shifts in corneal topography after radial and astigmatic keratotomy

1995-1996 Individual National Research Service Award, NEI/NIH: PI

Corneal neovascularization and the immunobiology of high-risk penetrating keratoplasty

1995-1996 Eye Bank Association of America Research Grant: PI

Role of corneal lymphangiogenesis in high-risk transplantation

1996-1997 Eye Bank Association of America Research Grant: Co-Investigator

Development of new photodynamic glue for corneal applications

1996-1997 Massachusetts Lions Eye Research Fund: Co-PI

New strategies for controlling ocular inflammation

1997-1998 SERI Institutional Research Grant: Co-PI

Cytokine modulation in atopic eye disease

1998-1999 Fight For Sight / Prevent Blindness America Grant-in-Aid: PI

Role of IL-1Ra in T cell responses in high-risk corneal transplantation

1998-1999 SERI Institutional Research Grant: Co-PI

Host T cell responses in corneal transplantation

1998-1999 Eye Bank Association of America (EBAA) Res. Award: PI

Topical modulation of IL-1 activity in corneal allotransplantation

1996-2000 NEI/NIH K08 Clinical Scientist Development Award: PI

Immunobiology of high-risk corneal transplantation

1997-2000 Sponsored Research Program Recipient, Amgen: PI

Proinflammatory cytokines in corneal inflammation and transplantation immunology

1999-2000 Research Support Agreement, Alcon: PI

Long-term efficacy and tolerability of silicone punctal occlusion in Sjogren's and dry eye syndromes

- 1999-2000 Research to Prevent Blindness William and Mary Greve Special Scholar Award: PI
Cytokine modulation in corneal transplantation
- 1999-2000 Research Grant, Harvard Department of Ophthalmology Joint Clinical Research Center: Co-PI
Harvard dry eye epidemiology study
- 1999-2000 Massachusetts Lions Eye Research Fund: Co-PI
Promotion of transplant survival without generalized immune suppression
- 1998-2001 Sponsored Research Program Recipient, Biogen: PI
Regulation of ocular immunity and inflammation through CD40L and Lymphotoxin-B blockade
- 2000-2001 Research Grant, Harvard Department of Ophthalmology Joint Clinical Research Center: Co-PI
Measurement of tear mucin levels in dry eye and allergic conjunctivitis patients
- 2000-2005 NIH R01 EY03306: Co-investigator (PI: Dr. I. Gipson)
Ocular surface mucins
- 2001-2002 Eye Bank Association of America (EBAA) Research Award: PI
Use of anti-apoptotic gene therapy for promotion of corneal transplant survival
- 2001-2003 Roche Organ Transplantation Research Fund: PI
Promotion of corneal graft survival by anti-apoptotic genes
- 2001-2004 Sponsored Research Program Recipient, Daiichi: PI
Multicenter study for development of global index of symptomatology in dry eye syndrome
- 2001-2004 Sponsored Research Program Recipient, Biogen: PI
Role of VLA-1 and VLA-4 in ocular immunity
- 2002-2003 TATRC grant to Schepens Eye Research Institute: Project PI
Gene therapy for donor corneal storage and prolonging graft survival
- 2000-2004 NEI/NIH R01: Co-investigator (PI: Dr. Wayne Streilein)
Immunobiology of corneal transplantation
- 2003-2004 Eye Bank Association of America (EBAA) Research Award: PI
Promotion of corneal transplant survival by integrin-based immunotherapy
- 2004-2005 Research Grant, Harvard Department of Ophthalmology Joint Clinical Research Center: Co-PI
Role of toll-like receptors (TLR) in innate immune response in dry eye syndromes
- 2003-2005 TATRC grant to Schepens Eye Research Institute: Project PI
Prevention of apoptotic cell death in cornea as result of injury and inflammation
- 2005-2007 NIH R21- EY015738: PI
Regulation of corneal apoptosis in corneal transplantation
- 2005-2007 Sponsored Research Program Recipient, Biogen-Idec: PI

- Role of matrix-binding integrins in regulation of ocular immunity and inflammation*
- 2004-2007 NIH/NCRR P20 RR20753: Co-PI (PI: Dr. D. Dartt)
Planning grant for research on blinding eye diseases
- 2005-2007 P20 Pilot Project Grant: PI
Regulation of adaptive and innate immunity in the eye
- 2006-2007 TATRC grant to Schepens Eye Research Institute: Project PI
Regulation of corneal inflammation
- 2006-2007 New England Eye Bank Corneal Transplantation Research Fund
Novel risk stratification approaches for high-risk keratoplasty (PI)
- 2004-2008 Sponsored Research Program, Johnson & Johnson-Vistakon: PI
Immunopathogenesis of dry eye-related ocular surface disease
- 2006-2008 Allergan: *Multicenter study to assess the safety and efficacy of intraocular implantation of a bioerodable extended release implant to deliver Dexamethasone (Posurdex) in treatment of patients with uveitis: Site PI*
- 2003-2008 NIH R01 EY14847: Co-investigator (PI: Dr. P. Argueso)
O-Glycans on mucins of the ocular surface
- 2007-2008 Lux Biosciences: *Multicenter dose-ranging study to assess the efficacy and safety of LX201 for prevention of corneal allograft rejection in patients at high risk for corneal transplant rejection: PI*
- 2007-2008 Lux Biosciences: *Multicenter (Phase II/III) dose-ranging study to assess the efficacy and safety of LX211 (a novel calcineurin inhibitor) in treatment of patients with uveitis: Site PI*
- 2007-2008 TATRC grant to Schepens Eye Research Institute: Project PI
Regulation of corneal angiogenesis
- 2007-2008 Eye Bank Association of America: *Kinetics and function of T regulatory cells (Tregs) in corneal transplantation: PI*
- 2007-2009 Allergan (Investigator-initiated): *Prospective randomized study to test the prophylactic use of topical Cyclosporine A 0.05% (Restasis) to prevent onset and progression of graft-versus-host disease-related dry eye (PI)*
- 2008-2009 Genentech: *Effectiveness and safety of topical ranibizumab for treatment of corneal neovascularization: PI*
- 2008-2010 Prevent Blindness America Investigator Award
Effectiveness and safety of topical bevacizumab (Avastin) for treatment of corneal neovascularization; PI
- 2009-2010 Pfizer: *Phase I/II prospective, randomized, double masked vehicle and comparator controlled, dose ranging study of CP-690,550 in dry eye disease; site PI*
- 2009-2010 Eye Bank Association of America: *Use of potentiated Tregs to promote corneal allograft survival: PI*
- 2009-2010 Eye Bank Association of America: *Prevention of endothelial cell loss in corneal storage: PI*
- 2009-2010 Eye Bank Association of America: *Function and role of decoy receptor D6 in corneal transplantation: PI*

- 2009-2010 TATRC grant to Schepens Eye Research Institute: Project PI
Regulation of corneal and ocular surface inflammation
- 2009-2011 International Agency for the Prevention of Blindness-National
Centre for Research for Prevention of Blindness and Low Vision
Rehabilitation
*Effectiveness and safety of topical interleukin-1 receptor
antagonist (IL-1Ra) in the treatment of corneal neovascularization;*
PI
- 2011-2012 Eye Bank Association of America: *Corneal transplantation in dry
eye disease:* PI
- 2011-2012 Eye Bank Association of America: *Effect of soluble VEGFR-3 on
corneal neovascularization and transplant survival:* PI
- 2011-2012 Eye Bank Association of America: *Effect of IL-6 blockade on
corneal allograft survival:* PI
- 2010-2011 Eye Bank Association of America: *Use of azithromycin to promote
corneal allograft survival:* PI
- 2010-2011 Eye Bank Association of America: *Use of aspirin-triggered
Lipoxin agonist (ATLa) to promote corneal allograft survival:* PI
- 2008-2013 NIH K24-EY019098: *New strategies for modulation of corneal
and ocular surface inflammation;* PI
- 2015-2016 Massachusetts Eye and Ear Cure For Kids Award: PI
Promotion of Corneal Transplant Survival in the Very Young
- 2012-2017 CDMRP Department of Defense Translational Research Award
DM120045: PI
*Safety and efficacy of bevacizumab in high-risk corneal
transplantation*
- 2017-2018 Eversight Eye Bank Research Award: Co-PI
Prolongation of corneal storage in eye banks
- 2017-2018 Eye Bank Association of America: PI/Mentor (W. Foulsham)
*The use of neuropeptides to prevent corneal endothelial cell loss in
storage and transplantation*

Report of Teaching, Curricular Offerings & Advisory Roles:

- 1994-1995 **Organizer, Immunology Seminar Series, Mass. Eye & Ear Infirmary**
- 1995 **Founder, Ocular Immunology Service, Brigham & Women's Hospital.** Developed new clinical and research program: focusing on inflammatory and immune diseases of the eye, providing novel and expanded patient care and educational services, as well as clinical research venues. This service became an integral part in the training of fellows in the joint Partners (Mass General-Brigham and Women's Hospital) Immunology and Allergy Program.
- 1995- **Postdoctoral Fellow Advisor**
- 5-7 clinical fellows (cornea and anterior segment services)/year
- 12-18 laboratory research fellows and pre-doctoral students (immunology)/year

- 1995-2002 **Anterior Segment Fellowship, combined Brigham and Women's and Mass Eye and Ear program**
- Co-Director (1995-1998); Director (1999-): supervised fellow and resident activities in the clinic and operating rooms; mentor research projects
 - 2 fellows (BWH) and 6 residents (MEEI)/year
- 1996-1997 **Joint Harvard-Affiliated program in Emergency Medicine**
- Instructor: essential concepts in care of corneal and external disease emergencies for ER residents
 - 6-8 residents/year
- 1996-2001 **Intensive Review of Infectious Diseases**
- Instructor: "Ocular infectious disease diagnosis and management"
 - 100-200 physicians/year
- 1996-2002 **Immunology Fellowship Program**
- Taught diagnosis and management of ocular inflammatory diseases to Allergy and Immunology (Department of Medicine) fellows rotating through cornea & ocular immunology clinics
 - 2 fellows/year
- 1997- **Cornea Service Attending, Mass. Eye & Ear Infirmary**
- Instructor: surgical and clinical care of patients with corneal and anterior segment disease; mentored research projects
 - 4-8 fellows/year
- 1997- **Faculty member, NIH/NEI T32 EY007145 Postdoctoral training program in molecular bases of eye disease (PI: A. Kazlauskas [1997-2001] & P D'Amore [2001-]) in inflammatory and immune-mediated ocular diseases**
- 1997-1998 **American Academy of Ophthalmology**
- Instructor and course co-organizer: "Emerging concepts in the pathogenesis and treatment of corneal and ocular surface diseases". Course provided overview of the fundamental molecular and cellular mechanisms of corneal and ocular surface diseases
- 1997-1998 **Harvard Medical School Postgraduate Rheumatology Course, "Advances in Rheumatology"**
- Instructor: "Ocular manifestations of rheumatic diseases"
80-100 residents and fellows
- 1997-1998 **BWH Primary Care Ophthalmology Rotation**
- Instructor: essential concepts in primary care ophthalmology
 - 3-4 residents/year
- 1997-2001 **Undergraduate Student Advisor, Harvard College**

Non-resident Tutor: Currier House, Cambridge

- 1998 **Intensive Review of Adult and Pediatric Allergy and Immunology**, (cosponsored by the American Academy of allergy, asthma, and immunology and Mass. General Hospital)
- Instructor, “Immunopathology of eye diseases; review of cellular and molecular mechanisms of immunity and inflammation in the eye”
- 1998-2002 **Intensive Review of Ophthalmology**
- Principal Instructor for Cornea and External Diseases (1998-), and Immunology and Uveitis (1999-) sections
- 1999-2003 **Board Review of Ophthalmology for Residents and Fellows**
- Instructor for Cornea/External and Inflammatory diseases
- 30 MEEI and affiliated institutions residents and fellows
- 1999 **Organizer, Boston Symposium on Sjogren’s Syndrome and Allied Disorders.** Organized the first Boston-wide symposium, involving 18 faculty members from area universities, and the NIH on the basic science and clinical aspects of autoimmune exocrinopathies.
- 1999 **Organizer, Mini-symposium on Corneal Transplant Immunology, Annual Scientific Meeting of the Castroviejo Cornea Society.** Organized and moderated a mini-symposium dedicated to review of new developments in corneal transplant immunology research.
- 2000-2010 **Faculty member, NIH/NEI T32 EY007156, Harvard program in Ocular Immunology** (PI: J. Stein-Streilein)
- 2001- **Faculty Member, Harvard Medical School Graduate Program in Immunology** (Committee on Immunology)
- 2002 **Course Co-Director, Harvard Medical International Master Workshop in Design and Conduct of Clinical Research, U. Tokyo, Tokyo, Japan**
- 2003 **Tutorial Instructor, Immunology, Microbiology and Infectious Diseases course** (IN704.0)
Harvard Medical School
- 2001-2008 **Lancaster Course in Ophthalmology, sponsored by the Harvard Department of Ophthalmology**
Instructor for Ocular surface inflammation and corneal transplantation sections of the course.
- 2001-2008 **Harvard Dept. of Ophthalmology/National Eye Institute Training Grant Program** NIH/NEI T32 EY007145

- Instructor for ocular immunology, “Biology of ophthalmic disease”
 - Course coordinator (2003-4)
- 2001- **Conference Co-Chair, Biennial Cornea Research Conference.**
- 2001-2010 **Course Organizer (2003-2004) and Instructor (2001-),** Biology of Ophthalmic Diseases (Neurobiology 300); Introduction to the Visual System (HBTM 303QC), Harvard Medical School
- 2004- **Director, Harvard Department of Ophthalmology Clinical Scientist Development (NIH-K12) Program**
- 2005- **Faculty Mentor, HMS Department of Ophthalmology Residency Program**
Mentor 1 to 3 residents per year
- 2005-2010 **Faculty member, NIH/NIAID T32 AI07498 Harvard PhD Program in Immunobiology (PI: M. Carroll)**
- 2007-2010 **Maintenance of certification (MOC) examination question preparer, American Board of Ophthalmology** (uveitis & ocular immunology)
- 2007-2013 **Associate Examiner, American Board of Ophthalmology**
- 2007-2010 **Senior Editor, *Encyclopedia of the Eye*, 2010, Elsevier UK**
- 2007- **American Academy of Ophthalmology, Cornea Subspecialty Day**
Instructor for course lectures and development of curricula dealing with the management of severe ocular surface disorders, corneal melts from infection and autoimmune diseases, and corneal neovascularization.
- 2010- **Faculty Member, Harvard Medical School Course in Advanced Ophthalmology OP502**
- 2010- **Director, Alcon Scholar Program, Massachusetts Eye and Ear, Harvard Department of Ophthalmology**
- 2017- **Expert Mentor, MIT 2 Global team, “Fabricating the Corneal Stroma”**

Names of Laboratory-Mentored Trainees and Current Positions:

- | | |
|-----------|--|
| 1996-2001 | Mini Balaram, MD, Postdoctoral fellow, “Ocular surface inflammatory diseases”. Currently: Director at Allergan. |
| 1996-1998 | Suning Zhu, MD, PhD, Postdoctoral Fellow, “Cytokine regulation of adhesion factors in corneal inflammation”. Currently: Research Scientist, Toronto General Hospital, Max Bell Research Institute, University of Toronto, Canada, and Professor, Department of Ophthalmology, First Affiliated Hospital, Zhejiang University, China. |

- 1997-1998 Elizabeth Davis, MD, Research Fellow (Schepens Eye Research Institute), and Resident (Massachusetts Eye & Ear Infirmary), “Corneal angiogenesis”. Currently: Minnesota Eye Consultants and University of Minnesota, Minneapolis, MN.
- 1997-1998 Iva Dekaris, MD, PhD candidate, “Molecular mechanisms of antigen-presenting cell motility in the cornea and ocular surface”. Currently: Professor, University Eye Clinic Svjetlost, Zagreb, Croatia, and past President of European Eye Bank Association.
- 1998-1999 Satoru Yamagami, MD, PhD, Postdoctoral Research Fellow, “Chemokine gene expression in corneal transplantation”. Currently: Professor and Chair of Ophthalmology, University of Tokyo, Japan.
- 1998-2001 Ying Liu, MD, PhD, Postdoctoral Research Fellow, “Induction of immunity to intracorneal antigens”, Schepens Eye Research Institute, Boston, MA. Currently: Physician, Cambridge, MA.
- 1998-2002 Ying Qian, MD, PhD, Postdoctoral Research Fellow, “Role of TNF superfamily receptors in corneal immunity”. Currently: Cornea Specialist, University of Rochester, Rochester, NY.
- 1999-2001 Pedram Hamrah, MD, Postdoctoral Research Fellow, “Corneal antigen-presenting cell function and activation”, Schepens Eye Research Institute, Boston, MA. Currently: Associate Professor, Tufts University Medical School, Boston, MA.
- 1999-2001 Vikas Tewari, Pre-doctoral student (Brown University), “Function of IL-12 in regulating immune response to transplant antigens”. Currently: Ophthalmologist, Caritas Good Samaritan Medical Center, Brockton, MA.
- 2000-2002 Sudhir Vora, Pre-doctoral student in Pasteur Research Program (Harvard), “Patterns of chemokine expression in ocular inflammatory diseases”. Currently: Ophthalmologist at Kaiser Permanente, San Diego, CA.
- 2001-2002 Flavia Mendes, MD, Postdoctoral Research Fellow, “Outcome measures in corneal transplantation”, Brigham and Women’s Hospital and Schepens Eye Research Institute, Boston, MA. Currently: Ophthalmologist, Toulouse, France.
- 2001-2003 Clay Beauregard, PhD, Postdoctoral Research Fellow, “Role of caspases in inflammation and apoptosis in the cornea”, Schepens Eye Research Institute, Boston, MA. Currently: Director of Therapeutic Development, Baylor Institute for Immunology Research.
- 2001-2003 Syed Huq, MD, Postdoctoral Research Fellow, “Mechanisms of allosensitization in high-risk corneal transplantation”. Currently: Physician-Scientist, Anesthesiology Department, University of Sydney, Australia.
- 2001-2004 Lu Chen, PhD, Postdoctoral Research Fellow, “Corneal dendritic cell trafficking”, Schepens Eye Research Institute, Boston, MA. Currently: Professor and Morton D. Sarver Endowed Chair, University of California, Berkeley, CA.
- 2001-2005 Abha Sood, MD, Postdoctoral Research Fellow, “Immunopathogenic mechanisms in ocular surface disease”, Schepens Eye Research Institute, Boston, MA. Currently: R&D Division, Ophthalmic Research Associates, North Andover, MA.

- 2002-2003 Komal Trivedi, MD, Postdoctoral Research Fellow, “Risk factors for pathogenesis of chronic ocular surface disease”. Currently: Ophthalmologist, Detroit, MI.
- 2002-2004 Claus Cursiefen, MD (co-mentored with Dr. Wayne Streilein), Post-Doctoral Research fellow, “Molecular regulation of angiogenesis and lymphangiogenesis in the cornea”. Currently: Professor and Chair, University of Cologne, Germany.
- 2003-2004 William Chen, MD, PhD, Postdoctoral Fellow, “Role of toll-like receptors in activation and function of corneal dendritic cells”, Schepens Eye Research Institute and Massachusetts Eye & Ear Infirmary, Boston, MA. Currently: Professor and Director of Cornea and Ocular Surface Diseases, Department of Ophthalmology, WenZhou Medical College, China.
- 2003-2006 Rita Barcia, PhD (Co-mentored with Dr. Andrius Kazlauskas), Postdoctoral Research fellow, “Molecular regulation of corneal endothelial cell apoptosis”, Schepens Eye Research Institute, Boston, MA. Currently: Research Scientist, Industry, Portugal.
- 2003-2007 LinLing Shen, PhD, Postdoctoral Research Fellow, “Mechanisms of tolerance and immune regulation including PD-L1 in the cornea”, Schepens Eye Research Institute, Boston, MA. Currently: Scientist at ETH Zurich, Basel, Switzerland.
- 2003-2005 Stefano Barabino, MD, PhD candidate, University of Genoa, Italy, “Molecular and cellular aspects of innate immunity in pathogenesis of dry eye disease”, Schepens Eye Research Institute and Massachusetts Eye & Ear Infirmary, Boston, MA. Currently: Associate Professor, University of Genoa, Italy.
- 2004-2005 Claudia Fabiani, MD/PhD candidate, University of Rome, Italy, “Corneal epithelial cell turnover in novel mouse model of dry eye”, Schepens Eye Research Institute, Boston, MA. Currently: Assistant Professor, Department of Ophthalmology, Humanitas Research Hospital, Milan, Italy.
- 2004-2006 Saadia Rashid, MD, Postdoctoral Fellow, “Immunopathogenesis of dry eye-related chronic ocular surface inflammation”, Schepens Eye Research Institute and Massachusetts Eye & Ear Infirmary, Boston, MA. Currently: Assistant Professor, Vitreoretinal Surgeon, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
- 2004-2006 Eva-Marie Chong, MD, Postdoctoral Fellow, “Molecular regulation of ocular surface immunity”, Schepens Eye Research Institute and Massachusetts Eye & Ear Infirmary, Boston, MA. Currently: Cornea Specialist, University of Arizona, Phoenix AZ.
- 2004-2010 Yiping Jin, MD, PhD, Postdoctoral Fellow, “Antigen-presenting cell trafficking and function of CCR7 chemokine receptor in cornea and ocular surface”, Schepens Eye Research Institute, Boston MA. Currently: Department of Medicine, Woodhull Medical Center, Brooklyn, NY.
- 2005-2007 Audrey Chan, MD, Postdoctoral Fellow, “Ocular surface disease in dry eye syndromes”, Massachusetts Eye & Ear Infirmary and Schepens Eye Research Institute, Boston MA. Currently: Cornea Specialist, Ophthalmic Consultants of Boston, Boston, MA.

- 2005-2007 Xian Zhang, MD, PhD, Postdoctoral Fellow, “Regulation of corneal alloimmunity by ex-vivo manipulation and leukocyte depletion of donor tissues”, Schepens Eye Research Institute, Boston MA. Currently: Physician, Saint Elizabeth’s Hospital, Washington, DC.
- 2005-2009 Daniel Saban, PhD, Postdoctoral Fellow, “Therapeutic induction of tolerance in transplantation”, Schepens Eye Research Institute, Boston MA. Currently: Associate Professor, Department of Ophthalmology, Duke University School of Medicine, Durham, NC.
- 2006-2007 Tatiana Ecoiffier, PhD Student, Ecole Supérieure de Biotechnologie de Strasbourg (France), “Regulation of ocular surface inflammation by integrins”, Schepens Eye Research Institute, Boston MA. Currently: Genentech, South San Francisco, CA.
- 2006-2008 Jaafar El Annan, MD, Postdoctoral Fellow, “Molecular mechanisms of corneal inflammation and function of PD-L1 in autoimmunity”, Schepens Eye Research Institute, Boston, MA. Currently: Assistant Professor, U Texas Medical Branch/ MD Anderson Cancer Center, Houston, TX.
- 2006-2007 Eui-Sang Chung, MD, PhD, Postdoctoral Fellow, “Regulation of corneal heme and lymphangiogenesis in ocular surface immunity”, Schepens Eye Research Institute, Boston MA. Currently: Associate Professor, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- 2006-2009 Sunil Chauhan, PhD, Postdoctoral Fellow, “Regulatory T cells in corneal transplantation and corneal inflammation”, Schepens Eye Research Institute, Boston MA. Currently: Associate Scientist, Schepens Eye Research Institute and Associate Professor, Harvard Department of Ophthalmology, Boston.
- 2006-2009 M. Dastjerdi, MD, Postdoctoral Fellow, “Ocular surface inflammation and angiogenesis in chronic corneal diseases”, Massachusetts Eye & Ear Infirmary and Schepens Eye Research Institute, Boston, MA. Currently: Assistant Professor, U Medicine & Dentistry of New Jersey (UMDNJ), Newark, NJ.
- 2007 Elizabeth Shields, Harvard College student, “Ex vivo expansion of epithelial cells for ocular surface reconstruction”, Schepens Eye Research Institute, Boston, MA.
- 2007-2008 Kathryn Masselam, MD, Clinical Fellow, “Limbal stem cell insufficiency”, Massachusetts Eye & Ear Infirmary, Boston, MA. Currently: Assistant Professor, Cornea Service, Massachusetts Eye and Ear Infirmary, Boston, MA.
- 2007-2008 Helene Lam, MD, Clinical fellow, “Pathophysiology of corneal transplant rejection”, Massachusetts Eye & Ear Infirmary, Boston, MA. Currently: Ophthalmologist, Harvard Vanguard Medical Associates, Boston, MA.
- 2007-2009 Sunali Goyal, MD, Postdoctoral Fellow, “Pre-clinical models of dry eye”, Schepens Eye Research Institute, Boston, MA. Currently: Assistant Professor, U. Arkansas, Little Rock, AR.
- 2007-2014 Zahra Parastoo Sadrai, MD, Postdoctoral Fellow, “Mechanisms of epithelial damage by proinflammatory cytokines in chronic ocular surface disease”, Schepens Eye Research Institute, Boston, MA. Currently:

- Department of Medicine, U Massachusetts Medical Center, Worcester MA.
- 2007-2010 Amir R. Hajrasouliha, MD; Postdoctoral Fellow, “Molecular regulation of corneal inflammation and lymphangiogenesis”, Schepens Eye Research Institute, Boston MA. Currently: Fellow in Retina, U California Davis, CA.
- 2007-2009 Toshi Funaki, MD, PhD, Postdoctoral Fellow, “Molecular mechanisms of corneal endothelial decompensation in corneal transplantation”, Schepens Eye Research Institute, Boston, MA. Currently: Associate Professor, Jutendo University School of Medicine, Tokyo, Japan.
- 2008-2009 Hyung K. Lee, MD, PhD, Postdoctoral Fellow, “Regulation of VEGF receptor signaling by PTK-7”, Schepens Eye Research Institute, Boston, MA. Currently: Professor, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea.
- 2008-2010 Thomas Fuchsluger, MD, PhD, Postdoctoral Fellow/Visiting Assistant Professor from Univ Hospital Essen, Germany, “Regulation of cell apoptosis in tissue preservation and transplantation”, Schepens Eye Research Institute, Boston MA. Currently: Professor and Head of Eye Bank, Friedrich Alexander Erlangen-Nuernberg Univ., Germany.
- 2008-2012 Nambi Nallasamy, MD, HST Student- Harvard/MIT, “Development of automated platform for quantification of corneal Neovascularization and nerves in human and animal corneas”, Massachusetts Eye & Ear Infirmary and Schepens Eye Research Institute, Boston, MA. Currently: Fellow in Cornea, Bascom Palmer Eye Institute, Miami FL.
- 2008-2009 Andre Okanobo, MD, Postdoctoral Fellow, “Pathogenesis of chronic corneal inflammation and neuropathy”, Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute, Boston, MA. Currently: Ophthalmologist at the State University of Campinas, Campinas, Brazil.
- 2008-2013 Yihe Chen, MD, Postdoctoral Fellow, “Role of Th17 cells in the immunopathogenesis of dry eye”, Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute, Boston MA. Currently: Senior Research Associate, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston.
- 2008-2010 Hiroki Ueno, MD, PhD, Postdoctoral Fellow, “Regulation of ocular surface stem cell niche”, Schepens Eye Research Institute, Boston MA. Currently: Assistant Professor, St. Marianna University School of Medicine, Kawasaki, Japan.
- 2009-2010 Giulio Ferrari, MD, Postdoctoral Fellow, “The role of corneal nerves in epithelial trophism and chronic ocular surface disease”, Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute, Boston MA. Currently: Associate Professor, San Raffaele Medical Center, Milan, Italy.
- 2009-2011 Takaaki Hattori, MD, PhD, Postdoctoral Fellow, “Tolerogenic mechanisms in ocular inflammation”, Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute, Boston MA. Currently: Associate Professor, Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.

- 2009-2012 Hyun Soo Lee, MD, PhD, Postdoctoral Fellow, “Pathophysiology of dry eye-associated chronic ocular surface disease”, Schepens Eye Research Institute, Boston MA. Currently: Associate Professor, The Catholic University of Korea, College of Medicine, Korea.
- 2009 Deniz Hos, Medical Student (University of Erlangen, Germany), “Role of VEGF in corneal wound healing”. Schepens Eye Research Institute, Boston MA; Currently: Ophthalmology Resident, University of Cologne, Cologne, Germany.
- 2009-2011 Yinan Lan, Medical Student, Boston University, “Function of mesenchymal stem cells in host response to corneal injury”, Schepens Eye Research Institute, Boston, MA.
- 2009-2013 Francisco Amparo, PhD, Postdoctoral Fellow, “Novel imaging platforms for assessment in ocular surface disease”, Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Boston MA. Currently: Senior Research Associate, Massachusetts Eye and Ear, Harvard Medical School, Boston MA.
- 2009-2011 Sheng-Fu (Jack) Cheng, PhD, Postdoctoral Fellow, “Therapeutic approaches to corneal angiogenesis”, Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Boston, MA. Currently: Ophthalmologist at the Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
- 2010-2013 Parisa Emami, MD, MPH, Postdoctoral Fellow, “Development of tolerogenic antigen-presenting cells in transplantation”, Schepens Eye Research, Boston MA. Currently: Resident in Ophthalmology, Kresge Eye Center, Detroit, MI.
- 2010-2011 Simona Schlereth, Graduate Student, University of Freiburg, Germany, "Phenotypic characterization of ocular antigen-presenting cells”, Schepens Eye Research Institute, Boston MA. Currently: Resident, Department of Ophthalmology at University of Cologne, Germany.
- 2010 Yesim Haussler-Sinangin MD, Postdoctoral Fellow, “Imaging lymphatics in ocular surface disease”, Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute, Boston MA. Currently: Assistant Professor, University of Frankfurt, Germany.
- 2010-2013 William Stevenson, MD, Postdoctoral Fellow, “Macrophage phenotype modulation in regulating corneal inflammation”, Schepens Eye Research Institute, Boston MA. Currently: Resident in Ophthalmology, University of Arizona College of Medicine, Tuscon, AZ.
- 2010-2013 Shilpa Kodati, MBBS, Postdoctoral Fellow, “Chemokine receptor expression by APCs in dry eye disease”, Schepens Eye Research, Boston MA. Currently: Resident in Ophthalmology, University of Pittsburgh, Pittsburgh, PA.
- 2010-2015 Jing Hua, MD, Postdoctoral Fellow, “Treg dysfunction in high-risk corneal transplantation and chronic ocular inflammation”, Schepens Eye Research Institute, Boston MA. Currently: MERSI, Waltham MA.
- 2011-2014 Thomas Dohlman, MD, Postdoctoral Fellow, “Molecular mechanisms of Th1 and Th17 cell homing in corneal inflammation”, Schepens Eye

- Research Institute, Boston, MA. Currently: Resident in Ophthalmology, Cornell Weill Medical College, New York NY.
- 2011 Belen Alfonso Bartolozzi, graduate student, University of Asturias, Spain, “Regulation of corneal angiogenesis”, Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute, Boston, MA. Currently: Resident in Ophthalmology, University of Oviedo, Asturias, Spain.
- 2011 Parisa Faridian, summer student from U.C. San Diego, “Computer-assisted imaging in corneal and ocular surface inflammation”, Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute, Boston, MA. Currently: Physician, San Diego, CA.
- 2011-2012 Narghes Calcagno, Student, U Milan, “Ex vivo expansion of corneal bone marrow-derived cells”, Schepens Eye Research Institute, Boston, MA. Currently: Postdoctoral Fellow in immunology, ALS Research Center, Harvard Medical School.
- 2011-2012 Ilya Leskov, Harvard Medical School student, “Chemokine-mediated mechanisms of leukocyte mobilization in corneal transplantation and inflammation”, Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute, Boston, MA. Currently: Assistant Professor, Feinberg School of Medicine, Department of Ophthalmology, Northwestern University, Chicago, IL.
- 2011-2013 Sumona Chaudhury, Harvard PhD candidate, Harvard U, “Risk factors in ocular surface inflammation”, Massachusetts Eye and Ear Infirmary, Boston, MA.
- 2011-2013 Hasanain Shikari, MD, Postdoctoral Fellow, “Graft-versus-host disease immunopathogenesis”, Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Boston MA. Currently: Medical Director, Arete Clinics, Opera House, Mumbai, Maharashtra 400004, India.
- 2011-2014 Masahiro Omoto, MD, PhD, Postdoctoral Fellow, “Development of novel model of endothelial keratoplasty in the mouse”, Schepens Eye Research Institute, Boston, MA. Currently: Physician-scientist, U Tokyo, Japan.
- 2012-2016 Maryam Tahvildari, MD, Postdoctoral Fellow, “Ex vivo manipulation of corneal bone marrow-derived cells for immunoregulatory applications in corneal transplantation”, Schepens Eye Research Institute, Boston, MA. Currently: Resident in Ophthalmology, Kresge Eye Institute, Wayne State U, Detroit MI
- 2012-2014 Sang-Mok Lee, MD, PhD, Postdoctoral Fellow, “Cross regulation of corneal nerves and immunity in ocular surface disease”, Schepens Eye Research Institute, Boston, MA. Currently: Associate Professor, Hallym University College of Medicine, Korea.
- 2012-2015 Tina Shiang, Boston University 7-year combined Liberal Arts/Medical Education program, “Early corneal endothelial changes in transplant rejection”, Schepens Eye Research Institute, Boston, MA.
- 2012-2013 Bracha Robinson, Yeshiva University (New York) College Student, Schepens Eye Research Institute, Boston, MA.

- 2012-2015 Ujwala Saboo, MD, Postdoctoral Fellow, “Ocular graft-versus-host disease.” Currently: Fellow in Pediatric Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX.
- 2012 Jennifer Galley, Medical/Graduate student from Royal College of Surgeons, Ireland, “Quantification of corneal neovascularization”, Schepens Eye Research Institute, Boston, MA.
- 2012 Negar Pirmadjid, Medical student from George’s College, University of London, Schepens Eye Research Institute, Boston, MA. Currently: St. George’s University of London
- 2012-2015 Takenori Inomata, MD, PhD, Juntendo University School of Medicine, Tokyo, Japan, “Dysfunction of peripherally induced T-regulatory cells in high-risk corneal transplantation”, Schepens Eye Research Institute, Boston, MA. Currently: Assistant Professor, Juntendo University School of Medicine
- 2012 Ben Chaon, Medical student, University of Iowa, Iowa City, IA. “Development of a survey to assess ocular pain”, Massachusetts Eye and Ear Infirmary, Boston, MA. Currently: St. George’s, University of London, London.
- 2012-2015 Alja Crnej, MD, Postdoctoral Fellow (co-mentored with Dr. Claes H. Dohlman), “Development of mouse model of keratoprosthesis”, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston MA. Currently:
- 2013-2015 Brinda Subbarayal, PhD, Post-doctoral fellow, “Interface between Th17 and B cell-mediated immunity in chronic dry eye disease”, Schepens Eye Research Institute, Boston, MA. Currently: Executive Director, Biopharma, Appasamy Associates, Chennai (Madras), India
- 2013-2014 Tulio Abud, MD, Postdoctoral Fellow, “Efficacy of topical tacrolimus in ocular graft-versus-host disease”, Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute, Boston, MA. Currently: Physician - Cataract, Cornea and Refractive Surgery Department, Santa Lucia Hospital, Uberaba-MG-Brazil.
- 2013-2014 Iris Hong Qi, MD, PhD, Postdoctoral Fellow, “Function of regulatory Th17 cells in abatement of ocular surface disease”, Schepens Eye Research Institute, Boston, MA. Currently: Professor of Ophthalmology, Peking University Eye Center, Peking University Third Hospital, Beijing, China
- 2013-2014 Göknül Gültekin, Medical student at Istanbul University, Cerrahpasa Faculty of Medicine, Turkey, Schepens Eye Research Institute, Boston, MA.
- 2013 Osman Aijazi, Tufts University student, Boston, MA, Schepens Eye Research Institute, Boston, MA.
- 2013-2015 Antonio DiZazzo, MD, Resident at University of Rome, Post-doctoral fellow, “Angiostatic function of Tregs in ocular inflammation”, Schepens Eye Research Institute, Boston, MA. Currently: Assistant Professor, University of Rome Campus Bio Medico, Rome.
- 2014-2015 Lang Bai, MD, Post-doctoral fellow, “Function and TLR regulation of Tregs in corneal inflammatory diseases”, Schepens Eye Research Institute,

- Boston MA. Currently: Chief Physician, Nanfang Hospital, Southern Medical University, Guangdong Sheng, China
- 2014-2015 Xuhua Tan, MD, PhD, Post-doctoral fellow, “The immunoregulatory role of corneal epithelium-derived TSP-1 in dry eye disease,” Schepens Eye Research Institute, Boston, MA. Currently: Attending Physician, Department of Cataract, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China
- 2014 Abigail Kaye, MB ChB, University of Bristol, UK, Research Intern, Schepens Eye Research Institute, Boston MA. Currently: U Bristol Medical School, UK.
- 2014 Alexandra Rezazadeh, Medical Student at University of Wisconsin School of Medicine, Madison WI, “Regulation of corneal angiogenesis”, Schepens Eye Research Institute, Boston, MA.
- 2014 Homer Chiang, Medical Student at University of Vermont College of Medicine, Burlington VT, Research Intern, “Biphasic response of inflammatory angiogenesis in the cornea” Schepens Eye Research Institute, Boston, MA. Currently: Ophthalmology resident, Univ. Texas San Antonio.
- 2014-2015 Merle Fernandes, MBBS, MS, Postdoctoral Fellow, “Immunoregulatory function of corneal epithelial PEDF in suppressing T cell mediated immunity”, Schepens Eye Research Institute, Boston, MA. Currently: Professor, LV Prasad Eye Institute, India.
- 2014-2016 Alireza Mashaghi, MD, PhD, Postdoctoral Fellow, “Contribution of aging to autoimmunity”, Schepens Eye Research Institute, Boston, MA. Currently: Assistant Professor, Leiden University, The Netherlands
- 2014-2017 Anna Marmalidou, MD, Postdoctoral Fellow, “Substance P-mediated dysfunction of T regulatory cells in dry eye disease”, Schepens Eye Research Institute, Boston, MA. Currently: Clinical Research Fellow, Mass Eye and Ear Retina Service, Boston
- 2014-2016 Josh Hong, MD, PhD, Post-doctoral Fellow, “Immune regulation of the ocular surface”, Schepens Eye Research Institute, Boston, MA. Currently: Associate Professor, Fudan University Eye Ear Nose and Throat Hospital, Shanghai, China.
- 2015- Afsaneh Amouzegar, MD (co-mentor with Dr. Sunil Chauhan), Postdoctoral Fellow, “Immune homeostasis in the cornea”, Schepens Eye Research Institute, Boston, MA. Currently:
- 2015-2018 Takeshi Nakao, MD, Mass Eye and Ear-Bausch & Lomb fellow, “Promotion of corneal transplant survival in the very young”, Schepens Eye Research Institute, Boston, MA.
- 2015 Fatemeh Ramazani, University of Alberta, Edmonton, Summer Student, “Imaging studies in ocular surface disorders”, Schepens Eye Research Institute, Boston, MA. Currently: U Alberta Medical School, Canada.
- 2015 Jessica Girgis, U. Massachusetts-Amherst Honors Commonwealth College summer student, “Neuro-immune basis of corneal inflammation”. Schepens Eye Research Institute, Boston, MA. Currently: Clinical Research Coordinator, Dana Farber Cancer Institute, Boston, MA.

- 2015-2016 Mohsen Tehrani, Post-doctoral Fellow, “Immunoregulatory mechanisms of Tregs in ocular inflammation”, Schepens Eye Research Institute, Boston, MA. Currently: Associate Professor, Mazandaran University of Medical Sciences, Iran.
- 2015-2016 Kunal Suri, MD, Post-doctoral Fellow, “Trophic factors for support of corneal endothelium”, Schepens Eye Research Institute, Boston, MA. Currently: Resident Physician, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio.
- 2015-2017 Vannarut Satitpitakul, MD, Postdoctoral Fellow, “Murine models for study of regenerative approaches to corneal endothelial dysfunction”, Schepens Eye Research Institute, Boston, MA. Currently: Attending Physician, Cornea and Refractive Unit, Department of Ophthalmology, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
- 2015-2017 Jia Yin, MD, PhD, Fellow, “Treg regulation of angiogenesis”, Massachusetts Eye and Ear Infirmary, Boston, MA. Currently: Attending Physician, Cornea Service, Massachusetts Eye and Ear, Boston, MA
- 2015-2017 Chunyi Shao, MD, PhD, Fellow, “Immune interactions of T cells with corneal endothelial cells in transplantation”, Schepens Eye Research Institute, Boston, MA. Currently: Attending Physician, Department of Ophthalmology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- 2016-2017 Mandy Yu, MD, PhD, Postdoctoral Fellow, “Function of alpha-2b adrenergic system in regulating T cell function”, Schepens Eye Research Institute, Boston, MA. Currently: Associate Professor, Department of Ophthalmology, Sichuan Academy of Medical Sciences, Chengdu, Sichuan Province, China.
- 2016- Zhongmou Sun, Pre-doctoral Student, “In vitro effect of nerve-derived factors on corneal endothelium”. Schepens Eye Research Institute, Boston, MA
- 2016- William Foulsham, MD, PhD, Postdoctoral Fellow, “Regulatory T cell dysfunction in high-risk corneal allograft rejection”, Schepens Eye Research Institute, Boston, MA
- 2017-2018 Giulia Coco, MD, Postdoctoral Fellow, “Role of regulatory T cells in preventing corneal endothelial cell loss”, Schepens Eye Research Institute, Boston, MA
- 2017- Rohan B Singh, MD, “Treg phenotypic and functional changes in autoimmunity”, Schepens Eye Research Institute, Boston MA
- 2017- Rani AlKarmi, MD, “Regulation of ocular redness”, Schepens Eye Research Institute and Mass Eye and Ear, Boston MA
- 2017- Yukako Taketani, MD, PhD, “Treg dysfunction in dry eye disease”, Schepens Eye Research Institute, Boston MA
- 2017- Lingjia (Helen) Liu, MD, “Regulation of ocular surface immunity by the adrenergic system”, Schepens Eye Research Institute, Boston MA
- 2017- Tatiana Carreno, MD, “Regulation of ocular surface stem cell function”, Schepens Eye Research Institute, Boston MA

- 2018- Zala Luznik, MD, PhD, “Treg regulation of angiogenesis”, Schepens Eye Research Institute, Boston MA.
- 2018- Tomas Blanco, PhD, “Tolerogenic APC of the ocular surface”, Schepens Eye Research Institute, Boston MA.
- 2018- Clotilde Jumelle, PhD, “Bioengineering corneal matrices and drug delivery platforms”, Schepens Eye Research Institute, Boston MA.

Clinical Fellows Mentored to Date (80 to date)

- 1995-1996 Joshua Young, MD
- 1996-1997 Amyna Sultan, MD
- 1996-1998 Tad Baum, MD
- 1996-1998 Esen Akpek, MD
- 1996-1998 Kathryn Colby, MD
- 1996-1998 Sonia Yoo, MD
- 1997-1998 Scott Hoffman, MD
- 1998-1999 Ignatius Cyriac, MD
- 1998-1999 Randa Garrana, MD
- 1997-1998 Farzad Yaghouti, MD
- 1998-2000 Eric Dudenhofer, MD
- 1998-2000 Victor Perez, MD
- 1998-2000 Samir Melki, MD
- 1998-2000 Stephen Stechschulte, MD
- 1999-2001 Natalie Afshari, MD
- 1999-2001 Sandeep Jain, MD
- 1999-2001 Jonathan Primack, MD
- 2000-2001 Richard Maw, MD
- 2000-2002 Shahzad Mian, MD
- 2000-2002 Kimberly Sippel, MD
- 2001-2002 David Yi, MD
- 2001-2003 Anh Nguyen, MD
- 2001-2003 Mahnaz Nouri, MD
- 2001-2003 Patrick Yeh, MD
- 2002-2003 Matthew Gardiner, MD
- 2002-2004 Joseph Ma, MD
- 2002-2004 Scott Barnes, MD
- 2003-2005 Mark Rosenblatt, MD
- 2004-2006 Ula Jurkunas, MD
- 2004-2006 Eva Chong, MD
- 2004-2006 Jose de la Cruz, MD
- 2005-2007 Mona Harissi-Daher, MD
- 2005-2007 Audrey Chan, MD
- 2005-2007 Ying Qian, MD
- 2006-2005 Pankaj Gupta, MD
- 2006-2008 Pedram Hamrah, MD
- 2006-2008 Helene Lam, MD
- 2006-2008 Kathryn Masselam Hatch, MD

2007-2009	Joseph Ciolino, MD
2007-2009	Jessica Ciralsky, MD
2007-2009	Pauline Lim, MD
2007-2009	Mira Lim, MD
2007-2009	Sangita Patel, MD
2008-2010	Anne Keating, MD
2008-2010	Ginny Kullman, MD
2008-2010	Aisha Traish, MD
2009-2011	John Clements, MD
2009-2011	Janie Yoo, MD
2009-2011	Kristen Hawthorne, MD
2009-2011	J. Richard Townley, MD
2010-2012	Houman Hemmati, MD
2010-2012	Sahar Kohanim, MD
2010-2012	Christina Prescott, MD
2011-2013	Peggy Chang, MD
2011-2013	Hyunjoo Lee, MD
2011-2013	Rony Sayegh, MD
2012-2014	Sara Bozorg, MD
2012-2014	Ramez Haddadin, MD
2012-2014	Cecily Hamill, MD
2013-2015	Deepika Shah, MD
2013-2015	Silva Odorcic, MD
2013-2015	Sunali Goyal, MD
2013-2015	Haunmith Kha-Farooqi, MD
2013-2015	Duna Raoof, MD
2014-2016	Hajirah Saeed, MD
2015-2016	Yuna Rapoport, MD
2015-2016	Steven Greenstein, MD
2015-2016	Shaohui Liu, MD
2015-2017	Jia Yin, MD, PhD
2016-2017	Emma Davies, MD
2016-2017	Charista Evangelista, MD
2016-2018	Reena Gupta, MD
2017-2018	Rohini Rao, MD
2017-2018	Grace Shih, MD
2018-2019	Kunal Merchant, MD
2018-2019	Yusra Siddiqui, MD
2018-2019	Shawn Lin, MD, PhD
2018-2020	Stephan Ong Tone, MD, PhD
2018-2020	Thomas Dohlman, MD

Report of Clinical Activities:

1. Clinical Practice: Cornea/External Disease, and Ocular Immunology.
Full-time hospital-based academic faculty at the Massachusetts Eye and Ear Infirmary, Boston. In addition, I am involved in clinical research in the

areas of ocular surface and ocular inflammatory diseases. Clinical activities comprised of medical and surgical subspecialty care of patients with corneal and inflammatory ocular diseases. All patients are evaluated and managed with trainees.

3. Contributions: Development of a new multidisciplinary Ocular Immunology service at the Brigham and Women's Hospital (BWH) in 1995 focusing on management of patients with ocular immuno-inflammatory conditions. This program streamlined the care of these patients, and provided new educational opportunities for Ophthalmology and Immunology fellows rotating through our service in the Longwood Medical Area. Upon the merger of the BWH Ophthalmology service and Mass Eye and Ear Infirmary, my related clinical activities were transferred entirely to Mass. Eye and Ear where the same interdisciplinary process in conjunction with Rheumatology (for autoimmune diseases) and Hematology (for graft-versus-host cases) was continued. Since assuming the directorship of the Cornea Service at MEEI in early 2006, my responsibilities have included oversight of the operations and academic programs of this service, comprised of 12-14 attending physicians and 6-8 clinical and clinical research fellows (in addition to 15-20+ postdoctoral laboratory-based research fellows), and >20 ancillary and technical staff. In addition, I have considerably expanded the translational and clinical research activities of the Cornea Service by creation of the Cornea Research Department and the Ocular Surface Imaging Center—the latter employs several full-time staff and leads numerous clinical research protocols, nearly all investigator-initiated. These studies have involved 9 physician-sponsored Investigational New Drug (IND) approvals from the FDA.

Selected Invited Talks (from 250+)

- 2018** Harvard Cornea Center of Excellence, **Boston, MA**
Duke U. Foster Visiting Professor, **Durham, NC**
Miguel Hernandez Institute of Neuroscience, **Alicante, Spain**
World Ophthalmology Congress, **Barcelona, Spain**
Academia Ophthalmologica Internationalis Chair LXXXIII lecture, **Barcelona**
Association for Research in Vision and Ophthalmology (ARVO), **Honolulu, HI**
Johns Hopkins University Wilmer Eye Institute, **Baltimore, MD**
Korean Ophthalmological Society Keynote Speaker, **Seoul, S Korea**
- 2017** PanCornea International Conference, **Miami, FL**
USAMMA on Novel Biomaterials for Cornea Repair, **Frederick, MD**
Plenary Address, 121st Mtg. Japanese Ophthalmological Society, **Tokyo, Japan**
Connecticut Society of Eye Physicians and Surgeons, **Farmington, CT**
Symposium on Aging & Immunosenescence, ARVO, **Baltimore, MD**
Special Interest Group-Mechanisms of ocular surface immunity, ARVO, **Baltimore**
Visiting Professorship, Yale U. Department of Ophthalmology, **New Haven, CT**
Streilein Lecture, Biennial Cornea Conference, **Boston, MA**
Symposium on Graft-versus-Host Disease, **Chicago, IL**
- 2016** International Symposium on Ocular Pharmacology & Therapeutics, **Rome, Italy**
Mooney Lecture, Irish College of Ophthalmologists, **Killarney, Rep. Ireland**
Endre A Balazs Prize, International Society for Eye Research, **Tokyo, Japan**
Visiting Professor, University of California San Diego, **San Diego, CA**
Roger Meyer Lecture, U Michigan Kellogg Eye Center, **Ann Arbor, MI**
U California Berkeley Visiting Professor- Oxyopia Lecture, **Berkeley, CA**
Mini-symposium on Ocular Graft-Versus-Host Disease, ARVO, **Seattle, WA**
Mass. General Hospital Division of Hematology-Oncology, **Boston, MA**
- 2015** Japan-China-USA Cornea Specialists' Translational Research Meeting, **Denver, CO**
Conference Address, European Assoc. for Vision and Eye Research, **Nice, France**
Special Interest Group Co-organizer & Moderator, ARVO, **Denver, CO**
Kersley Medal Lecture, British Ocular Surface Society, **London, UK**
VII World Cornea Congress, **San Diego, CA**
Distinguished Lecture in Vision Science, **SUNY Buffalo, NY**
New England Ophthalmological Society, **Boston, MA**
Frontiers of Corneal Research, Harvard Cornea Center of Excellence, **Boston, MA**
- 2014** Symposium Chair, World Ophthalmology Congress, **Tokyo, Japan**
International Sympos. on Ocular Pharmacology & Therapeutics, **Reykjavik, Iceland**
Joint Fudan University - Harvard Medical School Symposium, **Shanghai, China**
International Society for Eye Research XXI Biennial Meeting, **San Francisco, CA**
Thygeson Lecture, Ocular Microbiology and Immunology Group, **Chicago, IL**
New England Ophthalmological Society, **Boston, MA**

- 2013** International Symposium on Ocular Pharmacology & Therapeutics, **Paris, France**
Keynote Speaker, European Ophth Society Meeting, **Copenhagen, Denmark**
Keynote Address, 7th International TFOS Conference, **Taormina, Italy**
Inflammation and Ocular Surface Focus Group, **Hamburg, Germany**
ARVO Foundation Vision Innovation and Venture Forum, **Seattle, WA**
International Symposium on Corneal Research, **Boston, MA**
- 2012** International Society for Eye Research, **Berlin, Germany**
Visiting Professor, Fudan University, **Shanghai, China**
Harvard-Osaka-Xiamen Univ. Symposium on Ocular Regeneration, **Xiamen, China**
Distinguished Chancellor Lecture in Neurosciences, LSU, **New Orleans**
Conference Lecture, Gordon Research Conferences on Cornea, **Ventura, CA**
Cornea Day, ASCRS Annual Meeting, **Chicago, IL**
Special Interest Group on Biomarkers, ARVO, **Ft. Lauderdale, FL**
Case Western Reserve University Annual Scientific Meeting, **Cleveland, OH**
Visiting Professor, Washington University School of Medicine, **St. Louis, MO**
Frontiers in Corneal Research, Mass Eye and Ear, **Boston, MA**
- 2011** David Easty Lecture, Bowman Club, Royal College of Surgeons, **Edinburgh**
Symposium Organizer, French Ophthalmology Society, **Paris, France**
Meeting of the European Ophthalmology Society, **Geneva, Switzerland**
Atlantic Eye Symposium, **Halifax, Canada**
Joaquin Barraquer Lecture, Spanish Congress of Ophthalmology, **Oviedo, Spain**
Inflammation and Ocular Surface Focus Group, **Barcelona, Spain**
International Symposium on Ocular Pharmacology & Therapeutics, **Vienna, Austria**
ARVO Foundation for Frontiers in Eye Research, **Ft. Lauderdale, FL**
American Academy of Ophthalmology, Cornea Subspecialty Day, **Orlando, FL**
Grand Rounds, Massachusetts Eye and Ear Infirmary, **Boston, MA**
- 2010** 6th International TFOS Conference, **Florence, Italy**
Symposium on Transplantation, Asian Cornea Society, **Kyoto, Japan**
Dry Eye Summit, **Ft. Lauderdale, FL**
Visiting Professor, UCLA Jules Stein Eye Institute, **Los Angeles, CA**
Inflammation and Ocular Surface Focus Group, **Chicago, IL**
National Eye Institute Planning Workshop on Ocular Pain, **Airlie Center, VA**
World Cornea Congress VI, **Boston, MA**
AVS Symposium, Federation of Clinical Immunology Societies, **Boston, MA**
Greater Boston Sjogren's Syndrome Foundation, Tufts University, **Boston, MA**
- 2009** Visiting Professor, University of Montreal, **Montreal, CA**
Chair, Cornea Symposium, European Soc. Ophthalmology, **Amsterdam, Holland**
International Society for Contact Lens Research, **Crete, Greece**
Inflammation and Ocular Surface Focus Group, **Montreal, Canada**
International Symposium on Ocular Pharmacology & Therapeutics, **Rome, Italy**
Alcon Research Institute Award Lecture, **Fort Worth, Texas**
Visiting Professor, Columbia University, **New York, NY**

- Visiting Professor, Mount Sinai School of Medicine, **New York, NY**
Visiting Professor, Cole Eye Institute, Cleveland Clinic, **Cleveland, OH**
Editors' Choice Symposium, American Academy of Ophthalmology, **San Francisco, CA**
Frontiers in Vision Science, Tufts University, **Boston, MA**
- 2008** International Symposium on Ocular Pharmacology & Therapeutics, **Budapest**
Inflammation and Ocular Surface Focus Group, **Dublin, Ireland**
Workshop on Role of Lipids in Dry Eye and Inflammation, **Sanremo, Italy**
State of the Art Lecture, Int'l Congress of the Transplantation Society, **Sydney**
Pan-Hellenic Ocular Inflammation and Infection Meeting, **Thessaloniki, Greece**
Keynote Speaker, Iranian Congress of Ophthalmology, **Tehran, Iran**
Special Interest Group Co-organizer & Moderator, ARVO, **Ft. Lauderdale, FL**
Visiting Professor, Johns Hopkins University, Wilmer Eye Institute, **Baltimore, MD**
150th Anniversary Conference Lecture, Illinois Eye & Ear Infirmary, **Chicago, IL**
Dana-Farber/Harvard Cancer Care Blood and Marrow Transplant Center, **Boston**,
3rd Biennial Symposium on Traumatic Eye and Brain Injury, **Boston, MA**
New England Ophthalmological Society, **Boston, MA**
- 2007** Inflammation and Ocular Surface Focus Group, **Paris, France**
Combined Meeting of the European Ophthalmology Society and AAO, **Vienna**
Visiting Professor, Kresge Eye Institute, Wayne State University, **Detroit MI**
Cullen Symposium on Ocular Surface Inflammation, Baylor College Med., **Houston**
The 25th Boston Biennial Cornea Conference, **Boston, MA**
- 2006** International Symposium on Ocular Pharmacology and Therapeutics, **Berlin**
2nd International Workshop on Corneal Immunology, **Berlin, Germany**
International Congress for Eye Research, **Buenos Aires, Argentina**
Visiting Professor, U of Louisville Department of Ophthalmology, **Louisville, KY**
9th Annual Ocular Drug & Surgical Therapies Meeting, **Dana Point, CA**
Visiting Professor, Case Western Reserve University, **Cleveland, OH**
Grand Rounds Speaker, Department of Ophthalmology, UCSF, **San Francisco, CA**
Postgraduate Course: Basic Science Update, World Transplant Congress, **Boston**
New England Ophthalmological Society, **Boston, MA**
- 2005** Keynote Speaker, Paraguayan Ophthalmological Society, **Asuncion, Paraguay**
World Cornea Congress V, **Washington DC**
Cullen Symposium on Ocular Surface Inflammation, Baylor University, **Houston**
J&J Materials Symposium- New Technologies for Contact Lenses, **Jacksonville, FL**
National Eye Inst. Symposium on the Clinician Scientist, **Ft. Lauderdale, FL**
- 2004** Keynote Speaker, 28th All-Japan Cornea Conference, **Yonago, Japan**
Visiting Professor, Kyoto Prefectural University, **Kyoto, Japan**
Annual Meeting of the German Ophthalmological Society, **Berlin, Germany**
Symposium on Corneal Immunology, EVER, **Faro, Portugal**
Keynote Speaker, 4th TFOS Conference, **San Juan, Puerto Rico**
Alta Lecture, University of California-San Francisco, **San Francisco, CA**

- Folkman Angiogenesis Conference, U. Pittsburgh, **Pittsburgh, PA**
Grand Rounds, Brigham and Women's Division of Rheumatology, **Boston, MA**
Sjogren's Syndrome Foundation- New England Chapter, **Braintree, MA**
- 2003** International Workshop in Ocular Immunology, **Ettal, Germany**
Colorado Rheumatism Society, **Denver, CO**
Dept. of Immunology and Microbiology, Dartmouth Medical Center, **Hanover, NH**
First Harvard-wide Workshop on Cell Death and the Eye, **Boston, MA**
Dohlman Lecture, 23rd Boston Biennial Cornea Conference, **Boston, MA**
New England Ophthalmological Society, **Boston, MA**
- 2002** Visiting Professor, Kyoto Prefectural University, **Kyoto, Japan**
Course Co-Director, Harvard Medical International Master Workshop in Design and
Conduct of Clinical Research, **Tokyo, Japan**
International Workshop in Ocular Immunology, **Ettal, Germany**
International Symposium on Frontiers in Immunology, and Transplantation, **London, UK**
First International Workshop on Corneal Immunology, **Bermuda**
Peter C. Kronfeld Memorial Lecture, Illinois Eye & Ear Infirmary, **Chicago, IL**
Biennial Cornea Conference, Wills Eye Hospital, **Philadelphia, PA**
Transplantation Biology Research Center, Massachusetts General Hospital, **Boston**
New England Ophthalmological Society, **Boston, MA**
- 2001** Inst. Ophthalmology & Dept. of Immunology, University College London, **London**
Symposium on Corneal Immunology, EVER, **Alicante, Spain**
American Uveitis Society Winter Symposium, **Vail, CO**
Visiting Professor, Oregon Health Sciences University, **Portland, OR**
Minisymposium on Ocular Immune Regulation and Immunotherapy, **Ft. Lauderdale, FL**
Distinguished Speaker, U. of Alabama-Mobile, Department of Immunology, **Mobile, AL**
Annual Meeting of the American College of Rheumatology, **San Francisco, CA**
Rheumatology Grand Rounds, SUNY Stony Brook Dept. of Medicine, **Stony Brook NY**
Tufts University Department of Ophthalmology Research Conference, **Boston, MA**
Wellman Laboratory for Photomedicine, Mass. General Hospital, **Boston, MA**
Second Symposium on Sjogren's and Allied Disorders, **Boston, MA**
- 2000** Visiting Professor, Federal U. S. Paulo, Paulista Sch Medicine, **Sao Paulo, Brazil**
XIV International Congress of Eye Research, **Santa Fe, NM**
3rd International TFOS Conference, **Maui, HI**
American Academy of Ophthalmology, **Dallas, TX**
Visiting Professor, Tufts University-New England Eye Center, **Boston, MA**
50th Anniversary Scientific Symposium of Schepens Eye Research Inst. **Boston, MA**
New England Ophthalmological Society, **Boston, MA**
- 1999** International Workshop on the Meibomian Gland, **Coral Gables, FL**
Research to Prevent Blindness National Science Writers Seminar, **Los Angeles, CA**
10th National Conference on Sjogren's Syndrome, **Cleveland, OH**
Ocular Microbiology and Immunology Group, **Orlando, FL**

- Eye Bank Association of America, **Orlando, FL**
Symposium on Sjogren Syndrome and Allied Disorders, **Boston, MA**
Tufts University-New England Eye Center, **Boston, MA**
New England Ophthalmological Society, **Boston, MA**
- 1998** 1st International Symposium on Ocular Immunology, **Amsterdam, Netherlands**
Loma Linda University Department of Ophthalmology, **Loma Linda, CA**
Ocular Microbiology and Immunology Group, **New Orleans, LA**
Castroviejo Cornea Society, **New Orleans, LA**
Allergy and Immunology Conference, Children's Hospital, **Boston, MA**
Longwood Medical Area Ophthalmology Grand Rounds, **Boston, MA**
- 1997** Grand Rounds Speaker, Dept. of Medicine, NYU Medical School, **New York, NY**
Grand Rounds, Brigham and Women's Hospital Division of Rheumatology, **Boston**
- 1996** 4th New England Immune Regulation Meeting, U of Connecticut, **Farmington, CT**
- 1995** 3rd New England Immune Regulation Meeting, Brown University, **Providence, RI**
Grand Rounds, Brigham and Women's Hospital Division of Rheumatology, **Boston**
- 1994** Wills Eye Hospital Biennial Cornea Conference, **Philadelphia, PA**

Scientific Innovations / Patents

1. Dana R. Local use of IL-1Ra for prophylaxis and treatment of corneal transplant rejection and other immune and inflammatory disorders of the eye. US 60/077,186; PCT/US97/21393. Filed November 19, 1997
2. Dana R. Use of soluble tumor necrosis factor receptor I (sTNFRI) to promote survival of corneal transplants and treat inflammatory disorders of the eye. US60/107,351; PCT/US99/26262. Filed November 6, 1998.
3. Dana R, Vaishnav A, Burkly L, Adelman B. Use of CD40:CD154 binding interrupter to treat immunological complications of the eye. US 60/229,491; PCT/US00/28945. Filed August 31, 2000.
4. Dana R, Kazlauskas A. Promotion of corneal graft survival by anti-apoptotic gene therapy. US 60/304,975. Filed July 2001.
5. Dana R, Chen L, Streilein JW. Method of suppressing immunity by inhibiting trafficking of antigen-presenting cells. US Patent Application 60/447,570. Filed February 2003
6. Dana R, Schaumberg DA. Topical use of a combination of fatty acids for treatment of ocular surface and adnexal inflammation. US 60/475,194. Filed June 2003.
7. Dana R, Schaumberg DA, Molock F, Copper L, Mahadevan S, Lorenz K, Rashid S. Compositions and methods for treating eye disorders and conditions. US 60/584,514; PCT/US2005/223113. Filed June 30, 2006.
8. Dana R, Dastjerdi M. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues. US 60/965,135; PCT/US2008/009776. Filed August 15, 2008.
9. Dana R, Chauhan S. Therapeutic compositions for treatment of ocular inflammatory disorders. US 61/010,566; PCT/US2009/000114. Filed September 1, 2009.
10. Dana R, Dastjerdi, M. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues. US 61/130,687; PCT/US2008/009776. Filed August 16, 2008.
11. Serhan C, Dana R, Jin Y. Use of novel lipid mediators to inhibit angiogenesis. US 61/047,881; PCT/US2009/041759. Filed April 29, 2009.
12. Dana R, Dastjerdi M, Chauhan S. Therapeutic compositions for treatment of corneal disorders. US 61/143,561; PCT/US2010/020646. Filed January 3, 2011.
13. Dana R, Saban D. Compositions and methods for treating inflammatory conditions of the ocular surface. US 61/446,086; PCT/US2012/026495. Filed February 24, 2012.

14. Dana R, Chauhan S. Therapeutic compositions for the treatment of dry eye disease. US 61/331,278; PCT/US2011/026316. Filed November 5, 2012.
15. Dana R, Hamrah P, Cavalcanti B. Inflammatory eye disorders. US 61/601,149; PCT/US2013/027181. Filed February 21, 2013.
16. Dana R, Amparo Pulido F, Wang H. Calculating conjunctival redness. US 61/601,484; PCT/US2013/027132. Filed February 21, 2013.
17. Dana R, Chauhan S, Kodati S, Saban D. Use of C-C chemokine receptor type 7 (CCR7) inhibitors. US 61/736,976. PCT/US2013/075095. Filed December 12, 2013
18. Dana R. Corneal fluorescein staining quantifying system. US 61/988,144. Filed May 2, 2014.
19. Chauhan S, Dana R. Compositions and Methods for Prevention and Treatment of Corneal Haze and Scarring. US 62/217,611. Filed September 11, 2015.
20. Dana R, Chen Y. A novel therapeutic approach targeting memory Th17 cell-mediated ocular immunoinflammatory diseases. Filed February 2, 2015.
21. Dana R, Khademhosseini A, Kheirkhah A, Annabi N. Bioadhesive for Corneal Repair. US Provisional Application No. 62/292,752.

Publications: h-index = 77; i-10 index = 262; >22,000 citations per Google Scholar

Peer-Reviewed Publications (Select Publications highlighted):

1. Young EM, Olkowski ST, **Dana R**, Mallette RA, Stark WJ. Pretreatment of donor corneal endothelium with ultraviolet-B irradiation. *Transplantation Proc* 1989; 21:3145-6. PMID 2468253
2. **Dana R**, Tielsch JM, Enger C, Joyce E, Santoli JM, Taylor HR. Visual impairment in a rural Appalachian community. Prevalence and causes. *JAMA* 1990; 264: 2400-5. PMID: 2231996
3. **Dana R**, Olkowski ST, Ahmadian H, Stark WJ, Young EM. Low-dose ultraviolet-B irradiation of donor corneal endothelium and graft survival. *Invest Ophthalmol Vis Sci.* 1990; 31: 2261-8. PMID: 2242992
4. **Dana R**, Putz JL, Viana MAG, Sugar J, McMahon TT. Contact lens failure in keratoconus management. *Ophthalmology* 1992; 99: 1187-92. PMID: 1513569
5. **Dana R**, Werner MS, Viana MAG, Shapiro MJ. Spontaneous and traumatic vitreous hemorrhage. *Ophthalmology* 1993; 100: 1377-83. PMID: 8371927
6. **Dana R**, Mori MT, Chandler JW, McMahon TT. Artificial orbit for experimental surgery on the anterior segment. *Arch Ophthalmol* 1994; 112: 125-8. PMID: 8285880
7. **Dana R**, Hochman M, Viana MAG, Hill C, Sugar J. Ocular manifestations of leprosy in the United States. *Arch Ophthalmol* 1994; 112: 626-9. PMID: 8185519
8. **Dana R**, Viana MAG, Mori MT, Chandler JW, McMahon TT. Dynamic shifts in corneal topography after radial and transverse keratotomy. *Ophthalmology* 1994; 101: 1818-26. PMID: 7800363
9. Werner MS, **Dana R**, Viana MAG, Shapiro MJ. Predictors of occult scleral rupture. *Ophthalmology* 1994; 101: 1941-44. PMID: 7997332
10. **Dana R**, Goren MB, Gomes JAP, Laibson PR, Rapuano CJ, Cohen EJ. Suture erosion after penetrating keratoplasty. *Cornea* 1995; 14: 243-8. PMID: 7600806
11. Gomes JAP, **Dana R**, Dua HS, Goren MB, Laibson PR, Cohen EJ. Positive donor rim culture in penetrating keratoplasty. *Cornea* 1995; 14: 457-62. PMID: 8536457
12. **Dana R**, Moyes AL, Gomes JAP, Rosheim KM, Schaumberg DA, Sugar A, Holland EJ, Laibson PR, Sugar J. The indications for and outcome in pediatric keratoplasty: a multicenter study. *Ophthalmology* 1995; 102: 1129-1138. PMID: 9097737

13. **Dana R**, Schaumberg DA, Kowal VA, Goren MB, Rapuano CJ, Laibson PR, Cohen EJ. Corneal neovascularization after penetrating keratoplasty. *Cornea* 1995; 14: 604-9. PMID: 8575183
14. **Dana R**, Schaumberg DA, Moyes AL, Gomes JAP, Laibson PR, Holland EJ, Sugar A, Sugar J. Outcome of penetrating keratoplasty after ocular trauma in children. *Arch Ophthalmol* 1995; 113: 1503-7. PMID: 7487616
15. **Dana R**, Merayo-Llodes J, Schaumberg DA, Foster CS. Prognosticators for visual outcome in sarcoid uveitis. *Ophthalmology* 1996; 103: 1846-53. PMID: 8942880
16. Schaumberg DA, **Dana R**. The epidemiology of world blindness. *Prac Opt* 1996; 7: 192-6.
17. **Dana R**, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. *Invest Ophthalmol Vis Sci*. 1996; 37: 2485-94. PMID: 8933765
18. **Dana R**, Merayo-Llodes J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. *Ophthalmology* 1997; 104: 236-44. PMID:9052627
19. Goren MB, **Dana R**, Rapuano CJ, Gomes JAP, Cohen EJ, Laibson PR. Corneal topography after selective suture removal for astigmatism following keratoplasty. *Ophthalmic Surgery and Lasers* 1997; 28: 208-14. PMID: 9076794
20. **Dana R**, Yamada J, Streilein JW. Topical interleukin-1 receptor antagonist promotes corneal transplant survival. *Transplantation* 1997; 63: 1501-7. PMID: 9175817
21. Streilein JW, **Dana R**, Ksander BR. Immunity causing blindness. Five paths to herpes stromal keratitis. *Immunology Today* 1997; 18: 443-9. PMID: 9293161
22. **Dana R**, Chatzistefanou K, Schaumberg DA, Foster CS. Posterior capsular opacification after cataract surgery in uveitis patients. *Ophthalmology* 1997; 104: 1387-94. PMID: 9307631
23. **Dana R**, Schaumberg DA, Moyes AL, for the Multicenter Pediatric Keratoplasty Study Group. Corneal transplantation in children with Peters anomaly and other mesenchymal dysgeneses. A multicenter study. *Ophthalmology* 1997; 104: 1580-6. PMID: 9331194
24. Schaumberg DA, Snow KK, **Dana R**. The epidemic of Acanthamoeba keratitis. Where do we stand? *Cornea* 1998; 17: 3-10. PMID: 9436873
25. **Dana R**, Dai R, Zhu S, Yamada J, Streilein JW. Interleukin-1 receptor antagonist suppresses corneal Langerhans cell activity and promotes ocular immune privilege, *Invest Ophthalmol Vis Sci* 1998; 39: 70-7. PMID: 9430547

26. Sullivan DA, Rocha EM, Ullman MD, Krenzer KL, Gao J, Toda I, **Dana R**, Wickman LA. Androgen regulation of the meibomian gland. *Adv Exp Med Biol* 1998; 438: 327-31. PMID: 9634904
27. Schaumberg DA, **Dana R**, Christen WG, Glynn RJ. A systematic overview of the incidence of posterior capsular opacification. *Ophthalmology* 1998; 105: 1213-21. PMID: 9663224
28. **Dana R**, Zhu S, Yamada J. Topical modulation of interleukin-1 activity in corneal inflammatory neovascularization. *Cornea* 1998; 17: 403-9., PMID: 9430547
29. Yamada J, **Dana R**, Zhu S, Alard P, Streilein JW. Interleukin 1 receptor antagonist suppresses allosensitization in corneal transplantation. *Arch Ophthalmol* 1998; 116: 1351-57. PMID:9790635
30. Schaumberg DA, Ridker P, Glynn R, Christen W, **Dana R**, Hennekens C. High levels of plasma C-reactive protein and future risk of age-related cataract. *Ann Epidemiology* 1999; 9: 166-71. PMID: 10192648
31. Goslings WRO, Yamada J, **Dana R**, Streilein JW, Prodeus AP, Carroll MC, Jager MJ. Corneal transplantation in antibody-deficient hosts. *Invest Ophthalmol Vis Sci*.1999; 40:250-3. PMID: 9888452
32. Streilein JW, Yamada J, **Dana R**, Ksander BR. Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. *Transplantation Pr* 1999; 31: 1472-5. PMID: 10330973
33. Sullivan DA, Krenzer KL, Sullivan BD, Bazzinotti D, Toda I, **Dana R**. Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency? *Invest Ophthalmol Vis Sci*. 1999; 40: 1261-5. PMID: 10235562
34. Schaumberg DA, Moyes AL, Gomes AP, **Dana R**. Corneal transplantation in young children with hereditary endothelial dystrophy. *Am J Ophthalmol* 1999; 127: 373-8. PMID: 10218688
35. Dekaris I, Zhu S, **Dana R**. Tumor necrosis factor-alpha regulates corneal Langerhans cell migration. *J Immunol* 1999; 162: 4235-9. PMID: 10201952
36. Zhu S, **Dana R**. Expression of cell adhesion molecules on limbal and neovascular endothelium in corneal inflammatory neovascularization. *Invest Ophthalmol Vis Sci* 1999; 40: 1427-34. PMID: PMID: 10359324
37. Zhu SN, Dekaris I, Duncker G, **Dana R**. Early expression of pro-inflammatory cytokines interleukin-1 and tumor necrosis factor-alpha after corneal transplantation. *J Interfer Cytokine Res* 1999; 19: 661-9.

38. Sullivan DA, Wickham LA, Rocha EM, Krenzer KL, Sullivan BD, Steagall R, Cermak J, **Dana R** et al. Androgens and dry eye in Sjogren's syndrome. *Ann NY Acad Sci* 1999; 876: 312-24.
39. Yamagami S, Miyazaki D, Ono SJ, **Dana R**. Differential chemokine gene expression in corneal transplant rejection. *Invest Ophthalmol Vis Sci*. 1999; 40: 2892-7.
40. Dekaris I, Yamada J, Streilein JW, **Dana R**. Effect of topical interleukin-1 receptor antagonist (IL-1ra) on corneal allograft survival in presensitized hosts. *Curr Eye Res* 1999; 19: 456-9.
41. Yamada J, Streilein JW, **Dana R**. Role of tumor necrosis factor receptors TNFR-I (p55) and TNFR-II (p75) in corneal transplantation. *Transplantation* 1999; 68: 944-9.
42. Keane-Myers AM, Miyazaki D, Liu G, Dekaris I, Ono SJ, **Dana R**. Prevention of allergic eye disease by treatment with IL-1 receptor antagonist. *Invest Ophthalmol Vis Sci* 1999; 40: 3041-6.
43. Zhu SN, Yamada J, Streilein JW, **Dana R**. ICAM-1 deficiency suppresses host allosensitization and rejection of MHC-disparate corneal transplants. *Transplantation* 2000; 69: 1008-13.
44. **Dana R**, Qian Y, Hamrah P. Twenty-five year panorama of corneal immunology: Emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. *Cornea* 2000; 19: 625-43.
45. Qian Y, Dekaris I, Yamagami S, **Dana R**. Topical soluble tumor necrosis factor alpha receptor I suppresses ocular chemokine gene expression and rejection of allogeneic corneal transplants. *Arch Ophthalmol* 2000; 118: 1666-71.
46. Yamada J, Zhu SN, Streilein JW, **Dana R**. Interleukin-1 receptor antagonist therapy and induction of anterior chamber associated immune deviation (ACAID)-type tolerance after corneal transplantation. *Invest Ophthalmol Vis Sci*. 2000; 41: 4203-8.
47. Sullivan BD, Evans JE, Krenzer KL, **Dana R**, Sullivan DA. Impact of anti-androgen treatment on the fatty acid profile of neutral lipids in human meibomian gland secretions. *J Cl Endocr Metabolism* 2000; 85: 4866-73.
48. Krenzer KL, **Dana R**, Ullman MD, Cermak JM, Tolls DB, Evans JE, Sullivan DA. Effect of androgen deficiency on the human meibomian gland and ocular surface. *J Cl Endocr Metabolism* 2000; 85: 4874-82.
49. Graham M, Azar N, **Dana R**. Visual rehabilitation in children with congenital hereditary endothelial dystrophy. *Int Ophthalmol Cl* 2001; 41: 9-18.

50. Balaram M, Schaumberg DA, **Dana R**. Efficacy and tolerability outcomes after silicone punctal occlusion in dry eye syndromes. *Am J Ophthalmol* 2001; 131: 30-36.
51. Khadem J, **Dana R**. Photodynamic biologic tissue glue in perforating rabbit corneal wounds. *J Cl Laser Med Surg* 2001; 18: 125-9.
52. Qian Y, Boisgerault F, Benichou G, **Dana R**. Blockade of CD40-CD154 costimulatory pathway promotes survival of allogeneic corneal transplants. *Invest Ophthalmol Vis Sci*. 2001; 42: 987-94.
53. Qian Y, **Dana R**. Molecular mechanisms of immunity in corneal allotransplantation and xenotransplantation. *Expert Rev Mol Med* 2001; 3: 1-21.
54. Boisgerault F, Liu Y, Anosova N, Ehrlich E, **Dana R**, Benichou G. Role of CD4+ and CD8+ T cells in allorecognition. Lessons from corneal transplantation. *J Immunol* 2001; 167: 1891-1899.
55. Yamagami S, **Dana R**. The critical role of lymph nodes in corneal alloimmunization and graft rejection. *Invest Ophthalmol Vis Sci*. 2001; 42:1293-1298.
56. Liu Y*, **Dana R***, Tewari V, Taylor AW (*co-first authors). Immune response to intragraft antigen in draining lymph nodes after corneal transplantation is mediated by IL-12. *J Interfer Cytokine Res* 2001; 21: 813-819.
57. Balaram M, **Dana R**. Phacoemulsification in patients after allogeneic bone marrow transplantation. *Ophthalmology* 2001; 108: 1682-1687.
58. Schaumberg DA, Buring JE, Sullivan DA, **Dana R**. Hormone replacement therapy and dry eye syndrome. *JAMA* 2001; 286:2114-2119.
59. Hamrah P, Zhang Q, Liu Y, **Dana R**. Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. *Invest Ophthalmol Vis Sci*. 2002; 43: 639-646.
60. Sullivan DA, Sullivan BD, Evans JE, Schirra F, Yamagami H, Liu M, Richards SM, Suzuki T, Schaumberg DA, Sullivan RM, **Dana R**. Androgen deficiency, meibomian gland dysfunction, and evaporative dry eye. *Ann NY Acad Sci* 2002: 966:211-222.
61. Argueso P, Balaram M, Spurr-Michaud S, Keutmann HT, **Dana R**, Gipson IK. Decreased levels of goblet cell mucin MUC5AC in tears of Sjogren's syndrome patients. *Invest Ophthalmol Vis Sci*. 2002; 43: 1004-1011.
62. Sakai R, Kinouchi T, Kawamoto S, **Dana R**, Hamamoto T, Tsuru T, K Okubo, Yamagami S. Construction of human corneal endothelial cDNA library and identification of novel active genes. *Invest Ophthalmol Vis Sci* 2002; 43: 1749-1756.

63. Yamagami S, **Dana R**, Tsuru T. Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. *Cornea* 2002; 21: 405-9.
64. **Liu Y, Hamrah P, Zhang Q, Taylor AW, Dana R. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor MHC class II-positive dendritic cells derived from MHC class II-negative grafts. *J Exp Medicine* 2002; 195: 259-268.**
This article was the first to demonstrate that corneal dendritic cells (which our lab was the first to confirm reside normally in the cornea despite prior reports to the contrary) are poor in stimulating T cell responses due to low MHC class II expression. However, these cells acquire the capacity for T cell stimulatory function as they mature. Additionally, we demonstrated for the first time that corneal antigen-bearing dendritic cells migrate efficiently to draining lymphoid tissues, breaking the long-held tenet that corneal grafts are resistant to immunogenic inflammation in due to 'antigenic sequestration'.
65. Cermak JM, Papas AS, Sullivan RM, **Dana R**, Sullivan DA. Nutrient intake in women in primary and secondary Sjogren's syndrome. *Eur J Cl Nutr* 2003; 57: 328-334.
66. Suzuki T, Schaumberg DA, Sullivan BD, Liu M, Richards SM, Sullivan RM, **Dana R**, Sullivan DA. Do estrogen and progesterone play a role in the dry eye of Sjogren's syndrome? *Ann NY Acad Sci* 2002; 966: 223-225.
67. Qian Y, **Dana R**. Effect of locally administered anti-CD154 (CD40L) monoclonal antibody on survival of allogeneic corneal transplants. *Cornea* 2002; 21: 592-597.
68. Zierhut M, **Dana R**, Stern ME, Sullivan DA. Immunology of the lacrimal gland and ocular tear film. *Tr Immunol* 2002; 23: 333-335.
69. Yi DA, **Dana R**. Corneal edema after cataract surgery: incidence and etiology. *Sem Ophthalmol* 2002; 17:110-4.
70. Ohta K, Yamagami S, Wiggert B, **Dana R**, Streilein JW. Chemokine gene expression in iris-ciliary body during experimental autoimmune uveoretinitis. *Curr Eye Res* 2002; 24: 451-457.
71. Sullivan BD, Evans JE, Cermak JM, Krenzer KL, **Dana R**, Sullivan DA. Complete androgen insensitivity syndrome: effect on human meibomian gland secretions. *Arch Ophthalmol* 2002; 120:1689-1699.
72. Yamada J, **Dana R**, Sotozono C, Kinoshita S. Local suppression of IL-1 by receptor antagonist in the rat model of corneal alkali injury. *Exp Eye Res* 2003; 76:161-167.
73. Qian Y, Hamrah P, Boisgerault F, Yamagami S, Vora S, Benichou B, **Dana R**. Mechanisms of immunotherapeutic intervention by anti-CD154 (CD40L) Antibody in high-risk corneal transplantation. *J Interfer Cytokine Res* 2002; 22:1217-1225.

74. **Dana R.** Role of immunity and inflammation in corneal and ocular surface disease associated with dry eye. *Adv Exp Med Biol* 2002; 506: 729-738.
75. Hamrah P, Zhang Q, **Dana R.** Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in the conjunctiva: A potential link between lymphangiogenesis and leukocyte trafficking on the ocular surface. *Adv Exp Med Biol* 2002; 506: 851-860.
76. Schaumberg DA, Sullivan DA, **Dana R.** Epidemiology of dry eye syndrome. *Adv Exp Med Biol* 2002; 506: 989-998.
77. Sullivan RM, Cermak JM, Papas AS, **Dana R.**, Sullivan DA. Economic and quality of life impact of dry eye symptoms in women with Sjögren's Syndrome. *Adv Exp Med Biol* 2002; 506: 1183-1188.
78. Sullivan BD, Cermak JM, Sullivan RM, Papas AS, Evans JE, **Dana R.**, Sullivan DA. Correlations between nutrient intake and the polar lipid profiles of meibomian gland secretions in women with Sjögren's syndrome. *Adv Exp Med Biol* 2002; 506: 441-447.
79. Sullivan BD, Evans JE, **Dana R.**, Sullivan DA. Impact of androgen deficiency on the lipid profiles in human meibomian gland secretions. *Adv Exp Med Biol* 2002; 506: 449-458.
80. Sullivan DA, Yamagami H, Liu M, Steagall RJ, Schirra F, Suzuki T, Krenzer KL, Cermak JM, Sullivan RM, Richards S, **Dana R.**, Sullivan BD. Sex steroids, the meibomian gland and evaporative dry eye. *Adv Exp Med Biol* 2002; 506: 389-399.
81. Sullivan DA, Schaumberg DA, Suzuki T, Schirra F, Liu M, Richards S, Sullivan RM, **Dana R.**, Sullivan BD. Sex steroids, meibomian gland dysfunction and evaporative dry eye in Sjögren's syndrome. *Lupus* 2002; 11:667.
82. Hamrah P, Liu Y, **Dana R.** The corneal stroma is endowed with significant numbers of resident dendritic cells. *Invest Ophthalmol Vis Sci.* 2003; 44:581-589.
83. Cermak JM, Krenzer KL, Sullivan RM, **Dana R.**, Sullivan DA. Is complete androgen insensitivity syndrome associated with alterations in the meibomian gland and ocular surface? *Cornea* 2003; 22:516-521.
84. Schaumberg DA, Sullivan DA, Buring JE, **Dana R.** Prevalence of dry eye syndrome among US women. *Am J Ophthalmol* 2003; 136:318-326.
85. Hamrah P, Huq S, Liu Y, Zhang Q, **Dana R.** Corneal immunity is mediated by heterogeneous population of antigen-presenting cells. *J Leuk Bio* 2003; 4:172-176.
86. Mendes F, Schaumberg DA, Navon S, Steinert R, Sugar J, Holland EJ, **Dana R.** Assessment of visual function after corneal transplantation – The quality of life and psychometric assessment after corneal transplantation (Q-PACT) study. *Am J Ophthalmol* 2003; 135:785-793.

87. Cursiefen C, Chen L, **Dana R**, Streilein JW. Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. *Cornea* 2003; 22:273-281.
88. Hamrah P, Chen L, Zhang Q, **Dana R**. Novel expression of vascular endothelial growth factor receptor (VEGFR)-3 and VEGF-c on corneal dendritic cells. *Am J Path* 2003; 163:57-68.
89. Hamrah P, Liu Y, Qiang Z, **Dana R**. Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation. *Arch Ophthalmol* 2003; 121:1132-1140.
90. **Dana R**. Corneal antigen-presenting cells: Diversity, plasticity, and disguise [The Cogan Award Lecture]. *Invest Ophthalmol Vis Sci* 2004; 45:722-727.
91. Sullivan DA, Belanger, Cermak JM, Berube R, Papas AS, Sullivan RM, Yamagami H, **Dana R**, Labrie F. Are women with Sjogren's syndrome androgen-deficient? *J Rheum* 2003; 30: 2413-19.
92. Barabino S, **Dana R**. Animal models of dry eye: a critical assessment of opportunities and limitations. *Invest Ophthalmol Vis Sci* 2004; 45: 1641-46.
93. Cursiefen C, Masli S, Ng TF, **Dana R**, Bornstein P, Lawler J, Streilein JW. Roles of thrombospondin 1 and 2 in regulating corneal and iris angiogenesis. *Invest Ophthalmol Vis Sci* 2004; 45: 1117-24.
94. Qian Y, Leong F, Kazlauskas A, **Dana R**. Ex vivo adenovirus-mediated gene transfer to corneal graft endothelial cells in mice. *Invest Ophthalmol Vis Sci* 2004; 45: 2187-2193.
95. Cursiefen C, Chen L, Borges L, Jackson D, Cao J, Radziejewski C, D'Amore P, **Dana R**, Weigand SJ, Streilein JW. VEGF-A stimulates lymph- and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. *J Clin Invest* 2004; 113: 1040-50.
96. Hamrah P, Chen L, Cursiefen C, Zhang Q, Joyce NC, **Dana R**. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) on monocytic bone marrow-derived cells in the conjunctiva. *Exp Eye Res* 2004; 79: 553-561.
97. Cursiefen C, Chen L, Jackson D, **Dana R**, Streilein JW. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. *Investigative Ophthalmology and Vis Sci* 2004; 45: 2666-2673.
98. **Chen L, Hamrah L, Cursiefen C, Zhang Q, Pytowski B, Streilein JW, Dana R. Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) mediates induction of corneal immunity. Nature Med 2004; 10: 813-815.**

Access of antigen-presenting cells (APCs) to regional lymph nodes is a critical facet in induction of corneal adaptive immunity, but the molecular mechanisms that enable APC access to lymphatics remained incompletely understood. This article demonstrated for the first time that

acquisition of VEGFR-3 by corneal dendritic cells allows them to respond chemotactically to VEGF-C, and blockade of VEGFR-3-mediated signaling suppresses APC trafficking to the lymphoid compartment, thereby inhibiting allospecific immunity and promoting graft survival. The term 'molecular lymphadenectomy' was coined by us to reflect this immunomodulatory strategy. Of note, this pathway has also been shown to be relevant for peritumor monocytes and for tumor metastasis.

99. Barabino S, Chen W, **Dana R**. Tear film and ocular surface tests in animal models of dry eye. *Exp Eye Res* 2004; 79: 613-621.
100. **Huq S, Liu Y, Benichou G, Dana R. Relevance of the direct pathway of sensitization in corneal transplantation is dictated by the graft bed microenvironment. *J Immunol* 2004; 173: 4464-4469.**
The precise function of corneal graft-derived antigen-presenting cells (APC) presenting donor MHC ('direct priming') was the subject of significant controversy. In this article, we demonstrated for the first time, in any tissue, that the graft bed microenvironment dictates the functional maturity of graft APCs, and hence their relevance to alloimmunity: specifically, host beds at high risk of rejecting their transplants promote acquisition of high levels of MHC-II and accessory molecules (CD80/CD86/CD40) by APC that efficiently migrate out of the eye to lymphoid compartments to prime allospecific Th1 cells that effect graft destruction.
101. Khadem J, Martino M, Anatelli F, **Dana R**, Hamblin R. Healing of perforating rat corneal incisions closed with photodynamic laser-activated tissue glue. *Lasers Surg Med.* 2004; 35: 304-311.
102. Schaumberg DA, Mendes F, Balaram M, **Dana R**, Sparrow D, Hu H. Accumulated lead exposure and risk of age-related cataract in men. *JAMA* 2004; 292: 2750-54.
103. Yamagami S, Pedram Hamrah P, Dekaris I, Miyazaki D, Dawson T, Lu B, Gerard C, **Dana R**. CCR5 chemokine receptor mediates recruitment of MHC class II-positive Langerhans cells in the mouse corneal epithelium. *Invest Ophthalmol Vis Sci.* 2005; 46: 1201-7.
104. Yi D, Rashid S, **Dana R**. Acute unilateral leukemic hypopyon in relapsing acute lymphoblastic leukemia. *Am J Ophthalmol* 2005; 139: 719-721.
105. Cursiefen C, Ikeda S, Smith RS, Jackson J, Mo JS, Chen L, Pytowski B, **Dana R**, Streilein JW. Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3-signaling. *Am J Pathology* 2005; 166: 1367-77.
106. Barabino S, Shen LL, Chen L, Rashid S, Rolando M, **Dana R**. The controlled environment chamber: A new mouse model for dry eyes. *Invest Ophthalmol Vis Sci.* 2005; 46: 2766-2771. PMID: 16043849.
107. Yamagami S, Hamrah P, Zhang Q, Liu Q, Huq S, **Dana R**. Early ocular chemokine gene expression and leukocyte infiltration after high-risk corneal transplantation. *Mol Vision* 2005; 11: 632-640. PMID: 16145544.

108. Barabino S, Raghavan A, Loeffler J, **Dana R**. Radiotherapy-induced ocular surface disease. *Cornea* 2005; 8: 909-914. PMID: 16227831.
109. Miljanovic B, Trivedi KA, **Dana R**, Gilbard JP, Buring JE, Schaumberg DA. The relationship between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. *Am J Cl Nutr* 2005; 82: 887–93.
110. Balaram M, Rashid S, **Dana R**. Chronic ocular surface disease after allogeneic bone marrow transplantation. *Ocular Surface* 2005; 3: 203-210.
111. Chen L, Cursiefen C, Barabino S, Zhang Q, **Dana R**. Novel expression and characterization of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1) by conjunctival cells. *Invest Ophthalmol Vis Sci.* 2005; 46: 4536-40. PMID: 16303945.
112. Beauregard C, Huq SO, Barabino S, Zhang Q, Kazlauskas A, **Dana R**. Keratocyte apoptosis and failure of corneal allografts. *Transplantation* 2006; 81: 1577-82. PMC1479606.
113. Tsai PS, Evans JE, Green KM, Sullivan R, Schaumberg DA, Richards SM, **Dana R**, Sullivan DA. Proteomic analysis of human meibomian gland secretions. *Br J Ophthalmology* 2006; 90:372-7. PMC1856970.
114. Gulati A, Saccheti M, Bonini S, **Dana R**. Chemokine Receptor CCR5 Expression in conjunctival epithelium of patients with dry eye syndrome. *Arch Ophthalmol* 2006; 124: 710-716. PMID: 16682594. PMD: 1397798
115. **Dana R**, Nussenblatt R, Gordon L. Advances in immunology: From bench to bedside. *Ocular Immunol Infl* 2006; 14:1-6.
116. Sullivan BD, Evans JE, **Dana R**, Sullivan DA. Influence of aging on the polar and neural lipid profiles in human meibomian gland secretions. *Arch Ophthalmol* 2006; 124:1286-1292. PMID: 16966624.
117. **Dana R**. Angiogenesis and lymphangiogenesis: Novel implications for corneal immunity. *Sem Ophthalmol* 2006; 21:19-22.
118. Gulati A, Sullivan R, Buring JE, Sullivan DA, **Dana R**, Schaumberg DA. Validation and repeatability of a short questionnaire for dry eye syndrome. *Am J Ophthalmol* 2006; 142: 125-131. PMID: 16815260.
119. **Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S, Pytowski B, Persaud K, Wu Y, Streilein JW, Dana R. Nonvascular VEGFR-3 expression by corneal epithelium maintains avascularity and vision. Proc Nat Acad Sci USA 2006; 103: 11405-11410. PMC1544098.**

This article described a novel and critical mechanism contributing to corneal avascularity: VEGF receptor-3, normally present only on lymphatic and proliferating blood vascular endothelium, is constitutively expressed at high levels by the corneal epithelium but in a non-

signaling form that acts as a decoy receptor for VEGF-C and VEGF-D, thus binding these ligands and suppressing their ligation of VEGF receptors on vascular and lymphatic endothelial cells. This decoy receptor is mechanistically responsible for "corneal angiogenic privilege".

120. Schaumberg DA, Gulati G, Mathers WD, Clinch T, Lemp M, Nelson JD, Foulks GN, **Dana R**. Development and validation of a global dry eye symptom index. [Innovative Techniques and Technology] *Ocular Surface* 2007; 5: 50-57. PMID: 17252166.
121. Chen L, Huq S, Gardner H, de Fougères AR, Barabino S, **Dana R**. Very Late Antigen (VLA)-1 Blockade markedly promotes survival of corneal allografts. *Arch Ophthalmol* 2007; 125: 783-788. PMC2677688.
122. Hamrah P, Yamagami S, Liu Y, Zhang Q, Vora SS, Lu B, Gerard CJ, **Dana R**. Deletion of the chemokine receptor CCR1 prolongs corneal allograft survival. *Invest Ophthalmol Vis Sci.* 2007; 48: 1228-1236. PMC1868492.
123. Miljanović B, **Dana R**, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. *Am J Ophthalmol* 2007; 143: 409-15. PMC1847608.
124. Shen L, Barabino S, Taylor AW, **Dana R**. The effect of the ocular microenvironment in regulating corneal dendritic cell maturation. *Arch Ophthalmol* 2007; 125: 908-915. PMID: 17620569. NIHMSID: 370114.
125. No authorship. Research in dry eye: report of the research subcommittee of the international dry eye workshop. *Ocular Surface* 2007; 5:179-194. PMID: 17508121.
126. Barabino S, Rolando M, Chen L, **Dana R**. Exposure to a dry environment induces strain-specific responses in mice. *Exp Eye Res* 2007; 84:973-977. PMID: 17397831.
127. Collins JF, Dartt DA, **Dana R**. Mist delivery of eye medication to the anterior segment. *Am J Ophthalmol* 2007; 144:137-139. PMID: 17601439.
128. Jin Y, Shen L, Chong EM, Hamrah P, Zhang Q, Chen L, **Dana R**. The chemokine receptor CCR7 mediates corneal antigen-presenting cell trafficking. *Mol Vis* 2007; 13: 626-634. PMC2669510.
129. Chong E-M, **Dana R**. Immunologic mechanisms of corneal transplant rejection. *Int Ophthalmology* [Special Issue on Corneal Transplantation] 2007. PMID 17673946.
130. Barcia R, **Dana R**, Kazlauskas A. Corneal graft rejection is accompanied by apoptosis of the endothelium and is prevented by gene therapy with Bcl-xL. *Am J Transplantation*, 2007; 7:2082-2089. PMID: 17614980.
131. Nakao S, Hata Y, Miura M, Kimura YN, Kawahara S, Kita T, Jin Y, **Dana R**, Kuwano M, Ono M, Ishibashi T, Hafezi-Moghadam A. Dexamethasone inhibits IL-1 beta-induced corneal neovascularization: role of NF-κB-activated stromal cells in inflammatory angiogenesis. *Am J Pathol* 2007; 171: 1058-1065. PMC1959485.

132. Chen L, Hamrah P, Cursiefen C, Zhang Q, Pytowski B, Streilein JW, **Dana R**. VEGFR-3 mediates induction of corneal alloimmunity. *Ocul Immunol Inflamm* 2007; 15: 275-278. PMID: 17613841.
133. Harissi-Dagher MH, **Dana R**, Jurkunas U. Keratoglobus in association with posterior polymorphous dystrophy. *Cornea* 2007; 26: 1288-1891. PMID: 18043197.
134. Shen L, Jin Y, Freeman GJ, Sharpe AH, **Dana R**. The function of donor versus recipient PD-L1 in corneal allograft survival. *J Immunology* 2007; 179: 3672-3679. PMID: 17785803. PMC
135. **Dana R**. Comparison of topical interleukin-1 versus tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (AOS Thesis). *Trans Am Ophthalmol Soc* 2007; 105: 330-343. PMC2258099.
136. Rashid S, Jin Y, Ecoiffier T, Barabino S, Schaumberg DA, **Dana R**. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. *Arch Ophthalmol* 2008; 126: 219-225. PMID: 18268213.
137. Bachmann B, Bock F, Wiegand S, Maruyama K, **Dana R**, Kruse F, Luetjen-Drecoll E, Cursiefen C. Promotion of graft survival by vascular endothelial growth factor A neutralization after high-risk corneal transplantation. *Arch Ophthalmol* 2008; 126: 71-77. PMID: 18195221.
138. Ecoiffier T, El Annan J, Rashid S, Schaumberg DA, **Dana R**. Modulation of integrin Alpha-4 Beta-1 (VLA-4) in dry eye syndrome. *Arch Ophthalmol* 2008; 126: 1695-1699. PMID: 19064851.
139. Boisgérault F, Liu Y, Anosova N, **Dana R**, Benichou G. Differential roles of direct and indirect allorecognition pathways in the rejection of skin and corneal transplants. *Transplantation* 2009; 87: 16-23. PMC2698296.
140. El Annan J, Chauhan SK, Ecoiffier T, Zhang Q, Saban DR, **Dana R**. Characterization of effector T cells in dry eye disease. *Invest Ophthalmol Vis Sci* 2009; 50: 3802-3807. PMC2921683.
141. Chung ES, Saban DR, Chauhan SK, **Dana R**. Regulation of blood versus lymphatic growth in the cornea. *Invest Ophthalmol Vis Sci* 2009; 50: 1613-8. PMC2702143.
142. **Chauhan SK, Saban DR, Lee HK, Dana R. Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J Immunology 2009; 182: 148-153. PMC2610348.**
Foxp3+CD4+CD25+ regulatory T cells (Tregs) play a critical functional 'switch' in immunity by regulating the priming and effector function of T cells. This article showed that far more important than Treg frequency is their level of Foxp3 expression, which is directly associated

with their capacity to produce regulatory cytokines (e.g. IL-10) and suppress T cell activation/proliferation. This article also linked graft rejection to dysfunctional Tregs that express low levels of Foxp3, CD25, and regulatory factors.

143. Schaumberg DA, **Dana R**, Buring JE, Sullivan DA. Prevalence of dry eye disease among US Men: estimates from the physicians' health studies. *Arch Ophthalmol* 2009; 127: 763-768. PMC2836718.
144. Saban DR, Chauhan SK, Zhang X, El Annan J, Jin Y, **Dana R**. Chimeric grafts assembled from multiple allodisparate donors enjoy enhanced transplant survival. *Am J Transplantation* 2009; 9: 473-483. PMC2839405.
145. **Chauhan SK, El Annan J, Ecoiffier T, Goyal S, Zhang Q, Saban DR, Dana R. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunology 2009; 182: 1247-1252. PMC2630586.**
Dry eye disease (DED) is the most common eye pathology, but very little has been known about its immunopathogenesis. This article was the first to link dry eyes to pathogenic IL-17 secreting (Th17) cells, demonstrating that the pathogenicity of these cells is linked to a defect in T regulatory cells in suppressing the function and proliferation of autoreactive Th17 cells. Additionally, we showed that blockade of IL-17 can completely prevent the induction of dry eye disease in a murine model of DED.
146. Goyal S, Chauhan SK, Zhang Q, **Dana R**. Amelioration of murine dry eye disease by topical antagonist to CC Receptor 2. *Arch Ophthalmol* 2009; 127: 882-887. PMC3587314.
147. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas U, Pineda R, Pavan-Langston D, **Dana, R**. Topical Bevacizumab in the treatment of corneal neovascularization: results of a prospective open-label, non-comparative study. *Arch Ophthalmol* 2009; 127: 381-389. PMC2703579.
148. Zhang X, Shen L, Jin Y, Saban DR, Chauhan SK, and **Dana R**. Depletion of passenger leukocytes from corneal grafts: An effective means of promoting transplant survival? *Invest Ophthalmol Vis Sci* 2009; 50: 3137-44. PMC2739689.
149. Bachmann BO, Luetjen-Drecoll E, Bock F, Wiegand SJ, Hos D, **Dana R**, Kruse FE, Cursiefen C. Transient postoperative VEGF-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation. *Br J Ophthalmol* 2009; 93: 1075-1080. PMID19224901.
150. Fabiani C, Barabino S, Rashid S, **Dana R**. Corneal epithelial proliferation and thickness in a mouse model of dry eye. *Exp Eye Res* 2009; 89: 166-171. PMC2713794.
151. Hamrah P, Haskova Z, Taylor AW, Zhang Q, Ksander BR, **Dana R**. Local treatment with alpha-melanocyte stimulating hormone reduces corneal allojection. *Transplantation* 2009; 88: 180-7. PMC2735785.

152. Dastjerdi MH, Hamrah P, **Dana R**. High frequency topical Cyclosporine 0.05% in treatment of severe dry eye refractory to twice daily regimen. *Cornea* 2009; 28: 1091-1096. PMC2924632.
153. Patel S, **Dana R**. Corneal lymphangiogenesis: Implications in immunity. *Sem Ophthalmol* 2009; 24: 135-138.
154. Chauhan SK, **Dana R**. Role of Th17 cells in the immunopathogenesis of dry eye disease. *Mucosal Immunology* 2009; 2: 375-376. PMC2719854.
155. Jin Y, Arita M, Zhang Q, Saban DR, Chauhan SK, Chiang N, Serhan CN, **Dana R**. Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. *Invest Ophthalmol Vis Sci* 2009; 50: 4743-4752. PMC2763387.
156. Chung ES, Chauhan SK, Jin Y, Nakao S, Hafezi-Moghadam A, van Rooijen N, Zhang Q, Chen L, **Dana R**. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands. *Am J Pathol* 2009; 175: 1984-1992. PMC2774062.
157. Skobe M, **Dana R**. Blocking the path of lymphatic vessels. News and Views. *Nature Med* 2009; 15: 993-994. PMC2924617.
158. Mantelli F, Schaffer L, **Dana R**, Head SR, Argüeso P. Glycogene expression in conjunctiva of patients with dry eye: down regulation and notch signaling. *Invest Ophthalmol Vis Sci* 2009; 50: 2666-2672. PMC2693254.
159. Jin Y, Chauhan SK, Saban DR, **Dana R**. Role of CCR7 in facilitating direct allo-sensitization and regulatory T cell function in high-risk corneal transplantation. *Invest Ophthalmol Vis Sci* 2010; 51: 816-821. PMC2868459.
160. Dastjerdi M, Saban DR, Okanobo A, Nallasamy N, Sadrai Z, Chauhan SK, Hajrasouliha A, **Dana R**. Effects of topical and subconjunctival bevacizumab (Avastin) in high-risk corneal transplant survival. *Invest Ophthalmol Vis Sci* 2010; 51: 2411-2417. PMC2868492.
161. El Annan J, Goyal S, Sharpe A, Freeman G, Zhang Q, **Dana R**. Regulation of T-cell chemotaxis by programmed death-ligand 1 (PD-L1) in dry eye-associated corneal inflammation. *Invest Ophthalmol Vis Sci* 2010; 51: 3418-3423. PMID: 20019373, NIHMSID: 488556. PMC3979489.
162. Goyal S, Chauhan S, **Dana R**. Evidence for corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity? *Arch Ophthalmol* 2010; 128: 819-824. PMC3089983.
163. Ahmad S, Osei-Bempong C, **Dana R**, Jurkunas U. The culture and transplantation of human limbal stem cells. *J Cell Physiol* 2010; 225: 15-19. PMID: 20506173.

164. Saban DR, Chauhan SK, Masli S, **Dana R**. Thrombospondin-1 derived from antigen-presenting cells regulates their capacity for allosensitization. *J Immunol* 2010; 185: 4691-4697. PMC3090006.
165. Hamrah P, Cruzat A, Dastjerdi MH, Zheng L, Shahatit B, Bayhan HA, **Dana R**, Pavan-Langston D. Corneal sensation and subbasal nerve alterations in patients with herpes simplex keratitis: an in vivo confocal microscopy study. *Ophthalmology* 2010; 117: 1930-1936. PMC2949523.
166. Sadrai Z, Hajrasouliha A, Chauhan S, Saban D, Dastjerdi MH, **Dana R**. Effect of topical azithromycin on corneal innate immune responses. *Invest Ophthalmol Vis Sci* 2011; 52: 2525-2531. PMC3262402.
167. Ferrari G, Ueno H, **Dana R**. A novel mouse model for neurotrophic keratopathy: trigeminal nerve stereotactic electrolysis through the brain. *Invest Ophthalmol Vis Sci* 2011; 52:2532-2539. PMC3088548.
168. Asbell P, Stapleton F, Wickstrom K, Akpek E, Aragona P, **Dana R**, Lemp M, Nichols K. The international workshop on meibomian gland dysfunction: Report of the clinical trials subcommittee. *Invest Ophthalmol Vis Sci* 2011; 52: 2065-2085. PMC3072164.
169. Jin Y, Chauhan S, Sharpe A, **Dana R**. Novel function for programmed death ligand-1: regulation of angiogenesis. *Am J Pathology* 2011; 178: 1922-1929. PMC3078456.
170. Fuchsluger T, Kazlauskas A, Jurkunas U, **Dana R**. Corneal endothelial cells are protected from apoptosis by gene therapy. *Human Gene Therapy* 2011; 22: 549-558. PMC30814401.
171. Lee HS, Chauhan S, Okanobo A, Nallasamy N, **Dana R**. Therapeutic efficacy of topical epigallocatechin gallate (EGCG) in murine dry eye. *Cornea* 2011; 30: 1465-1472. PMC3703663.
172. Fuchsluger T, Jurkunas U, Kazlauskas A, **Dana R**. Anti-apoptotic gene therapy prolongs survival of corneal endothelial cells during storage. *Gene Therapy* 2011; 18: 778-787. PMC3587653.
173. Cursiefen C, Maruyama K, Bock F, Saban D, Sadrai Z, Lawler J, **Dana R**, Masli S. Thrombospondin 1 inhibits inflammatory lymphangiogenesis via CD36-mediated monocyte regulation. *J Exp Med* 2011; 208: 1083-1092. PMC3092349.
174. Fuchsluger T, Jurkunas U, Kazlauskas A, **Dana R**. Viral vectors for gene delivery to corneal endothelial cells. *Klinische monatsblätter für Augenheilkunde* 2011; 228: 498-503. PMID: 21656431.
175. Hattori T, Chauhan S, Ueno H, **Dana R**, Kaplan D, Saban DR. Characterization of langerin expressing dendritic cell subsets in the normal cornea. *Invest Ophthalmol Vis Sci* 2011; 52: 4598-4604. PMC3175952.

176. Lee HK, Chauhan SK, Kay ED, **Dana R**. Flt-1 regulates vascular endothelial cell migration via a protein tyrosine kinase-7-dependent pathway. *Blood* 2011; 117: 5762-5771. PMC3110033.

Little has been known about the function of 'pseudokinases' including PTK-7. This paper demonstrated the critical role of PTK-7 in mediating VEGFR-1 (Flt-1)-mediated signaling. Using both immunoprecipitation and immunoblotting, PTK-7 was found to join a receptor complex with Flt-1 but not with KDR/Flk-1 (VEGFR-2) or Flt-4 (VEGFR-3). Angiogenesis induced by VEGF-A was significantly suppressed by siRNA targeting PTK7, demonstrating for the first time that PTK-7 serves an essential role in Flt-1-mediated angiogenesis.

177. Cruzat A, Witkin D, Baniasadi N, Zheng L, Jurkunas UV, Ciolino JB, Chodosh J, Pavan-Langston D, **Dana R**, Hamrah P. Inflammation and the nervous system: the connection in the cornea in patients with infectious keratitis. *Invest Ophthalmol Vis Sci* 2011; 52: 5136-5143. PMC3176064.

178. Chauhan SK, Jin Y, Goyal S, Lee HS, Fuchslugar T, Lee HK, **Dana R**. A novel pro-lymphangiogenic function for Th17/IL17. *Blood* 2011; 118: 4630-4634. PMC3208279.

This paper was the first to establish a link between IL-17, a critical cytokine in a wide array of inflammatory disorders, and growth of new lymphatics through the regulation of VEGF-D. This finding has broad and important implications (including cancer metastasis and non-ocular autoimmune diseases) since it explains that some of the function of IL-17 in amplifying adaptive T cell-mediated immunity may reside in its ability to promote access of tissue antigens and antigen-presenting cells to the lymphoid compartment where antigen-specific immunity is induced.

179. Dastjerdi M, Sadrai Z, Saban D, Zhang Q, **Dana R**. Corneal penetration of topical and subconjunctival bevacizumab (Avastin). *Invest Ophthalmol Vis Sci* 2011; 52: 8718-8723. PMC3230312.

180. Chen Y, Chauhan SK, Saban DR, Sadrai Z, Okanobo A, **Dana R**. Interferon- γ -secreting NK cells promote induction of dry eye disease. *J Leukoc Biol* 2011; 89: 965-72. PMC3100760.

181. Cursiefen C, Colin J, **Dana R**, Diaz-Llopis M, Faraj L, Garcia-Delpech S, Geerling G, Price F, Remeijer L, Rouse B, Seitz B, Udaondo P, Meller D, Dua H. Consensus statement on indications for antiangiogenic therapy in the management of corneal diseases associated with neovascularization: An expert roundtable outcome. *Ophthalmology* 2011; 96: 3-9. PMID: 21712359.

182. Stevenson W, Chauhan SK, **Dana R**. Dry eye disease: an immune-mediated ocular surface disorder. *Arch Ophthalmol* 2012; 130:90-100. PMC3677724.

183. Goyal S, Chauhan SK, **Dana R**. Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease. *Arch Ophthalmol* 2012; 130:84-9. PMC3629840.

184. Ueno H, Ferrari G, Saban D, Chauhan S, **Dana R**. Dependence of corneal stem/progenitor cells on ocular surface innervation. *Invest Ophthalmol Vis Sci* 2012; 53: 867-872. PMC3317425.
185. **Hattori T, Saban DR, Emami P, Chauhan SK, Ueno H, Dana R. Donor derived tolerogenic dendritic cells suppress immune rejection in the indirect allosensitization dominant setting of corneal transplantation. J Leuk Biol 2012; 91: 621-627. PMC3317274.**
In Huq et al (JI 2004) we had formally shown the functional relevance of the direct pathway of allosensitization in hosts with inflamed graft beds and at high-risk of rejecting their transplant. Here, we demonstrated that we can employ donor-derived dendritic cells, treat them with a 'cocktail' of regulatory cytokines which render them tolerogenic and able to significantly suppress host T cell allosensitization and promote allograft survival.
186. Hajrasouliha AR, Funaki T, Sadrai Z, Hattori T, Chauhan SK, **Dana R**. Vascular endothelial growth factor-C promotes alloimmunity by amplifying antigen presenting cell maturation and lymphangiogenesis. *Invest Ophthalmol Vis Sci* 2012; 53: 1244-1250. PMC3339906.
187. Stevenson W, Cheng SF, Dastjerdi MH, Ferrari G, **Dana R**. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs. bevacizumab (Avastin). *Ocul Surf* 2012; 10: 67-83. PMC3471139.
188. Cheng SF, Dastjerdi MH, Ferrari G, Okanobo A, Bower KS, Ryan DS, Amparo F, Stevenson W, Hamrah P, Nallasamy N, **Dana R**. Short-term topical bevacizumab in the treatment of stable corneal neovascularization. *Am J Ophthalmol* 2012; 154: 940-948. PMC3498533.
189. Hajrasouliha AR, Sadrai Z, Chauhan S, **Dana R**. b-FGF induces corneal blood and lymphatic growth in a spatially distinct pattern. *Cornea* 2012; 53: 1244-1250. PMC3669545.
190. Hamrah P, Sahin A, Dastjerdi MH, Shahatit BM, Bayhan HA, **Dana R**, Pavan-Langston D. Cellular changes of the corneal epithelium and stroma in herpes simplex keratitis: an in vivo confocal microscopy study. *Ophthalmology* 2012; 119: 1791-7. PMC3426622.
191. Sadrai Z, Stevenson W, Okanobo A, Chen Y, Dohlman T, Hua J, Amparo F, Chauhan S, **Dana R**. PDE4 inhibition suppresses IL17-associated immunity in dry eye disease. *Invest Ophthalmol Vis Sci*. 2012; 53: 3584-91. PMC3406685.
192. Okanobo A, Chauhan SK, Dastjerdi M, Kodati S, **Dana R**. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. *Am J Ophthalmol* 2012; 154: 63-71. PMC3378826.
193. Ferrari G, Ueno H, Bignami F, Rama P, **Dana R**. Trigeminal stereotactic electrolysis induces dry eye in mice. *Acta Ophthalmologica* 2013; 91: 162-3. PMC3676178.

194. Lee HS, Hattori T, Park EY, Stevenson W, Chauhan SK, **Dana R**. Expression of toll-like receptor (TLR) 4 contributes to corneal inflammation in experimental dry eye disease. *Invest Ophthalmol Vis Sci* 2012; 53: 5632-40. PMC3711695.
195. Shim J, Park C, Lee HS, Park MS, Lim HT, Chauhan S, **Dana R**, Lee H, Lee HK. Change in prostaglandin expression levels and synthesizing activities in dry eye disease. *Ophthalmology* 2012; 119: 2211-9. PMC3689228.
196. Stevenson W, Cheng SF, Emami-Naeini P, Hua J, Paschalis E, **Dana R**, Saban DR. Gamma-irradiation reduces the allogenicity of donor corneas. *Invest Ophthalmol Vis Sci* 2012; 53: 7151-8. PMC3474589.
197. Amparo F, Sadrai Z, Jin Y, Alfonso-Bartolozzi B, Wang H, Shikari H, Ciolino JB, Chodosh J, Jurkunas U, Schaumberg DA, **Dana R**. Safety and efficacy of the multi-targeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization. *Invest Ophthalmol Vis Sci* 2013; 54: 537-44. PMC3558296.
198. Hamrah P, Cruzat A, Dastjerdi MH, Prüss H, Zheng L, Shahatit BM, Bayhan HA, **Dana R**, Pavan-Langston D. Unilateral herpes zoster ophthalmicus results in bilateral corneal nerve alteration: an *in vivo* confocal microscopy study. *Ophthalmology* 2013; 120: 40-7. PMC3575640.
199. Ferrari G, Sadrai Z, Hajrasouliha A, Ueno H, Chauhan S, **Dana R**. Nerves and neovessels inhibit each other in the cornea. *Invest Ophthalmol Vis Sci* 2013; 54: 813-20. PMC3562120.
200. Chen Y, Chauhan SK, Lee HJ, Stevenson W, Schaumberg C, Sadrai Z, Saban D, Kodati S, Stern M, **Dana R**. Effect of desiccating environmental stress versus systemic muscarinic AChR blockade on dry eye immunopathogenesis. *Invest Ophthalmol Vis Sci* 2013; 54: 2457-64. PMC3623599.
201. Ferrari G, Dastjerdi MH, Okanobo A, Cheng S, Amparo F, Nallasamy N, **Dana R**. Topical ranibizumab as a treatment of corneal neovascularization. *Cornea* 2013; 32: 992-997. PMC3920979.
202. Dohlman TH, Chauhan SK, Kodati S, Hua J, Chen Y, Omoto M, Sadrai Z, **Dana R**. The CCR6/CCL20 axis mediates Th17 cell migration to the ocular surface in dry eye disease. *Invest Ophthalmol Vis Sci* 2013; 54: 4081-91. PMC3681477.
203. Ferrari G, Nalassamy N, Downs H, **Dana R**, Oaklander AL. Corneal innervation as a window to peripheral neuropathies. *Experimental Eye Res* 2013; 113: 148-50. PMC3737766.
204. Amparo F, Wang H, Emami-Naeini P, Karimian P, **Dana R**. The Ocular Redness Index: a novel automated method for measuring ocular injection. *Invest Ophthalmol Vis Sci* 2013; 54: 4821-4826. PMC3720148.

205. Amparo F, Dastjerdi MH, Okanobo A, Ferrari G, Smaga L, Hamrah P, Jurkunas U, Schaumberg DA, **Dana R**. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. *JAMA Ophthalmology* 2013; 131: 715-23. PMC4167802.
206. Amparo F, Jin Y, Hamrah P, Schaumberg DA, **Dana R**. What is the value of incorporating tear osmolarity measurement in assessing patient response to therapy in dry eye disease? *Am J Ophthalmol* 2014; 157: 69-77. PMC3865167.
207. Stevenson W, Shikari H, Saboo U, Amparo F, **Dana R**. Bilateral corneal ulceration in ocular graft-versus-host disease. *Clin Ophthalmol*. 2013; 2153-2158. PMC3817064.
208. **Dana R**, Miller JW. On The Edge: The Clinician-Scientist in Ophthalmology. *JAMA Ophthalmology* 2013; 131: 1401-1402. PMID: 24077531. PMC – in process.
209. Ogawa Y, Kim SK, **Dana R**, Clayton J, Jain S, Rosenblatt MI, Perez VL, Shikari H, Riemens A, Tsubota K. International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: Proposed Diagnostic Criteria for Chronic GVHD (Part I). *Nature Scientific Reports* 2013; 3419. PMC3851919.
210. Hajrasouliha AR, Sadrai Z, Lee HK, Chauhan S, **Dana R**. Expression of the chemokine decoy receptor D6 mediates dendritic cell function and promotes corneal allograft rejection. *Mol Vis* 2013; 2517-2525. PMC3867163.
211. **Chen Y, Chauhan S, Lee HS, Saban D, Dana R. Chronic dry eye disease is principally mediated by effector memory Th17 cells. Mucosal Immunology 2014; 38-45. PMC3732510.**

The relationship between immunity/inflammation and dry eye disease (DED) has been a matter of significant controversy for years, with some claiming that ocular surface inflammation seen in DED is simply a result of ongoing desiccating stress on the epithelium. In this paper, a chronic model of dry eye was created: after a short period of placing healthy mice in a dry eye chamber they were placed for many months in normal ambient conditions. Despite this, the surface epitheliopathy that had developed acutely during the desiccating stress never resolved entirely, and we showed that the maintenance of chronic epitheliopathy was associated with generation of effector memory (CD44^{hi}CD62L⁻) Th17 cells. Moreover adoptive transfer of these memory cells to normal mice led to heightened disease in mice even after a short period of desiccation. This was the first paper to relate dry eye disease to generation of classic immunologic memory, linking chronic epithelial disease incontrovertibly to Th17 cells.

212. Stevenson W, Dohlman T, Chauhan SK, **Dana R**. Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity. *Cornea* 2014; 33:177-83. PMID 24342887.

213. **Chauhan SK, Saban DR, Dohlman TH, Dana R. CCL-21 conditioned Tregs induce allotolerance through enhanced homing to lymphoid tissue. J Immunol 2014; 192:817-23. PMC3947335.**

Tregs play a critical function in inducing and maintaining immune tolerance. While many methods have been developed for their in vitro expansion, strategies to promote in vivo

mobilization of Tregs have been limited (low-dose IL-2 can be used to expand Tregs). Here we demonstrate that CCL-21 binds Treg CCR7 and specifically enhances Treg homing to the immune synapse in lymphoid tissues, thereby suppressing allosensitization and promoting allotolerance.

214. Katikireddy K, **Dana R**, Jurkunas UV. Differentiation potential of limbal fibroblasts and bone marrow mesenchymal stem cells to corneal epithelial cells. *Stem Cells* 2014; 32: 717-29. PMID: 24022965; PMC – In process.
215. Cade F, Paschalis E, Regatieri C, Vavvas D, **Dana R**, Dohlman CH. Alkali Burn to the Eye: Protection using TNF-[alpha] Inhibition. *Cornea* 2015; 33: 382-9. PMID: 24488127. PMC – In process.
216. Campbell A, Jakobiec FA, Rashid A, **Dana R**, Yoon MK. Bilateral sequential dacryocystitis in a patient with graft-versus-host disease. *Ophthal Plast Reconst Surg* 2014; PMID: 25192327 PMC – In process.
217. Lee H, Schlereth SL, Park EY, Emami-Naeini P, Chauhan S, **Dana R**. A novel pro-angiogenic function for interferon- γ -secreting natural killer cells. *Invest Ophthalmol Vis Sci* 2014; 55: 2885-92. PMC4010366.
218. Crnej A, Omoto M, Dohlman TH, Graney J, Dohlman CH, Drnovsek-Olup B, **Dana R**. A novel murine model for keratoprosthesis. *Invest Ophthalmol Vis Sci* 2014; 55(6): 3681-5. PMC4059078.
219. Jakobiec FA, Rashid A, Bozorg MS, **Dana R**. Unusual large unioocular elastoid and collagenous pinguecula. *Graefes Arch Clin Exp Ophthalmol*. 2014; 7: 1173-1175. PMID 24807233; PMC – In process.
220. Emami-Naeini P, Dohlman TH, Omoto M, Hattori T, Chen Y, Lee HS, Chauhan SK, **Dana R**. Soluble vascular endothelial growth factor receptor-3 suppresses allosensitization and promotes corneal allograft survival. *Graefes Arch Clin Exp Ophthalmol*. 2014; 11:1755-1762. PMC4221529.
221. Stevenson W, Chen Y, Lee S, Lee HS, Hua J, Dohlman TH, Shiang T, **Dana R**. Extraorbital lacrimal gland excision: a reproducible model of severe aqueous tear deficient dry eye disease. *Cornea* 2014; 33: 1336-41. PMID: 25255136. PMC – In process.
222. Kodati S, Chen Y, Dohlman TH, Chauhan SK, Saban DR, **Dana R**. CCR7 is critical for the induction and maintenance of Th17 immunity in dry eye disease. *Invest Ophthalmol Vis Sci* 2014; 55: 5871-7. PMC4168741.
223. Hua J*, Jin Y*, Inomata T, Lee H, Chauhan S, Petasis NA, Serhan CN, **Dana R**. The resolvin D1 analogue controls maturation of dendritic cells and suppresses alloimmunity in corneal transplantation. *Invest Ophthalmol Vis Sci* 2014; 55: 5944-51. PMC4172301.*co-first authors.

224. Schroedl F, Kaser-Eichberger A., Schlereth S, Bock F, Regenfuss B, Reitsamer HA, Luttj GA, Maruyama K, Chen L, Luetjen-Drecoll E, **Dana R**, Kerjaschki D, Alitalo K, De Stafano ME, Junghans BM, Heindl LM, Cursiefen C. Consensus statement on the immunohistochemical detection of ocular lymphatic vessels. *Invest Ophthalmol Vis Sci* 2014; 55:6440-2. PMC4580075.
225. Crnej A, Omoto M, Dohlman TH, Dohlman CH, **Dana R**. Corneal inflammation after miniature keratoprosthesis implantation. *Invest Ophthalmol Vis Sci* 2014; 56: 185-9. PMID: 25580370. PMC4290558.
226. Chauhan SK, Dohlman TH, **Dana R**. Corneal lymphatics: Role in ocular inflammation as inducer and responder of adaptive immunity. *J of Clin Cell Immunol* 2014; 5.pii. 1000256. PMC4287999.
227. Chauhan SK, Jurkunas UV, Funaki T, Dastjerdi M, **Dana R**. Quantification of allospecific and non-specific corneal endothelial cell damage after corneal transplantation. *Eye* 2015; 29: 136-44. PMC4289838.
228. Shikari H, Amparo F, Saboo U, **Dana R**. Onset of chronic ocular graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *Cornea* 2015; 34: 243-7. PMC4318713.
229. Dohlman TH, Omoto M, Hua J, Stevenson W, Lee SM, Chauhan SK, **Dana R**. VEGF-trap aflibercept significantly improves long-term graft survival in high-risk corneal transplantation. *Transplantation* 2015; 99: 678-686. PMID 25606789; PMC – In process.
230. Kheirkhah A, Dohlman TH, Amparo F, Arnoldner AA, Jamali A, Hamrah P, **Dana R**. Effects of corneal nerve density on the response to treatment in dry eye disease. *Ophthalmology* 2015; 122: 662-668. PMC4372494.
231. Saboo U, Amparo F, Shikari H, Jurkunas UV, **Dana R**. Outcomes of phacoemulsification in patients with chronic ocular graft-versus-host disease. *Graefes Arch Clin Exp Ophthalmol*. 2015; 253: 901-907. PMID: 25619668; PMC4447562.
232. Kheirkhah A, Saboo U, Abud TB, Dohlman TH, Arnoldner MA, Hamrah P, **Dana R**. Reduced corneal endothelial cell density in patients with dry eye disease. *Am J Ophthalmol* 2015; 159:1022-1026. PMID: 25782347; PMC4427236.
233. Amparo F, Schaumberg D, **Dana R**. Comparison of two questionnaires for dry eye symptom assessment: the ocular surface disease index and the symptom assessment in dry eye. *Ophthalmology* 2015; 122: 1498-1503. PMID: 25863420; PMC4485570.
234. Hamrah P, Sahin A, Dastjerdi MH, Shahatit BM, Bayhan HA, **Dana R**, Pavan-Langston D. In vivo confocal microscopical changes of the corneal epithelium and stroma in patients with herpes zoster ophthalmicus. *Am J Ophthalmol* 2015; 159: 1036-1044. PMID: 25748579; PMC4788981.

235. Lee HS, Hos D, Blanco T, Bock F, Reyes NJ, Mathew R, Cursiefen C, **Dana R**, Saban DR. Involvement of corneal lymphangiogenesis in a mouse model of allergic eye disease. *Invest Ophthalmol Vis Sci* 2015; 56: 3140-3148. PMID: 26024097; PMC4451613.
236. Uchino Y, Mauris J, Woodward AM, Dieckow J, Amparo F, **Dana R**, Mantelli F, Argüeso P. Alteration of galectin-3 in tears of patients with dry eye disease. *Am J Ophthalmol* 2015; 159: 1027-1035. PMID: 25703476; PMC4426220.
237. Saboo U, Amparo F, Abud T, Schaumberg DA, **Dana R**. Vision-related quality of life in patients with ocular graft-versus-host disease. *Ophthalmology* 2015; 122: 1669-1674. PMID: 26001816; PMC4516685.
238. Chauhan SK, Lee HK, Lee HS, Park EY, Jeong E, **Dana R**. PTK7+ mononuclear cells express VEGFR2 and contribute to vascular stabilization by upregulating angiopoietin-1. *Arterioscler Thromb Vasc Biol.* 2015; 35: 1606-1615. PMID: 25997931; PMC4483153.
239. Müller RT, Abedi F, Cruzat A, Witkin D, Baniasadi N, Cavalcanti BM, Jamali A, Chodosh J, **Dana R**, Pavan-Langston D, Hamrah P. Degeneration and regeneration of subbasal corneal nerves after infectious keratitis: A longitudinal in vivo confocal microscopy study. *Ophthalmology* 2015; 122: 2200-2209. PMID: 26256833. PMC4623997.
240. Robert MC, Črnej A, Shen L, Papaliadis G, **Dana R**, Foster CS, Chodosh J, Dohlman CH. Infliximab after Boston keratoprosthesis in Stevens-Johnson syndrome. *Ocular Immunology and Inflammation* 2016; 25: 1-5. PMID: 27015032; PMC – In progress.
241. Cruzat A, Schrems WA, Schrems-Hoesl LM, Cavalcanti BM, Baniasadi N, Witkin D, Pavan-Langston D, **Dana R**, Hamrah P. Contralateral clinically unaffected eyes of patients with unilateral infectious keratitis demonstrate a sympathetic immune response. *Invest Ophthalmol Vis Sci* 2015; 56: 6612-6620. PMID: 26465889. PMC4611956.
242. Inomata T, Mashaghi-Tabari A, DiZazzo A, **Dana R**. Ocular surgical models for immune and angiogenic responses. *J Biologic Methods* 2015; 2: e27. PMID: 26550579. PMC4636218.
243. Kheirkhah A, Rahimi R, Cruzat A, Hajrasouliha A, Witkin D, Wong D, **Dana R**, Hamrah P. Corneal epithelial immune dendritic cell alterations in subtypes of dry eye disease: An in vivo confocal microscopy study. *Invest Ophthalmol Vis Sci.* 2015; 56: 7179-7185. PMID: 26540656; PMC4640475.
244. Heindl LM, Kaser-Eichberger A, Schlereth SL, Bock F, Regenfuss B, Reitsamer HA, McMenamin P, Luty GA, Maruyama K, Chen L, **Dana R**, Kerjaschki D, Alitalo K, De Stefano ME, Junghans BM, Schroedl F, Cursiefen C. Sufficient evidence for lymphatics in the developing and adult human choroid? *Invest Ophthalmol Vis Sci* 2015; 56: 6709-6710. PMID: 26588256; PMC4911099.

245. Kheirkhah A, Saboo US, Marmalidou A, **Dana R**. Overestimation of Corneal Endothelial Cell Density in Smaller Frame Sizes in *In Vivo* Confocal Microscopy. *Cornea* 2016; 35: 363-369. PMID: 26606299.
246. Tahvildari M, Omoto M, Chen Y, Emami P, Inomata T, Dohlman T, Kaye AE, Chauhan S, **Dana R**. **In vivo expansion of regulatory T cells by low-dose interleukin-2 treatment increases allograft survival in corneal transplantation.** *Transplantation* 2016; 100: 525-532. PMC4764457.
Our previous work had shown that Treg function is impaired in allograft rejectors due to induced Treg instability and subsequent dysfunction, characterized by low expression of secreted regulatory factors (IL-10) as well as co-inhibitory surface expressed molecules such as CTLA4. This paper showed that low-dose IL-2 can be used to expand functional Tregs characterized by high Foxp3, CTLA4 and IL-10 expression which suppress allosensitization and promote graft survival.
247. Dohlman TH, Di Zazzo A, Omoto M, Hua J, Ding J, Hamrah P, Chauhan S, **Dana R**. E-selectin mediates immune cell trafficking in corneal transplantation. *Transplantation* 2016; 100: 772-780. PMC4801688.
248. Abud T, Amparo F, **Dana R**. A clinical trial comparing the safety and efficacy of topical Tacrolimus versus Methylprednisolone in ocular graft-versus-host disease. *Ophthalmol* 2016; 123: 1449-57. PMID: 27086024; PMC4921308.
249. Crnej A, Omoto M, Dohlman T, Gonzalez M, Paschalis E, Cruzat A, Doorenbos M, Chen DF, Dohlman C, **Dana R**. Effect of penetrating keratoplasty and keratoprosthesis implantation on the posterior segment of the eye. *Invest Ophthalmol Vis Sci* 2016; 57: 1927-1938. PMID: 27054516; PMC4829084.
250. Hua J, Stevenson W, Dohlman T, Inomata T, Tahvildari M, Calcagno N, Pirmadjid N, Sadrai Z, Chauhan S, **Dana R**. Graft site microenvironment determines dendritic cell trafficking through the CCR7 CCL19/21 axis. *Invest Ophthalmol Vis Sci* 2016; 57: 1457-1467. PMC4819620.
251. Amouzegar A, Chauhan S, **Dana R**. Alloimmunity and tolerance in corneal transplantation. *J Immunol* 2016; 196: 3938-91; PMID: 27183635, PMC4874505.
252. Saboo U, Amparo F, Shikari H, **Dana R**. Prevalence of ocular hypertension and glaucoma in patients with chronic ocular graft-versus-host disease. *Graefes Arch Clin Exp Ophthalmol* 2016; 254: 923-928. PMID: 26968719, PMC4842331.
253. Qazi Y, Hurwitz S, Khan S, Jurkunas U, **Dana R**, Hamrah P. Validity and reliability of novel ocular pain assessment survey in quantification and monitoring of corneal and ocular surface pain. *Ophthalmology* 2016; 123: 1458-68. PMID: 27089999, PMC5512896.
254. Di Zazzo A, Tahvildari M, **Dana R**. Ocular manifestations of inherited phospholipase-C γ 2-associated antibody deficiency and immune dysregulation. *Cornea* 2016; 35: 1656-1657. PMID: 27442322, PMC5250612.

255. Crnej A, Kheirkhah A, Ren A, Mullins A, Lavric A, Suri K, Hamrah P, **Dana R**. Patients' perspectives on their dry eye disease. *Ocul Surf* 2016; 14: 440-446. PMID: 27395775,
256. Mashaghi A, Marmalidou A, Tehrani M, Grace PM, Pothoulakis C, **Dana R**. Neuropeptide substance P and the immune response. *Cell Mol Life Sci* 2016; 73: 4249-4264. PMID: 27314883. PMC5056132
257. Mashaghi A, Hong J, Chauhan S, **Dana R**. Ageing and ocular surface immunity. *Br J Ophthalmol*. 2016; 101: 1-5. PMID: 27378485, PMC5583682.
258. Subbarayal B, Chauhan SK, Di Zazzo A, **Dana R**. IL-17 Augments B cell activation in ocular surface autoimmunity. *Journal of Immunology* 2016; 197:3464-3470. PMC5101134.
259. Kheirkhah A, Qazi Y, Arnoldner MA, Suri K, **Dana R**. In vivo confocal microscopy in dry eye disease associated with chronic graft-versus-host disease. *Invest Ophthalmol Vis Sci* 2016; 57: 4686-91. PMID: 27607414.
260. Hattori T, Takahashi H, **Dana R**. Novel insights into the immunoregulatory function and localization of dendritic cells. *Cornea* 2016; 35. PMID: 27631349, PMC5067968.
261. Abud TB, Di Zazzo A, Kheirkhah A, **Dana R**. Systemic Immunomodulatory Strategies in High-risk Corneal Transplantation. *J Ophthalmic Vis Res* 2017; 12: 81-92. PMID: 28299010. PMC5340067.
262. Chen Y, Chauhan SK, Tran X, **Dana R**. Interleukin-7 and -15 Maintain Pathogenic Memory Th17 Cells in Autoimmunity. *Journal of Autoimmunity* 2017; 77: 96-103. PMID: 27899224, PMC5276802.
- The mechanisms responsible for maintaining memory Th17 cells have not been elucidated; work to date focusing on memory CD8 and Th1 cells. For the first time, we demonstrate the critical role of IL-7 and IL-15 in maintaining the memory Th17 pool in ocular surface autoimmunity. This work is significant since it demonstrates that strategies for suppressing Th17-mediated chronic diseases cannot rely solely on suppressing differentiation of cells into effector Th17 cells but also require suppressing the maintenance of the memory pool.*
263. Inomata T, Hua J, Di Zazzo, A, **Dana R**. Impaired function of peripherally induced regulatory T cells in hosts at high risk of graft rejection. *Sci. Rep.* 2016; 6: 39924. PMC5180229.
- Tregs play a critical function in maintaining corneal allotolerance as previously shown by us (Journal of Immunol 2009). In this paper, we show for the first time that antigen-specific peripherally-induced Tregs, but not thymic natural Tregs, lose their regulatory phenotype and function, expressing lower levels of Foxp3, CTLA4, IL-10 and TGF- β and exhibiting lower anti-proliferative activity, in hosts that have inflamed beds and are at high risk for graft rejection. This is the first paper characterizing Treg dysfunction in transplantation and linking it with poor graft outcomes.*

264. Arafat SN, Robert MC, Abud T, Spurr-Michaud S, Amparo F, Dohlman CH, **Dana R**, Gipson IK. Elevated neutrophil elastase in tears of ocular graft-versus-host disease patients. *Am J Ophthalmol*. 2017; 176: 46-52. PMID: 28073648.
265. Inomata T, Mashaghi A, **Dana R**. Kinetics of angiogenic response in corneal transplantation. *Cornea* 2017; 36: 491-496. PMID: 28060028, PMC5334361.
266. Dohlman TH, Ding J, **Dana R**, Chauhan SK. T cell-derived GM-CSF contributes to dry eye disease pathogenesis by promoting CD11b+ myeloid cell maturation and migration. *Invest Ophthalmol Vis Sci* 2017; 58: 1330-1338. PMID: 28241321. PMC5341624.
267. Kheirkhah A, Satitpitakul V, Hamrah P, **Dana R**. Patients with dry eye disease and low subbasal nerve density are at high risk for an accelerated corneal endothelial cell loss. *Cornea* 2017; 36: 196-201. PMID: 28060067, PMC5298224.
268. Di Zazzo , Tahvildari M, Subbarayal B, Yin J, Dohlman TH, Inomata T, Mashaghi A, Chauhan SK, **Dana R**. Proangiogenic function of T cells in corneal transplantation. *Transplantation* 2017; 101: 778-785. PMID: 27490416. PMC5290298.
269. Hong J, Yang Y, Cursiefen C, Mashaghi A, Wu D, Liu Z, Sun X, **Dana R**, Xu J. Optimising keratoplasty for Peters' anomaly in infants using spectral-domain optical coherence tomography. *Br J Ophthalmol* 2017; 101: 820-827. PMID: 27660330.
270. Kheirkhah A, Crnej A, Ren A, Mullins A, Satitpitakul V, Hamrah P, Schaumberg D, **Dana R**. Patients' perceived treatment efficacy in dry eye disease. *Cornea* 2017; 36: 893-897. PMID: 28481835.
271. Paschalis E, Zhou C, Fengyang, Scott N, Kapoulea V, Robert M, Vavvas D, **Dana R**, Chodosh J, Dohlman CH. Mechanisms of retinal damage following ocular alkali burns. *Am J Pathol*. 2017; 187: 1327-1342. PMID: 28412300.
272. Kheirkhah A, Di Zazzo A, Satitpitakul V, Fernandez M, Magilavy D, **Dana R**. A Pilot randomized trial on safety and efficacy of a novel topical combined inhibitor of Janus Kinase 1/3 and Spleen Tyrosine Kinase for GVHD-associated ocular surface disease. *Cornea* 2017; 36: 799-804. PMID: 28445193.
273. Tahvildari M, Emami-Naeini P, Omoto M, Mashaghi A, Chauhan SK, **Dana R**. Treatment of donor corneal with immunomodulatory cytokines: a novel strategy to promote survival in high-risk corneal transplantation. *Scientific Reports* 2017; 7(1):971. doi: 10.1038/s41598-017-01065-z. PMID: 28428556, PMC5430534.
- High-risk corneal transplants are prone to very high rejection rates even with maximal local or systemic immune suppression. This paper demonstrates for the first time that corneal donor tissues can be made to induce active tolerance (enhanced regulatory T cells and suppressed T cell allosensitization) and prolonged transplant survival if treated with TGF-beta and interleukin-10. Given that donor tissues are kept in culture prior to use, this is a translatable strategy for preventing allograft rejection.*

274. Jones L, Downie LE, Korb DR, Benitez-del-Castillo JM, **Dana R**, Deng SX, Dong PN, Geerling G, Hida RY, Liu Y, Seo KY, Tauber J, Wakamatsu TH, Xu J, Craig JP. Report of the Management and Therapy Subcommittee of the Tear Film and Ocular Surface Society Dry Eye Workshop II (DEWS II). *The Ocular Surface* 2017; 15:575-628. doi: 10.1016/j.jtos.2017.05.006. PMID: 28736343
275. Kheirkhah A, Syed ZA, Satitpitakul V, Goyal S, Müller R, Tu EY, **Dana R**. Sensitivity and specificity of laser-scanning in vivo confocal microscopy for filamentous fungal keratitis: role of observer experience. *Am J Ophthalmol* 2017; 179: 81-89. PMID: 28445703.
276. Satitpitakul V, Kheirkhah A, Crnej A, Hamrah P, **Dana R**. Determinants of ocular pain severity in patients with dry eye disease. *Am J Ophthalmol* 2017; 179: 198-204. PMID: 28528121.
277. Lee HS, Amouzegar A, **Dana R**. Kinetics of corneal antigen presenting cells in experimental dry eye disease. *BMJ Open Ophthalmol* 2017; in press.
278. Amparo F, Wang H, Yin J, Marmalidou A, **Dana R**. Evaluating corneal fluorescein staining using a novel automated method. *Invest Ophthalmol Vis Sci* 2017; 58: BIO168-BIO173. PMID: 28693042.
279. Hos D, Bukowiecki A, Horstmann J, Bock F, Bucher F, Heindl LM, Siebelmann S, Steven P, **Dana R**, Eming S, Cursiefen C. Transient ingrowth of lymphatic vessels into the physiologically avascular cornea regulates corneal edema and transparency. *Sci Reports* 2017; 7:7227. doi: 10.1038/s41598-017-07806-4. PMID: 28775329.
280. Aggarwal S, Yamaguchi T, **Dana R**, Hamrah P. Exophiala phaeomuriformis fungal keratitis-Case Report and In Vivo Confocal Microscopy Findings. *Eye Contact Lens* 2017; 43: e4-e6. PMID: 26513718; PMC – In progress.
281. Chen Y, Chauhan S, Shao C, Omoto M, Inomata T, **Dana R**. Interferon- γ -expressing Th17 cells are required for development of severe ocular surface autoimmunity. *J Immunol* 2017; 199: 1163-1169. PMID: 28637904.
282. Inomata T, Hua J, Chen Y, Nakao T, Shiang T, Chiang H, Amouzegar A, **Dana R**. Corneal tissue from dry eye donors leads to enhanced graft rejection. *Cornea* 2018; 37: 95-101. Doi: 10.1097/ICO.0000000000001400. PMID: 29023237.
283. Amparo F, Yin J, Di Zazzo A, Abud T, **Dana R**. Evaluating changes in ocular redness using a novel automated method. *Translational Vis Sci Tech* 2017; 6: 13. Doi:10.1167/tvst.6.4.13. PMID: 28736686
284. Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, **Dana R**, Deng SX, Dong PN, Geerling G, Hida RY, Liu Y, Seo KY, Tauber J, Wakamatsu TH, Xu J, Wolffsohn JS, Craig JP. TFOS DEWS II Management and Therapy Report. *Ocul Surf.* 2017; 15:575-628. doi: 10.1016/j.jtos.2017.05.006. PMID: 28736343.

285. Inomata T, Mashaghi A, Hong J, Nakao T, **Dana R**. Scaling and maintenance of corneal thickness during aging. *Plos One* 2017; 12(10):e0185694. doi: 10.1371/journal.pone.0185694. PMID: 28985226.
286. Eslani M, Putra I, Shen X, Hamouie J, Afsharkhamseh N, Besharat S, Rosenblatt MI, **Dana R**, Hematti P, Djalilian AR. Corneal mesenchymal stromal cells are directly anti-angiogenic via PEDF and sFLT-1. *Invest Ophthalmol Vis Sci*. 2017; 58:5507-5517. doi: 10.1167/iovs.17-22680. PMID: 29075761.
287. Dohlman CH, Cade F, Regatieri CV, Zhou C, Lei F, Crnej A, Harissi-Dagher M, Robert MC, Papaliodis GN, Chen D, Aquavella JV, Akpek EK, Aldave AJ, Sippel KC, D'Amico DJ, Dohlman JG, Fagerholm P, Wang L, Shen LQ, Gonzalez-Andrades M, Chodosh J, Kenyon KR, Foster CS, Pineda R, Melki S, Colby KA, Ciolino JB, Vavvas DG, Kinoshita S, **Dana R**, Paschalis EI. Chemical Burns of the Eye: The Role of Retinal Injury and New Therapeutic Possibilities. *Cornea* 2018; 37: 248-251. Doi: 10.1097/ICO.0000000000001438. PMID: 29135604.
288. Kheirkhah A, Satitpitakul V, Syed ZA, Muller R, Goyal S, Tu EY, **Dana R**. Factors influencing the diagnostic accuracy of laser-scanning in vivo confocal microscopy for acanthamoeba keratitis. *Cornea* 2018; 37(7): 88-823 doi: 10.1097/ICO.0000000000001507. PMID: 29303889.
289. Tahvildari M, Amouzegar A, Foulsham W, **Dana R**. Therapeutic approaches for induction of tolerance and immune quiescence in corneal transplantation. *Cell Mol Life Sci*, 2018; 75(9): 1509-1520. doi: 10.1007/s00018-017-2739-y. PMID: 29307015
290. Qi H, Chen Y, Inomata T, Amouzegar A, **Dana R**. IL-10-producing Th17 cells: A potentially regulatory cell population in dry eye disease. *Journal of Immunology and Immunotherapy* 2018; in press.
291. Eslani M, Putra I, Shen X, Hamouie J, Tadepalli A, Anwar K, Kink J, Ghassemi S, Agnihotri G, Reshetylo S, Mashaghi A, **Dana R**, Hematti P, Djalilian A. Cornea derived MSCs therapeutically modulate macrophage immunophenotype and angiogenic function. *Stem Cells*. 2018; 36(5):775-784. doi: 10.1002/stem.2781. PMID: 29341332.
292. Amparo F, **Dana R**. Web-Based longitudinal remote assessment of dry eye symptoms. *The Ocular Surface* 2018; 16(2):249-253: doi.org/10.1016/j.jtos.2018.01.002. PMID: 29409963.
293. Paschalis EI, Thanos A, Kapoulea V, Chodosh J, Dohlman CH, Lei D, **Dana R**, Zhou C, Vavvas D. The role of microglia and peripheral monocytes in retinal damage following corneal chemical injury.. *Am J Pathology* 2018; S0002-9440(17)31228-2. doi: 10.1016/j.ajpath.2018.03.005. PMID: 29630857.
294. Sullivan DA, **Dana R**, Sullivan RM, Krenzer KL, Sahin A, Arica B, Liu Y, Kam WR, Papas AS, Cermak JM. Meibomian gland dysfunction in primary and secondary Sjögren

- syndrome. *Ophthalmic Res* 2018; 59(4): 193-205. doi: 10.1159/000487487. PMID: 29627826.
295. Kheirkhah A, Coco G, Satitpitakul V, **Dana R**. Subtarsal fibrosis is associated with ocular surface epitheliopathy in graft-versus-host disease. *Am J Ophthalmol* 2018; 189:102-110. doi.org/10.1016/j.ajo.2018.02.020. PMID: 29505774.
296. Hua J, Inomata T, Chen Y, Foulsham W, Stevenson W, Shiang T, Bluestone J, **Dana R**. Pathological conversion of regulatory T cells is associated with loss of allotolerance. *Sci Rep*. 2018; 8(1):7059. doi: 10.1038/s41598-018-25384. PMID: 29728574. PMC5935752.
297. Yin J, Kheirkhah A, Dohlman T, Saboo U, **Dana R**. Reduced efficacy of low-dose topical steroids in dry eye disease associated with graft-versus-host disease. *Am J Ophthalmol* 2018; 190: 17-23. doi: 10.1016/j.jjo.2018.03.024. PMID: 29572107.
298. Satitpitakul V, Kheirkhah A, Sun Z, Amouzegar A, Reddy K, Suri K, Jurkunas U, **Dana R**. Vasoactive Intestinal Peptide promotes corneal allograft survival. *Am J Pathology* 2018; 188:2016-2024. doi: 10.1016/j.ajpath.2018.05.010. PMID: 30097165.
299. Amparo F, Shikari H, Saboo U, **Dana R**. Assessment of corneal fluorescein staining and ocular symptoms, but not Schirmer Test, is useful as indicators of response to therapy in chronic ocular GVHD. *Ocular Surface* 2018; 16: 377-381. doi: 10.1016/j.jtos.2018.05.002. PMID: 29763694.
300. Tan X, Chen Y, Foulsham W, Amouzegar A, Inomata T, Liu Y, Chauhan SK, **Dana R**. The immunoregulatory role of corneal epithelium-derived Thrombospondin-1 in dry eye disease. *The Ocular Surface* 2018; doi: 10.1016/j.jtos.2018.07.005. PMID: 30055331.
301. **Dana R**, Bradley JL, Guerin A, Pivneva I, Evans AM, Stillman IO. Proportion of comorbidities and prescribed medications in patients with or without dry eye disease: A population-based study. *Am J Ophthalmology* 2018; in press.
302. Foulsham W, Mittal S, Nakao T, Coco G, Taketani Y, Chauhan S, **Dana R**. The purinergic P2X receptor antagonist oxidized adenosine triphosphate promotes corneal allograft survival without expanding regulatory T cells. *Sci Reports: Under Review*.

Other Contributions to Peer-Reviewed Scholarship

303. **Dana R**. Ocular disease in rheumatoid arthritis. In: Schur PH, ed. UpToDate in Rheumatology: Official educational program of the American College of Rheumatology. Wellesley: UpToDate Inc., 1997. (revised annually)
304. Tolentino M, **Dana R**. Retinal vasculitis associated with systemic disorders and infections. In: Schur PH, ed. UpToDate in Rheumatology: Official educational program of the American College of Rheumatology. Wellesley: UpToDate Inc., 1998. (revised annually)

305. Tolentino M, **Dana R**. Retinal vasculitis associated with primary ocular disorders. In: Schur PH, ed. UpToDate in Rheumatology: Official educational program of the American College of Rheumatology. Wellesley: UpToDate Inc., 1998. (revised annually)
306. Maw R, Pasquale LR, Pineda R, **Dana R**. Traumatic ruptured globe injuries in children. *Int Ophthalmol Cl* 2002; 42:157-165. PMID: 12131592
307. **Dana R**. Ocular atopic diseases. In: Schur PH, ed. UpToDate in Allergy and Immunology. Wellesley: UpToDate Inc., 2002 (revised annually)
308. Singer MS, **Dana R**. Recent advances in the global effort to eradicate trachoma. *Int Ophthalmol Cl* 2006; 46: 79-90. PMID: 16770156.
309. Chong E-M, **Dana R**. Acanthamoeba keratitis. *Int Ophthalmol Cl* 2007; 47:33-46. PMID: 17450005.
310. **Dana R**. Episcleritis. In: Schur PH, ed. UpToDate in Rheumatology: Official educational program of the American College of Rheumatology. Wellesley: UpToDate Inc., 2007 (revised annually)
311. **Dana R**. Clinical manifestations and diagnosis of scleritis. In: Schur PH, ed. UpToDate in Rheumatology: Official educational program of the American College of Rheumatology. Wellesley: UpToDate Inc., 2007 (revised annually)
312. Lam H, **Dana R**. Corneal graft rejection- Pathophysiologic mechanisms. *Int Ophthalmol Cl* 2009; 49: 31-41.
313. Hamrah P, Langston DP, **Dana R**. Herpes simplex keratitis and dendritic cells at the crossroads: Lessons from the past and a view into the future. *Int Ophthalmol Clin* 2009; 49: 53-62. PMC4313552.
314. Hatch KM, **Dana R**. The structure and function of the limbal stem cell and the disease states associated with limbal stem deficiency. *Int Ophthalmol Cl* 2009; 49: 43-52. PMID: 19125063.
315. Dastjerdi M, Hamrah P, **Dana R**. Corneal nerve alterations in dry eye-associated ocular surface disease. *Int Ophthalmol Cl* 2009; 49: 11-20.
316. Hamrah P, **Dana R**. Vernal keratoconjunctivitis. In: UpToDate in Allergy. Wellesley, MA: UpToDate Inc., 2010 (revised annually)
317. Clements JL and **Dana R**. Inflammatory corneal neovascularization: Etiopathogenesis. *Seminars in Ophthalmology*, 2011; 26: 235-245. PMID: 21958169.
318. Yoo J, Chodosh J, **Dana R**. Relapsing polychondritis: systemic and ocular manifestations, differential diagnosis, management, and prognosis. *Seminars in Ophthalmology*, 2011; 26: 261-269. PMID: 21958172.

319. Hawthorne K, **Dana R**, Chodosh J. Delayed type hypersensitivity in the pathogenesis of recurrent herpes stromal keratitis *Seminars in Ophthalmology* 2011; 26: 246-250. PMID: 21958170.
320. Townley JR, **Dana R**, Jacobs DS. Kerato conjunctivitis sicca manifestations in ocular graft-versus-host disease (GVHD): Pathogenesis, prevention, and treatment. *Seminars in Ophthalmology* 2011; 26: 251-260. PMID: 21958171.
321. Bourne R, Price H, Stevens G; for the Global Burden of Disease Vision Loss Expert Group. Global burden of visual impairment and blindness. *Arch Ophthalmol.* 2012; 130:645-7. PMID: 22652851
322. Barabino S, Chen Y, Chauhan SK, **Dana R**. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. *Progress in Retinal and Eye Research.* 2012; 31: 271-85
323. Bourne RR, Stevens GA, White RA, Smith JL, SR, Price H, Jonas JB, Keeffe J, Leasher J, Naidoo K, Pesudovs K, Resnikoff S, Taylor HR; for The Vision Loss Expert Group of the Global Burden of Disease Study. Causes of vision loss worldwide, 1990-2010: a systematic analysis. *Lancet Glob Health.* 2013 1(6):e339-49. doi: 10.1016/S2214-109X(13)70113-X. Epub 2013 Nov 11. PMID: 25104599.
324. Shikari H, Antin, J, **Dana R**. Ocular graft-versus-host disease: a review. *Survey of Ophthalmology.* 2013; 58: 233-51. PMID: 23541042.
325. Bourne RR, Jonas JB, Flaxman SR, et al. for The Vision Loss Expert Group. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990–2010. *British J Ophthalmology* 2014; 98: 629-638. PMID: 24665132
326. Khairallah M, Kahloun R, Flaxman SR, et al. for The Vision Loss Expert Group. Prevalence and causes of vision loss in North Africa and the Middle East: 1990–2010. *British J Ophthalmology* 2014; 98: 605-611. PMID: 24590555
327. Naidoo K, Gichuhi S, Basáñez M, et al. for The Vision Loss Expert Group. Prevalence and causes of vision loss in sub-Saharan Africa: 1990–2010. *British J Ophthalmology* 2014; 98: 612-618. PMID: 24568870
328. Leasher JL, Lansingh V, Flaxman SR, et al. for The Vision Loss Expert Group. Prevalence and causes of vision loss in Latin America and the Caribbean: 1990–2010. *British J Ophthalmology* 2014; 98: 619-628. PMID: 24518073
329. Jonas JB, George R, Asokan R, et al. for The Vision Loss Expert Group. Prevalence and causes of vision loss in Central and South Asia: 1990–2010. *British J Ophthalmology* 2014; 98: 592-598. PMID: 24457361
330. Keeffe J, Taylor HR, Fotis, K, et al. for The Vision Loss Expert Group. Prevalence and causes of vision loss in Southeast Asia and Oceania: 1990–2010. *British J Ophthalmology*

- 2014; 98: 586-591. PMID: 24407561
331. Wong TY, Zheng Y, Jonas JB, et al. for The Vision Loss Expert Group. Prevalence and causes of vision loss in East Asia: 1990–2010. *British J Ophthalmology* 2014; 98: 599-604. PMID: 24390167
332. Di Zazzo A, Kheirkhah A., Abud TB, Goyal S, **Dana R**. Management of high-risk corneal transplantation. *Survey of Ophthalmology* 2017; 62: 816-827. PMID: 28012874.
333. Syed ZA, **Dana R**. Novel treatments for corneal angiogenesis. *Int Ophthalmol Cl.* 2017; 57: 31-38. PMID: 28885245.
334. Foulsham W, Marmalidou A, Amouzegar A, Coco G, Chen Y, **Dana R**. The function of regulatory T cells at the ocular surface. *Ocular Surface* 2017; 15(4): 652-659. doi: doi.10.1016/j.jtos.2017.05.013. PMID: 28576753.
335. Bourne RRA, Flaxman SR, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Resnikoff S, Silvester A, Stevens GA, Tahhan N, Wong TY, Taylor HR for The Vision Loss Expert Group. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. *Lancet Glob Health.* 2017; 5(9):e888-e897. doi: 10.1016/S2214-109X(17)30293-0. PMID: 28779882.
336. Marmalidou A, Kheirkhah A, **Dana R**. Conjunctivochalasis. *Surv Ophthalmol* 2018; 63(4):554-564. PMID: 29128574.
337. Flaxman SR, Bourne RA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeff J, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Silvester A, Stevens GA, Tahhan N, Wong TY, Taylor HR, on behalf of the Vision Loss Expert Group of the Global Burden of Disease Study. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. *Lancet Global Health,* 2017; 5: 30393-5. PMID: 29032195.
338. Foulsham W, Coco G, Amouzegar A, Chauhan SK, **Dana R**. When clarity is crucial: regulatory ocular surface immunity. *Trends in Immunology* 2018; 39(4):288-301. PMID: 29248310.
339. **Dana R**. A new frontier in curing corneal blindness [Invited Editorial]. *New England J Medicine.* 2018; 378(11):1057-1058. PMID: 29539278.
340. Asbell PA, Maguire MG, Pistilli M, Ying GS et al for The Dry Eye Assessment and Management Study Research Group. N-3 fatty acid supplementation for the treatment of dry eye disease. *New England J Medicine* 2018; 378(18):1681-1690 (Notes: R. Dana-Clinical Center Principal Investigator) DOI: 10.1056/NEJMoa1709691.
341. Tahvildari M, Inomata T, Amouzegar A, Dana R. Regulatory T cell modulation of cytokine and cellular networks in graft rejection. *Curr Ophthalmology Rep* 2018; in press.

342. Leasher JL, Braithwaite T, Furtado JM, Flaxman SR, Lansingh VC, Silva JC, Resnikoff S, Taylor HR, Bourne RRA; Vision Loss Expert Group of the Global Burden of Disease Study. Prevalence and causes of vision loss in Latin America and the Caribbean in 2015: magnitude, temporal trends and projections. *Br J Ophthalmol*. 2018 Sep 12. pii: bjophthalmol-2017-311746. doi: 10.1136/bjophthalmol-2017-311746. PMID: 30209083.

Reviews & Chapters

343. **Dana R.** Cataract surgery in the uveitis patient. *Rev Ophthalmology* 1997; 4: 190-4.
344. Davis E, **Dana R.** Pregnancy and the Eye. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. 2nd Ed., Vol. 5: 4767-83; Philadelphia: WB Saunders Co., 1999.
345. **Dana R.**, Reddy CV, Foster CS. Adult Rheumatoid Arthritis. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. 2nd Ed., Vol. 5: 4555-62; Philadelphia: WB Saunders Co., 1999.
346. **Dana R.**, Reddy CV, Foster CS. Scleroderma. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. 2nd Ed., Vol. 5: 4589-95; Philadelphia: WB Saunders Co., 1999.
347. Kim R, **Dana R.** Graft-versus-host disease. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. 2nd Ed., Vol. 5: 4994-01; Philadelphia: WB Saunders Co., 1999.
348. **Dana R.** Uveitis in juvenile rheumatoid arthritis (JRA). In: Fraunfelder FT, Roy H. Current Ocular Therapy. Fifth Edition: 176-178; Philadelphia: WB Saunders Co., 1999.
349. **Dana R.** Uveitis in leptospirosis. In: Foster CS (Ed.) Textbook of Uveitis. Philadelphia: WB Saunders Co., 2002: 273-77.
350. **Dana R.** Ocular immunology. Chapter IX, Section 8, *Basic and Clinical Science Course, American Academy of Ophthalmology*, San Francisco, 2002: 183-191.
351. **Dana R.** Clinical approaches to immune-related disorders of the external eye. Chapter IX, Section 9, *Basic and Clinical Science Course, American Academy of Ophthalmology*, San Francisco, 2002: 193-228.
352. **Dana R.** Wound healing of the conjunctiva, cornea, and sclera. Chapter XIX, Section 8, *Basic and Clinical Science Course, American Academy of Ophthalmology*, San Francisco, 2002: 359-362.

353. **Dana R.** Toxic and traumatic injuries of the anterior segment. Chapter XX, Section 8, *Basic and Clinical Science Course, American Academy of Ophthalmology*, San Francisco, 2002: 363-396.
354. **Dana R.** Introduction to surgery of the ocular surface. Chapter XXI, Section 8, *Basic and Clinical Science Course, American Academy of Ophthalmology*, San Francisco, 2002: 399-401.
355. **Dana R.** Surgical procedures of the ocular surface. Chapter XXII, Section 8, *Basic and Clinical Science Course, American Academy of Ophthalmology*, San Francisco, 2002: 403-418.
356. Sullivan DA, Schaumberg DA, Schirra F, Suzuki T, Liu M, Richards SM, Sullivan RM, **Dana R**, Sullivan BD. Hormone therapy for dry eye- Topical androgen administration may be an effective therapy for the treatment of dry eye syndromes. *Rev Ophthalmol* March 2002: 73-76.
357. **Dana R.** Transplantation Immunology. Chapter XXII, Section 8, *Basic and Clinical Science Course, American Academy of Ophthalmology*, San Francisco, 2002: 421-424.
358. Cursiefen C, Seitz B, **Dana R**, Streilein JW. Angiogenesis und Lymphangiogenese. *Der Ophthalmologe* 2003; 100: 292-299.
359. Sullivan DA, Schaumberg DA, Schirra F, Suzuki T, Richards SM, Liu M, Sullivan RM, **Dana R**, Sullivan BD. Sex, sex steroids, and dry eye syndromes. In: Zierhut M, Ed. *Immunology of the Lacrimal Gland and Ocular Tear Film*. Swets & Zeitlinger, 2003: 389-399.
360. Gulati A, **Dana R.** Eye complications after hematopoietic stem cell transplantation. In: Atkinson K, Ed. *Clinical Bone Marrow and Blood Stem Cell Transplantation*. Third Ed. Cambridge U Press, 2004: 1550-1561.
361. Gulati, A, **Dana R.** Keratoconjunctivitis sicca. In: Foster CS, Azar DT, Dohlman CH, Eds. *Smolin & Thoft's The Cornea*. Fourth Ed. Lippincott Williams & Wilkins, 2004: 603-627.
362. Hamrah P, Huq SO, Gulati A, **Dana R.** Mechanisms of the ocular surface immune response. In: Pflugfelder S, Beuerman R, Stern M, Eds. *Dry Eye and Ocular Surface Disorders*. Chapter 6, pp: 111-142, Marcel Dekker, 2004.
363. Gardner MF, Pineda R, **Dana R.** Laser cataract surgery: past, present, and evolving technologies. *Int Ophthalmol Clin*. 2004; 44:113-21
364. **Dana R**, Hamrah P. Corneal antigen-presenting cells: function and identity. In: Zierhut M, Stern ME, Sullivan DA, Eds. *Immunology of the Lacrimal Gland, Tear Film, and Ocular Surface*. Taylor and Francis Group, London, 2005: 141-149.

365. Gulati A, **Dana R**. The dry eye. In: Wallace DJ, Ed. *The New Sjogren's Syndrome Handbook*. Third Ed. Oxford U Press, 2005: 41-51.
366. **Dana R**. Corneal Antigen Presentation: Molecular regulation and functional implications. *Ocular Surface* 2005; 3: S169-172.
367. McDermott AM et al. Pathways of corneal and ocular surface inflammation: a perspective from the Cullen Symposium. *Ocular Surface* 2005; 3: S131-138.
368. **Dana R**. Normal physiology of the ocular surface. Chapter III, Section 8, *Basic and Clinical Science Course, American Academy of Ophthalmology*, San Francisco, 2006.
369. **Dana R**. Diagnostic approach to ocular surface disease. Chapter IV, Section 8, *Basic and Clinical Science Course, American Academy of Ophthalmology*, San Francisco, 2006.
370. **Dana R**. Ocular immunology. Chapter VIII, Section 8, *Basic and Clinical Science Course, American Academy of Ophthalmology*, San Francisco, 2006.
371. **Dana R**. Degenerative and aging changes of the conjunctiva, cornea, and sclera. Chapter XVI, Section 8, *Basic and Clinical Science Course, American Academy of Ophthalmology*, San Francisco, 2006.
372. **Dana R**. Clinical approach to depositions and degenerations of the conjunctiva and cornea. Chapter XVII, Section 8, *Basic and Clinical Science Course, American Academy of Ophthalmology*, San Francisco, 2006.
373. **Dana R**. Wound healing of the conjunctiva, cornea, and sclera. Chapter XVIII, Section 8, *Basic and Clinical Science Course, American Academy of Ophthalmology*, San Francisco, 2006.
374. **Dana R**. Clinical aspects of toxic and traumatic injuries of the anterior segment. Chapter XIX, Section 8, *Basic and Clinical Science Course, American Academy of Ophthalmology*, San Francisco, 2006.
375. Barabino S, **Dana R**. Dry eye syndromes. In: Niederkorn JY, Kaplan H. *Immune Response and the Eye*. *Chemical Immunol Allergy* 2007; 92: 176-184.
376. Barabino S, Rashid S, **Dana R**. Modulation of inflammation and immunity in dry eye disease. In: Asbell P, Lemp M. *Dry Eye Disease*. Thieme Medical Publishers, Pennsylvania. Chap 8, pp: 95-100.
377. **Dana R**. Corneal antigen-presenting cells (APC): What have we learned from transplantation? In: Zierhut M et al, Eds. *Antigen-Presenting Cells and the Eye*. Informa Healthcare, New York, 2007: 151-156.
378. Rashid S, **Dana R**. Cicatrizing and autoimmune disorders. In: Niederkorn JY, Kaplan H. *Immune Response and the Eye*. *Chemical Immunol Allergy* 2007; 92:195-202.

379. Hamrah P, **Dana R**. Cornea antigen-presenting cells. In: Niederhorn JY, Kaplan H. Immune Response and the Eye. *Chemical Immunol Allergy* 2007; 92: 58-70.
380. **Dana R**, Chong E-M, Foster CS. Adult rheumatoid arthritis. In: Albert DS, Miller JW, Azar DT, Blodi BA, eds. *Albert & Jakobiec's Principles & Practice of Ophthalmology*. 3rd Ed. Philadelphia: Saunders Elsevier; 2008: 4417-4427.
381. **Dana R**, Chong E-M, Foster CS. Scleroderma. In: Albert DS, Miller JW, Azar DT, Blodi BA, eds. *Albert & Jakobiec's Principles & Practice of Ophthalmology*. 3rd Ed. Philadelphia: Saunders Elsevier; 2008: 4461-4468.
382. Chong E-M, Harissi-Dagher M, **Dana R**. Wetting of the ocular surface and dry eye disorders. In: Albert DS, Miller JW, Azar DT, Blodi BA, eds. *Albert & Jakobiec's Principles & Practice of Ophthalmology*. 3rd Ed. Philadelphia: Saunders Elsevier; 2008: 773-788.
383. **Dana R** and Foster CS. Immunology- an overview. In: Albert DS, Miller JW, Azar DT, Blodi BA, eds. *Albert & Jakobiec's Principles & Practice of Ophthalmology*. 3rd Ed. Philadelphia: Saunders Elsevier; 2008: 43-45.
384. Kim SS, Kim RY, **Dana R**. Graft-versus-host disease. In: Albert DS, Miller JW, Azar DT, Blodi BA, eds. *Albert & Jakobiec's Principles & Practice of Ophthalmology*. 3rd Ed. Philadelphia: Saunders Elsevier; 2008: 4821-4830.
385. **Dana R**, Streilein JW. T-Lymphocyte responses. In: Albert DS, Miller JW, Azar DT, Blodi BA, eds. *Albert & Jakobiec's Principles & Practice of Ophthalmology*. 3rd Ed. Philadelphia: Saunders Elsevier; 2008: 67-70.
386. **Dana R** and Foster CS. Regulation of immune responses. In: Albert DS, Miller JW, Azar DT, Blodi BA, eds. *Albert & Jakobiec's Principles & Practice of Ophthalmology*. 3rd Ed. Philadelphia: Saunders Elsevier; 2008: 91-99.
387. Reeves SW, Davis EA and **Dana R**. Pregnancy and the eye. In: Albert DS, Miller JW, Azar DT, Blodi BA, eds. *Albert & Jakobiec's Principles & Practice of Ophthalmology*. 3rd Ed. Philadelphia: Saunders Elsevier; 2008: 4587-4604.
388. Niederhorn J and **Dana R**. Immune system and the eye. In: Yorio T, Clark AF, Wax M. *Ocular Therapeutics: An Eye on New Discoveries*. Academic Press, Elsevier, 2008: 199-233.
389. Pflugfelder SC, Stern ME; Symposium Participants. Immunoregulation on the ocular surface: 2nd Cullen Symposium. *Ocular Surface* 2009; 7:67-77.
390. Saban DR, **Dana R**. Corneal graft rejection. In: Levin and Albert eds. *Ocular Disease: Mechanisms and Management*. Elsevier, 2009.

391. **Dana R.** Floppy eyelid syndrome. In: Price FW and Letko E, eds. *Curbside Consultation in Cornea*. Slack, 2009; 107-110.
392. **Dana R.** Episcleritis. In: Melki S, ed. *Atlas of Clinical Wisdom; Cornea, Refractive and External Disease*. Slack, 2010; 119-123.
393. **Dana R.** Corneal transplant rejection. In: Melki S, ed. *Atlas of Clinical Wisdom; Cornea, Refractive and External Disease*. Slack, 2010; 197-202.
394. Hamrah P and **Dana R.** Antigen-presenting cells in the eye and ocular surface. In: Dartt, Besharse and Dana eds. *Encyclopedia of the Eye*. Elsevier, 2010; 120-127.
395. Gulati A, **Dana R.**, Foulks GN. The dry eye. In *The Sjogren's Syndrome Handbook*. Oxford University Press, 2012; 147-156.
396. Shikari H. and **Dana R.** Graft-versus-host disease. In: Benitez-del-Castillo, J. and Lemp, M. eds. *Ocular Surface Disorder*. London: JP Medical Publishers; 2013; Chapter 13, 117-125.

Communications, Proceedings & Transactions

397. **Dana R.**, Rosheim K. Case-control study of retinal vein occlusion [Letter]. *Ophthalmology* 1992; 99: 1754-5.
398. **Dana R.**, Wilensky JT. Immune-related disease and normal-tension glaucoma [Letter]. *Arch Ophthalmol* 1993; 111: 22-3.
399. McMahon TT, **Dana R.**, Sugar J. Keratoconus contact lens failure [Letter]. *Ophthalmology* 1993; 100: 147-8.
400. **Dana R.**, Werner MS. "Sterile" endophthalmitis after sutureless cataract extraction [Letter]. *Ophthalmology* 1993; 100: 441-2.
401. Schaumberg DA, **Dana R.** Is smoking a risk factor for non-arteritic AION? [Letter] *Ophthalmology* 1994; 101: 1765.
402. Schaumberg DA, **Dana R.** Visual prognosticators in Behçet uveitis [Letter]. *Ophthalmology* 1995; 102: 1739.
403. **Dana R.** Outcomes in pediatric keratoplasty [Letter]. *Ophthalmology* 1996; 103: 202-3.
404. Yamada J, **Dana R.**, Zhu S, Streilein JW. Promotion of allogeneic corneal transplant survival by interleukin-1 receptor antagonist is mediated by suppression of allosensitization. *Fifth Basic Sciences Symposium of the Transplantation Society* 1997.
405. **Dana R.** Dry eye syndrome. *HealthNews* (patient educational publication of the *New England Journal of Medicine*), 1998; 4: 3.

406. Schaumberg DA, **Dana R**, Foster CS. Posterior capsule opacification after cataract surgery. *Ophthalmology* 1998; 105: 943-4.
407. Streilein JW, Yamada J, **Dana R**, Ksander BR. Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. *Transplantation Pr* 1999; 31: 1472-5.
408. **Dana R**, Yamagami S, Hamrah P, Dekaris I, Zhu S. Inflammatory cytokines and cytokine receptors in corneal inflammation and immunity. *Proceedings of the International Society for Eye Research*, Volume XIV, 2000: S184.
409. **Dana R**, Sullivan DA, Parke AL. Toward optimal health: Experts discuss dry eye syndrome. *J Womens Health Gend Based Med* 2001; 10: 725-729.
410. **Dana R**. Phacoemulsification in Behcet's syndrome [Commentary]. *Ocular Surgery News* 2001; 12: 52.
411. **Dana R**. Remembrance of J. Wayne Streilein MD. *Ocular Immunology and Inflammation* 2007; 15: 151-155.
412. **Dana R**. Discussion of McCulley JP, Petroll WM. Quantitative assessment of corneal wound healing following IntraLasik using in vivo confocal microscopy. *Trans Am Ophthalmol Soc*. 2008; 106: 84-90.
413. Chauhan S, **Dana R**. My "favorite" molecule (IL-17) and cell (Th17). *Sjogren's Quarterly*. 2009; 4:1.
414. Kheirkhah A, Kempen J, **Dana R**. Seinsitivity and specificity of laser-scanning in vivo confocal microscopy for filamentous fungal keratitis: methodological issues on validity and reliability. *Am J Ophthalmol*, 2017; 182: 201-202.

Professional Educational Materials

415. **Dana R**. Uveitis in juvenile rheumatoid arthritis. E-Medicine Textbook of Ophthalmology, 1999.
416. **Dana R**. Anterior uveitis: The Uveitis Disease Center, YourDoctor.com, 2000.
417. **Dana R**. Uveitis and ocular inflammation: Vcure.com, 2000.
418. **Dana R**. Cataract: Vcure.com, 2000.
419. **Dana R**. Dry eyes and Sjogren's syndrome: Vcure.com, 2000.

420. **Dana R.** Ocular allergy: Vcure.com, 2000.
421. **Dana R.** Ocular herpetic infections: Vcure.com, 2000.
422. **Dana R.** Systemic diseases and the eye: Vcure.com, 2000.
423. **Dana R.** Ocular trauma: Vcure.com, 2000.
424. **Dana R.** Corneal transplantation: Vcure.com, 2001.
425. **Dana R.** Corneal dystrophies and genetic anomalies: Vcure. Com, 2001.

Books and Monographs

1. Section co-editor for Eye and Systemic Disease. Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. 2nd Ed., Philadelphia: WB Saunders Co., 1999
2. Section co-editor for Immunology. Albert DM, Jakobiec FA. Principles and Practice of Ophthalmology. 3rd Ed. Philadelphia: WB Saunders Co., 2007.
3. Senior Editor. *Encyclopedia of the Eye*. Elsevier, 2010.
4. Editor, *Immunology, Inflammation and Diseases of the Eye*. Elsevier, 2011.
5. Editor, *Ocular Disorders*. Elsevier, 2011.
6. **Dana R.**, Jakobiec FA, section Eds. The Eye and Systemic Disease. In: Albert DM, Jakobiec FA. Principles and Practice of Ophthalmology. 2nd Ed. Philadelphia: WB Saunders Co., 1999.
7. Editorial Board Member, Cornea and external diseases, Section 8, *Basic and Clinical Science Course, American Academy of Ophthalmology*, San Francisco, 2002 and 2006 editions.
8. **Dana R.**, Foster CS, section eds. Immunology. In: Albert DM, Jakobiec FA. Principles and Practice of Ophthalmology. 3rd Ed. Philadelphia: WB Saunders Co., 2007.
9. Colby K, **Dana R.** *Foundations of Corneal Disease*. Springer, 2019 (Exp.)

Course Syllabi

1. Dana R. New curriculum for Cornea/External Disease section of Harvard Intensive Review of Ophthalmology Course, 1998: Developed 60+ page handout for course covering corneal anatomy, dystrophies, degenerations, metabolic disorders, ocular atopy, corneal and ocular surface inflammatory conditions, sicca syndromes, scleritis and corneal manifestations of connective tissue diseases, and corneal and conjunctival surgery.
2. Dana R. Curriculum for Ocular Immunology section of Harvard Intensive Review of Ophthalmology Course, 1999: Developed 40+ handout for course covering fundamentals of immunology, and clinical aspects of ocular immunology, uveitis and infectious and autoimmune uveo-retinal syndromes.

Abstracts (Excludes 345 abstracts published already as articles)

1. Hos D, Bock F, Saban DR, Regenfuss B, Onderka J, Masli S, **Dana R**. Corticosteroids inhibit inflammatory corneal lymphangiogenesis *in vivo*, but display proangiogenic properties *in vitro*. *ARVO abstract* 2010; 5695.
2. Sharma S, Fuchsluger T, **Dana R**, Jurkunas U. Evaluation of human derived feeder layers for ex vivo cultivation of oral epithelium for corneal surface reconstruction. *American Society of Cataract and Refractive Surgery poster* 2010; P337.
3. Hua J, Hattori T, Sharma S, Amparo F, Calcagno N, Saban D, **Dana R**. Ex vivo expansion of bone marrow derived cells from normal human cornea. *ARVO abstract* 2011; 1116.
4. Funaki T, Matsuda A, Ebihara N, Murakami A, Chauhan S, Jurkunas U, **Dana R**. ATP contributes corneal endothelial wound healing via P2x7 receptor. *ARVO abstract* 2011; 6436.
5. Krauss A, Amparo F, Okanobo A, Gale DC, Wilde TC, Sychterz C, Apfelbaum R, Saha P, Cermak J, **Dana R**. Improvement of corneal staining by a Sirt1 activator in a mouse model of dry eye. *ARVO abstract* 2012; 2343.
6. Kodati S, Stevenson W, Omoto M, Hattori T, Dohlman T, Saban D, Chauhan S, **Dana R**. The effect of IL-6 neutralization on corneal allograft survival. *ARVO abstract* 2012; 2378.
7. Katikireddy KR, **Dana R**, Jurkunas U. Differentiation potential of limbal fibroblasts and bone marrow mesenchymal stem cells to corneal epithelial cells. *ARVO abstract* 2013; 981.
8. Dastjerdi J, Ghandi J, **Dana R**. Effects of dry eye on corneal nerve regeneration after refractive surgery. *AAO Refractive Surgery Subspecialty Day poster* 2013; 165.
9. Emami-Naeini P, Amparo F, **Dana R**. Paradoxical effect of artificial tear use on signs and symptoms of patients with dry eye disease. *ASCRS poster* 2014.
10. Hua J, Stevenson W, Inomata T, Chen Y, Dohlman TH, Lee H, Shiang T, Omoto M, **Dana R**. Elevated IL-6 and IL-23 in dry eye hosts disrupt peripheral induction of Tregs and exacerbate corneal allograft rejection. *ARVO abstract* 2014; 3216.
11. Lee S, Sadrai Z, Lee H, Stevenson W, Chen Y, Hua J, Katikireddy K, Dohlman TH, Chauhan SK, **Dana R**. Increased substance P expression in the ocular surface in murine dry eye disease. *ARVO abstract* 2014; 3664.
12. Furfine ES, **Dana R**, Wheeler C, Celniker A, Goldstein MH. Topical interleukin-1 (IL-1) receptor inhibition reduces ocular pain. *ARVO abstract* 2014; 3686.
13. Fernandes M, Subbarayal B, Chauhan SK, **Dana R**. Corneal epithelial pigment epithelium derived factor is reduced in a murine model of dry eye disease; *ARVO abstract* 2015; 335.

14. **Dana R.** Mechanisms of APC-lymphatic interaction, immune induction, and inflammatory resolution; *ARVO abstract* 2015; 1683.
15. Kheirkhah A, Raju V K, Hamrah P, **Dana R.** Ultraviolet A/Riboflavin collagen cross-linking for Conjunctiva. *ARVO abstract* 2016.
16. Marmalidou A, Mashaghi-Tabari A, Inomata T, Chen Y, Chauhan S, **Dana R.** Substance P suppresses Foxp3 expression in regulatory T-cells in dry eye disease. *ARVO abstract* 2016.
17. Chen Y, Chauhan S K, Marmalidou A, **Dana R.** Interleukin-23, but not interleukin-2, promotes the generation of memory Th17 cells in dry eye disease. *ARVO abstract* 2016.
18. Nakao T, Inomata T, Tahvildari M, **Dana R.** Corneal transplant survival in young mice. *ARVO abstract* 2016.
19. Kheirkhah A, Noshadi I, Annabi N, Khademhosseini A, **Dana R.** A new bioadhesive for rapid and long-term repair of corneal stromal defects. *AAO poster* 2016.
20. Schaumberg DA, Bradley JL, Guerin A, Pivneva I, Evans AM, Özer Stillman I, **Dana R.** Adherence and persistence with cyclosporine ophthalmic emulsion for treatment of dry eye disease in a large US healthcare system. *American College of Clinical Pharmacy* 2016.
21. Bradley JL, Guerin A, Pivneva I, Evans AM, Stillman IO, Schaumberg D, **Dana R.** Incidence and prevalence of dry eye disease in a large US healthcare system across a wide range of ages. *AAO poster* 2016.
22. Kheirkhah A, Sharifi S, Annabi N, Khademhosseini A, **Dana R.** A New Bioadhesive for rapid and long-term repair of corneal stromal defects. *Fall Educational Symposium of Cornea Society, Chicago, Illinois, USA, October* 2016.
23. Foulsham W, Tan X, Chen Y, Amouzegar A, Chauhan S, **Dana R.** Corneal Epithelium-derived Thrombospondin-1 Regulates Dendritic Cell Maturation in Dry Eye Disease. *ARVO Abstract* 2017.
24. Marmalidou A, Chen Y, Kakao T, Shao C, Chauhan SK, **Dana R.** Substance P mediates dysfunction of NK1R+ Tregs in dry eye disease. *ARVO Abstract* 2017.
25. Tahvildari M, Moein H, Jamali A, Lopez MJ, Harris DL, **Dana R.**, Hamrah P. The role of corneal plasmacytoid dendritic cells in immune sensitization after corneal transplantation. *ARVO Abstract* 2017.
26. Nakao T, Inomata T, Tahvildari M, **Dana R.** Interferon gamma-positive killer cells contribute to corneal allograft rejection in young mice. *ARVO Abstract* 2017.
27. Yu M, Hong J, Amouzegar A, Fernandes M, Chen Y, Nakao T, **Dana R.** Topical pigment epithelium-derived factor suppresses corneal epitheliopathy and inflammation in dry eye disease. *ARVO Abstract* 2017.

28. Amparo F, **Dana R**. Is the Ocular Surface Disease Index (OSDI) the right tool to measure patient perception of ocular surface symptoms? *ARVO Abstract* 2017.
29. Sun Z, Satitpitakul V, Kheirkhah A, Crnej A, Hamrah P, **Dana R**. Ocular pain in patients with dry eye disease. *ARVO Abstract* 2017.
30. Foulsham W, Chen Y, Nakao T, Yu M, Chauhan S, **Dana R**. Severe dry eye disease in aged mice is associated with an expanded memory Th17 cell response and higher frequencies of IFN- γ -expressing Th17. *ARVO Abstract* 2018.
31. Al Karmi R, Sun Z, Kheirkhah, A, Shirzaei Sani E, Annabi N, **Dana R**. Sutureless, minimally invasive sealing of corneal lacerations with a novel bioadhesive material. *ARVO Abstract* 2018.
32. Sun Z, Kheirkhah A, Al Karmi R, Foulsham W, Shirzaei Sani E, Annabi N, **Dana R**. A novel GelMA-based bioadhesive for repair of corneal stromal defects. *ARVO Abstract* 2018.
33. Chen Y, Shao C, Nakao T, Chauhan S K, **Dana R**. Interleukin-23 is essential for development of pathogenic Memory T Helper-17 Cells in chronic dry eye disease. *ARVO Abstract* 2018.
34. Nakao T, Inomata T, Tahvildari M, Amouzegar A, **Dana R**. Higher corneal allograft rejection rates in the very young are associated with a heightened NK cell response in the setting of regulatory T cell dysfunction. *ARVO Abstract* 2018.
35. Singh RB, Al Karmi R, Yu M, Yin J, **Dana R**. Outcomes of cyanoacrylate glue application for corneal perforation. *ARVO Abstract* 2018.
36. Taketani Y, Yu M, Chen Y, **Dana R**. Interleukin-6 is responsible for regulatory T cell dysfunction in dry eye disease. *ARVO Abstract* 2018.
37. Yin J, Shao C, Tahvildari M, **Dana R**. Differential contribution of regulatory T cells derived from low-risk vs. high-risk transplants to corneal angiogenesis. *ARVO Abstract* 2018.
38. Carreno-Galeano J T, Coco G, Amparo F, **Dana R**. Oral guaifenesin for treatment of filamentary keratitis. *ARVO Abstract* 2018.
39. Coco G, Kheirkhah A, Satitpitakul V, **Dana R**. Limbal and conjunctival epithelium thickness in Ocular Graft-versus-Host Disease. *ARVO Abstract* 2018.